


Attorney Docket No.: PR60689USw

Amendments to the Claims:

Please amend the claims as follows:

1. (Currently Amended) A compound of formula (I)



or a salt including salts, solvates, and physiologically functional derivatives thereof, wherein

R¹ is -(Q¹)_x-R³;

Q¹ is C₁-C₆ alkylene;

x is 0 or 1;

R³ is H, alkyl, alkenyl, alkynyl, haloalkyl, or cycloalkyl, -CF₃, or cyclopropyl;

R² is -(Q²)_y-(Q⁴)-R⁶, or -(Q³)-CN;

Q² is C₁-C₆ alkylene;

Q⁴ is -C(O)-, -C(S)-, or -C(NR⁷)-;

R⁷ is H or alkyl;

R⁶ is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, hydroxy, C₁-C₆ alkoxy, aryloxy, phenoxy, benzyloxy, or -N(R⁸)(R⁹);

R⁸ and R⁹ each independently are H, hydroxy, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, -(Q⁵)_z-C₂-C₆ cycloalkyl, -N(R¹⁰)(R¹¹), or R⁸ and R⁹ combine with the nitrogen atom to which they are attached to form an optionally substituted 4 to 8 membered ring that may contain additional heteroatoms and may contain one or more degrees of unsaturation;

Q³ is C₁-C₆ alkylene;

y is 0 or 1;

R¹⁰ and R¹¹ each independently are H or C₁-C₆ alkyl;

R⁵ is -CN, -NO₂, or halogen; and

R⁵ is -CN, -NO₂, halogen, C₁-C₆ haloalkyl, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, hydroxyl, C₁-C₆ alkoxy, aryl, aryloxy, phenyl, naphthyl, phenoxy or benzyloxy.

- 2-7. (Cancelled)

8. (Original) The compound of claim 1 wherein R³ is -CN.

Serial No.:10/598,508

Author Search

=> FILE HCAPLUS

FILE 'HCAPLUS' ENTERED AT 10:21:14 ON 26 SEP 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Sep 2008 VOL 149 ISS 14

FILE LAST UPDATED: 25 Sep 2008 (20080925/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.


'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

=> D STAT QUE L34

L1 STR

G2³ Cy 1

Ak²G1



G1 CF3, [01]
G2 CF3, [01]
G3 [02], [03]
G4
G5
G6 CN,NO2, X


Structure attributes must be viewed using STN Express query preparation.

L3 774 SEA FILE=REGISTRY SSS FUL L1

L4 37 SEA FILE=HCAPLUS ABB=ON PLU=ON L3

L10


STR

G2³ Cy¹Ak²G1

G1 CF3, [01]
 G2 CF3, [01]
 G3 [02], [03]
 G4
 G5
 G6 CN, NO2, X
 G7 O, S, N

Structure attributes must be viewed using STN Express query preparation.

L12 395 SEA FILE=REGISTRY SUB=L3 SSS FUL L10
 L13 16 SEA FILE=HCAPLUS ABB=ON PLU=ON L12
 L14 STR

G2³ Cy¹Ak²G1

G1 CF3, [01]
 G2 CF3, [01]
 G3 [02], [03]
 G4
 G5
 G6 CN, NO2, X
 G7 NO2, X

Structure attributes must be viewed using STN Express query preparation.

L16 SCR 342 OR 286
 L17 2 SEA FILE=REGISTRY SSS SAM L16 AND L14
 L27 62 SEA FILE=HCAPLUS ABB=ON PLU=ON TURNBULL P?/AU
 L28 17 SEA FILE=HCAPLUS ABB=ON PLU=ON CADILLA R?/AU

Serial No.:10/598,508

L29 675 SEA FILE=HCAPLUS ABB=ON PLU=ON COWAN D?/AU
L30 250 SEA FILE=HCAPLUS ABB=ON PLU=ON LARKIN A?/AU
L31 71 SEA FILE=HCAPLUS ABB=ON PLU=ON KALDOR I?/AU
L32 479 SEA FILE=HCAPLUS ABB=ON PLU=ON STEWART E?/AU
L33 1513 SEA FILE=HCAPLUS ABB=ON PLU=ON (L27 OR L28 OR L29 OR L30 OR
L31 OR L32)
L34 6 SEA FILE=HCAPLUS ABB=ON PLU=ON L33 AND (L4 OR L17 OR L13)

=> FILE WPIX

FILE 'WPIX' ENTERED AT 10:21:27 ON 26 SEP 2008

COPYRIGHT (C) 2008 THOMSON REUTERS

FILE LAST UPDATED: 20 SEP 2008 <20080920/UP>

MOST RECENT UPDATE: 200860 <200860/DW>

DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> Now containing more than 1.1 million chemical structures in DCR <<<

>>> IPC Reform backfile reclassifications have been loaded to the end of
June 2008. No update date (UP) has been created for the
reclassified documents, but they can be identified by
20060101/UPIC and 20061231/UPIC, 20070601/UPIC, 20071001/UPIC,
20071130/UPIC, 20080401/UPIC and 20080701/UPIC.
ECLA reclassifications to June and US national classifications to
the end of April 2008 have also been loaded. Update dates
20080401 and 20080701/UPEC and /UPNC have been assigned to these. <<<

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,

PLEASE VISIT:

http://www.stn-international.de/training_center/patents/stn_guide.pdf

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE

<http://scientific.thomsonreuters.com/support/patents/coverage/latestupdates/>

EXPLORE DERWENT WORLD PATENTS INDEX IN STN ANAVIST, VERSION 2.0:

http://www.stn-international.com/archive/presentations/DWPIAnaVist2_0608.pdf

>>> HELP for European Patent Classifications see HELP ECLA, HELP ICO <<<

'BI,ABEX' IS DEFAULT SEARCH FIELD FOR 'WPIX' FILE

=> D STAT QUE L38

L8 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

L27 62 SEA FILE=HCAPLUS ABB=ON PLU=ON TURNBULL P?/AU
L28 17 SEA FILE=HCAPLUS ABB=ON PLU=ON CADILLA R?/AU
L29 675 SEA FILE=HCAPLUS ABB=ON PLU=ON COWAN D?/AU
L30 250 SEA FILE=HCAPLUS ABB=ON PLU=ON LARKIN A?/AU
L31 71 SEA FILE=HCAPLUS ABB=ON PLU=ON KALDOR I?/AU
L32 479 SEA FILE=HCAPLUS ABB=ON PLU=ON STEWART E?/AU
L33 1513 SEA FILE=HCAPLUS ABB=ON PLU=ON (L27 OR L28 OR L29 OR L30 OR
L31 OR L32)
L36 109 SEA FILE=WPIX SSS FUL L8
L37 2 SEA FILE=WPIX ABB=ON PLU=ON L36/DCR
L38 2 SEA FILE=WPIX ABB=ON PLU=ON L33 AND L37

=> DUP REM L34 L38

FILE 'HCAPLUS' ENTERED AT 10:21:37 ON 26 SEP 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIX' ENTERED AT 10:21:37 ON 26 SEP 2008

COPYRIGHT (C) 2008 THOMSON REUTERS

PROCESSING COMPLETED FOR L34

PROCESSING COMPLETED FOR L38

L41 6 DUP REM L34 L38 (2 DUPLICATES REMOVED)
 ANSWERS '1-6' FROM FILE HCAPLUS

=> D IBIB ED ABS HITSTR 1-6

L41 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2006:1122964 HCAPLUS Full-text

DOCUMENT NUMBER: 145:455269

TITLE: Preparation of N-cyanoaryl amino acid amides for
 treating endometriosis or uterine fibroids

INVENTOR(S): Jones, David G.; Kaldor, Istvan; Liang, Xi;
 Turnbull, Philip Stewart; Hammond, Marlys;
 Kallander, Lara S.; Thompson, Scott Kevin; Washburn,
 David

PATENT ASSIGNEE(S): SmithKline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 71pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006113552	A2	20061026	WO 2006-US14286	20060414
WO 2006113552	A3	20070531		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
EP 1871379	A2	20080102	EP 2006-750349	20060414
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
JP 2008536868	T	20080911	JP 2008-506790	20060414
US 20080194536	A1	20080814	US 2007-911537	20071015
PRIORITY APPLN. INFO.:			US 2005-671592P	P 20050415
			WO 2006-US14286	W 20060414

OTHER SOURCE(S): MARPAT 145:455269

ED Entered STN: 27 Oct 2006

AB The invention relates to amino acid amides NC-Ar-N(CHR1R1')CR2R2'CONR3R3' [Ar is Ph or naphthyl which may be further substituted; R1, R1' are independently H, (un)substituted alkyl, cycloalkyl, aryl, heteroaryl, or together form a cycloalkyl or cycloalkenyl group; R2, R2' are independently H, (un)substituted alkyl, cycloalkyl, or R4(CH2)m-X-, where R4 is cycloalkyl, Ph, or pyridyl, m is 0-4, and X is a bond, O, or S; R3, R3' are independently (un)substituted alkyl, alkenyl, propargyl; or NR3R3' is heterocycloalkyl (with provisos)] or their pharmaceutically-acceptable salts and their use for treating endometriosis or uterine fibroids. Thus, N2-[(2-chlorophenyl)methyl]-N2-[4-cyano-3-(trifluoromethyl)phenyl]-N1,N1-dimethyl-L-alaninamide was prepared via amidation, arylation, and alkylation reactions. One hundred twenty-two synthesized compds. showed IC50 < 10 μ M in the PR binding assay.


IT 913288-02-5P 913288-03-6P 913288-04-7P
913288-05-8P 913288-06-9P 913288-07-0P
913288-08-1P 913288-09-2P 913288-10-5P
913288-11-6P 913288-12-7P 913288-13-8P
913288-14-9P 913288-15-0P 913288-16-1P
913288-17-2P 913288-18-3P 913288-19-4P
913288-20-7P 913288-21-8P 913288-22-9P
913288-23-0P 913288-24-1P 913288-25-2P
913288-26-3P 913288-27-4P 913288-28-5P
913288-29-6P 913288-30-9P 913288-31-0P
913288-32-1P 913288-33-2P 913288-34-3P
913288-35-4P 913288-36-5P 913288-37-6P
913288-38-7P 913288-39-8P 913288-40-1P
913288-41-2P 913288-42-3P 913288-43-4P
913288-44-5P 913288-45-6P 913288-46-7P
913288-47-8P 913288-48-9P 913288-49-0P
913288-50-3P 913288-51-4P 913288-52-5P
913288-53-6P 913288-54-7P 913288-58-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-cyanoaryl amino acid amides for treating endometriosis or uterine fibroids)


RN 913288-02-5 HCAPLUS

CN Pentanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-N,N-dimethyl- (CA INDEX NAME)




RN 913288-03-6 HCAPLUS

CN Hexanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-N,N-dimethyl- (CA INDEX NAME)




RN 913288-04-7 HCAPLUS

CN Propanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl]-(2,2,2-trifluoroethyl)amino]-N,N-bis(2-methylpropyl)- (CA INDEX NAME)




RN 913288-05-8 HCAPLUS

CN Propanamide, N,N-dibutyl-2-[[4-cyano-3-(trifluoromethyl)phenyl]-(2,2,2-trifluoroethyl)amino]- (CA INDEX NAME)




RN 913288-06-9 HCAPLUS

CN Propanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl]-(2,2,2-trifluoroethyl)amino]-N-(1,1-dimethylethyl)-N-methyl- (CA INDEX NAME)




RN 913288-07-0 HCAPLUS

CN Propanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-N-methyl-N-2-propyn-1-yl- (CA INDEX NAME)




RN 913288-08-1 HCAPLUS

CN Propanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-N-ethyl-N-propyl- (CA INDEX NAME)




RN 913288-09-2 HCAPLUS

CN Propanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-N-ethyl-N-(1-methylethyl)- (CA INDEX NAME)




RN 913288-10-5 HCAPLUS

CN Propanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-N-ethyl-N-methyl- (CA INDEX NAME)




RN 913288-11-6 HCAPLUS

CN Propanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-N,N-dipropyl- (CA INDEX NAME)




RN 913288-12-7 HCAPLUS

CN Propanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-N,N-diethyl- (CA INDEX NAME)



RN 913288-13-8 HCAPLUS



CN Benzonitrile, 4-[[1-methyl-2-oxo-2-(1-piperidinyl)ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 913288-14-9 HCAPLUS


Serial No.:10/598,508

CN Benzonitrile, 4-[[2-(1-azetidiny1)-1-methyl-2-oxoethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 913288-15-0 HCAPLUS

CN Propanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-N-methyl-N-propyl- (CA INDEX NAME)




RN 913288-16-1 HCAPLUS

CN Propanamide, N-butyl-N-(cyanomethyl)-2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]- (CA INDEX NAME)




RN 913288-17-2 HCAPLUS

CN Propanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-N-(2-methoxyethyl)-N-propyl- (CA INDEX NAME)




RN 913288-18-3 HCAPLUS

CN Propanamide, N,N-bis(2-cyanomethyl)-2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]- (CA INDEX NAME)





RN 913288-19-4 HCAPLUS

CN Benzonitrile, 4-[[1-methyl-2-(4-morpholinyl)-2-oxoethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 913288-20-7 HCAPLUS


CN Propanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-N-(cyclopropylmethyl)-N-propyl- (CA INDEX NAME)




RN 913288-21-8 HCAPLUS
 CN Propanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-N-cyclohexyl-N-methyl- (CA INDEX NAME)




RN 913288-22-9 HCAPLUS
 CN Propanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-N-(2-methoxyethyl)-N-methyl- (CA INDEX NAME)



RN 913288-23-0 HCAPLUS
 CN Benzonitrile, 4-[[1-methyl-2-oxo-2-(4-thiomorpholinyl)ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 913288-24-1 HCAPLUS
 CN Propanamide, N-(2-cyanoethyl)-2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-N-methyl- (CA INDEX NAME)




RN 913288-25-2 HCAPLUS

CN Benzonitrile, 4-[[1-methyl-2-oxo-2-(1-pyrrolidinyl)ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 913288-26-3 HCAPLUS

CN Propanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-N-methyl-N-(1-methylethyl)- (CA INDEX NAME)




RN 913288-27-4 HCAPLUS

CN Propanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-N,N-di-2-propen-1-yl- (CA INDEX NAME)




RN 913288-28-5 HCAPLUS

CN Propanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-N-methyl-N-2-propen-1-yl- (CA INDEX NAME)




RN 913288-29-6 HCAPLUS

CN Butanamide, N,N-dibutyl-2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]- (CA INDEX NAME)




RN 913288-30-9 HCAPLUS

CN Butanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-N-(1,1-dimethylethyl)-N-methyl- (CA INDEX NAME)




RN 913288-31-0 HCAPLUS

CN Butanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-N-methyl-N-2-propyn-1-yl- (CA INDEX NAME)




RN 913288-32-1 HCAPLUS

CN Butanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-N-ethyl-N-propyl- (CA INDEX NAME)




RN 913288-33-2 HCAPLUS

CN Butanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-N-ethyl-N-(1-methylethyl)- (CA INDEX NAME)




RN 913288-34-3 HCAPLUS

CN Butanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-N,N-bis(2-methylpropyl)- (CA INDEX NAME)




RN 913288-35-4 HCAPLUS

CN Butanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl] (2,2,2-trifluoroethyl)amino]-N-ethyl-N-methyl- (CA INDEX NAME)




RN 913288-36-5 HCAPLUS

CN Butanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl] (2,2,2-trifluoroethyl)amino]-N,N-dipropyl- (CA INDEX NAME)




RN 913288-37-6 HCAPLUS

CN Butanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl] (2,2,2-trifluoroethyl)amino]-N,N-diethyl- (CA INDEX NAME)





RN 913288-38-7 HCAPLUS

CN Benzonitrile, 4-[[1-(1-piperidinylcarbonyl)propyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 913288-39-8 HCAPLUS

CN Benzonitrile, 4-[[1-(1-azetidinylcarbonyl)propyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 913288-40-1 HCAPLUS

CN Butanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-N-methyl-N-propyl- (CA INDEX NAME)




RN 913288-41-2 HCAPLUS

CN Butanamide, N-butyl-N-(cyanomethyl)-2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]- (CA INDEX NAME)




RN 913288-42-3 HCAPLUS

CN Butanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-N-(2-methoxyethyl)-N-propyl- (CA INDEX NAME)




RN 913288-43-4 HCAPLUS

CN Butanamide, N,N-bis(cyanomethyl)-2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]- (CA INDEX NAME)




RN 913288-44-5 HCAPLUS

CN Benzonitrile, 4-[[1-(4-morpholinylcarbonyl)propyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 913288-45-6 HCAPLUS

CN Butanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-N-(cyclopropylmethyl)-N-propyl- (CA INDEX NAME)




RN 913288-46-7 HCAPLUS

CN Butanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-N-cyclohexyl-N-methyl- (CA INDEX NAME)




RN 913288-47-8 HCAPLUS

CN Benzonitrile, 4-[[1-(4-thiomorpholinylcarbonyl)propyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 913288-48-9 HCAPLUS

CN Butanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-N-(2-methoxyethyl)-N-methyl- (CA INDEX NAME)




RN 913288-49-0 HCAPLUS

CN Butanamide, N-(2-cyanoethyl)-2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-N-methyl- (CA INDEX NAME)




RN 913288-50-3 HCAPLUS

CN Benzonitrile, 4-[[1-(1-pyrrolidinylcarbonyl)propyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 913288-51-4 HCAPLUS

CN Butanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-N-methyl-N-(1-methylethyl)- (CA INDEX NAME)




RN 913288-52-5 HCAPLUS

CN Butanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-N,N-di-2-propen-1-yl- (CA INDEX NAME)




RN 913288-53-6 HCAPLUS

CN Benzonitrile, 4-[[1-(3-thiazolidinylcarbonyl)propyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 913288-54-7 HCAPLUS

CN Butanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-N-methyl-N-2-propen-1-yl- (CA INDEX NAME)



RN 913288-58-1 HCAPLUS

CN Propanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl]-(3,3,3-trifluoropropyl)amino]-N,N-dimethyl- (CA INDEX NAME)




IT 864283-58-9P 913288-72-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of N-cyanoaryl amino acid amides for treating endometriosis or uterine fibroids)


RN 864283-58-9 HCAPLUS

CN Alanine, N-[4-cyano-3-(trifluoromethyl)phenyl]-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 913288-72-9 HCAPLUS

CN Alanine, N-[4-cyano-3-(trifluoromethyl)phenyl]-N-(2,2,2-trifluoroethyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)



L41 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 2
 ACCESSION NUMBER: 2005:1004698 HCAPLUS Full-text
 DOCUMENT NUMBER: 143:286689
 TITLE: Preparation of aniline amino acid derivatives as selective androgen receptor modulators
 INVENTOR(S): Turnbull, Phillip Stewart; Cadilla, Rodolfo; Cowan, David John; Larkin, Andrew Lamont; Kaldor, Istvan; Stewart, Eugene Lee
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
 SOURCE: PCT Int. Appl., 120 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005085185	A1	20050915	WO 2005-US7245	20050303
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1725522	A1	20061129	EP 2005-730067	20050303
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV				
JP 2007526336	T	20070913	JP 2007-502061	20050303
US 20070191479	A1	20070816	US 2006-598508	20060901
PRIORITY APPLN. INFO.:			US 2004-549794P	P 20040303
			WO 2005-US7245	W 20050303

OTHER SOURCE(S): CASREACT 143:286689; MARPAT 143:286689

ED Entered STN: 16 Sep 2005

AB The invention relates to non-steroidal compds. 3,4-R4R3C6H3NR1R2 [R1 is - (Q1)0-1-R5, where Q1 is alkylene and R5 is H, alkyl, alkenyl, alkynyl, haloalkyl or cycloalkyl; R2 is -Q3-Q4-R6 or -Q3-CN, where Q3 is alkylene, Q4 is CO, CS, C:NR7, R7 is H or alkyl; R6 is alkyl, alkenyl, alkynyl, hydroxy, alkoxy, aryloxy or an amino group; R3 is CN, NO2 or halo; R4 is CN, NO2, halo, haloalkyl, alkyl, alkenyl, alkynyl, hydroxy, alkoxy, aryl or aryloxy] and their salts, solvates and physiol. functional derivs., that are modulators of


androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, as well as methods for their synthesis and use. Thus, N2-[4-cyano-3-(trifluoromethyl)phenyl]-N2-(cyclopropylmethyl)-N1- methylglycinamide was prepared from 4-fluoro-2-(trifluoromethyl)benzonitrile by reaction with cyclopropylmethylamine and tert-Bu bromoacetate, followed by ester cleavage and methylamidation.

IT 864283-35-2P 864283-36-3P 864283-46-5P
 864283-47-6P 864283-48-7P 864283-57-8P
 864283-58-9P 864283-59-0P 864283-68-1P
 864283-71-6P 864284-22-0P 864284-40-2P
 864284-52-6P 864284-55-9P 864284-74-2P
 864284-76-4P 864284-84-4P 864284-95-7P
 864285-03-0P 864285-13-2P 864285-15-4P
 864285-17-6P 864285-25-6P 864285-37-0P
 864285-45-0P 864285-47-2P 864285-55-2P
 864285-57-4P 864285-65-4P 864285-67-6P
 864285-69-8P 864285-77-8P 864285-79-0P
 864285-85-8P 864285-87-0P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of aniline amino acid derivs. as selective androgen receptor modulators)


RN 864283-35-2 HCAPLUS

CN Glycine, N-[4-cyano-3-(trifluoromethyl)phenyl]-N-(cyclopropylmethyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864283-36-3 HCAPLUS

CN Glycine, N-[4-cyano-3-(trifluoromethyl)phenyl]-N-(cyclopropylmethyl)- (CA INDEX NAME)




RN 864283-46-5 HCAPLUS

CN Glycine, N-[4-cyano-3-(trifluoromethyl)phenyl]-N-(2,2,2-trifluoroethyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864283-47-6 HCAPLUS

CN Glycine, N-[4-cyano-3-(trifluoromethyl)phenyl]-N-(2,2,2-trifluoroethyl)-
(CA INDEX NAME)




RN 864283-48-7 HCAPLUS

CN Acetamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]- (CA INDEX NAME)




RN 864283-57-8 HCAPLUS

CN Alanine, N-[4-cyano-3-(trifluoromethyl)phenyl]-N-(2,2,2-trifluoroethyl)-, methyl ester (CA INDEX NAME)




RN 864283-58-9 HCAPLUS

CN Alanine, N-[4-cyano-3-(trifluoromethyl)phenyl]-N-(2,2,2-trifluoroethyl)-
(CA INDEX NAME)




RN 864283-59-0 HCAPLUS

CN Propanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]- (CA INDEX NAME)




RN 864283-68-1 HCAPLUS

CN Butanoic acid, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864283-71-6 HCAPLUS

CN Butanoic acid, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]- (CA INDEX NAME)




RN 864284-22-0 HCAPLUS

CN Alanine, N-[4-cyano-3-(trifluoromethyl)phenyl]-N-(cyclopropylmethyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864284-40-2 HCAPLUS

CN Propanoic acid, 3-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-2-methyl-, methyl ester (CA INDEX NAME)




RN 864284-52-6 HCAPLUS

CN Glycine, N-[4-cyano-3-(trifluoromethyl)phenyl]-N-(3,3,3-trifluoropropyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864284-55-9 HCAPLUS

CN Acetamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](3,3,3-trifluoropropyl)amino]- (CA INDEX NAME)




RN 864284-74-2 HCAPLUS

CN Glycine, N-(3-chloro-4-cyanophenyl)-N-(2,2,2-trifluoroethyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864284-76-4 HCAPLUS

CN Glycine, N-(3-chloro-4-cyanophenyl)-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 864284-84-4 HCAPLUS

CN Alanine, N-(3-chloro-4-cyanophenyl)-N-(2,2,2-trifluoroethyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864284-95-7 HCAPLUS

CN Butanoic acid, 2-[(3-chloro-4-cyanophenyl)(2,2,2-trifluoroethyl)amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864285-03-0 HCAPLUS

CN Glycine, N-(3-chloro-4-cyanophenyl)-N-(cyclopropylmethyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864285-13-2 HCAPLUS

CN Benzonitrile, 2-chloro-4-[(cyanomethyl)(cyclopropylmethyl)amino]- (CA INDEX NAME)




RN 864285-15-4 HCAPLUS

CN Alanine, N-(3-chloro-4-cyanophenyl)-N-(cyclopropylmethyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864285-17-6 HCAPLUS

CN Alanine, N-(3-chloro-4-cyanophenyl)-N-(cyclopropylmethyl)- (CA INDEX NAME)




RN 864285-25-6 HCAPLUS

CN Butanoic acid, 2-[(3-chloro-4-cyanophenyl)(cyclopropylmethyl)amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864285-37-0 HCAPLUS

CN Glycine, N-(3,4-dicyanophenyl)-N-(2,2,2-trifluoroethyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864285-45-0 HCAPLUS

CN Alanine, N-(3,4-dicyanophenyl)-N-(2,2,2-trifluoroethyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864285-47-2 HCAPLUS

CN Alanine, N-(3,4-dicyanophenyl)-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 864285-55-2 HCAPLUS

CN Butanoic acid, 2-[(3,4-dicyanophenyl)(2,2,2-trifluoroethyl)amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864285-57-4 HCAPLUS

CN Butanoic acid, 2-[(3,4-dicyanophenyl)(2,2,2-trifluoroethyl)amino]- (CA INDEX NAME)




RN 864285-65-4 HCAPLUS

CN Glycine, N-(cyclopropylmethyl)-N-(3,4-dicyanophenyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864285-67-6 HCAPLUS

CN Glycine, N-(cyclopropylmethyl)-N-(3,4-dicyanophenyl)- (CA INDEX NAME)




RN 864285-69-8 HCAPLUS

CN Acetamide, 2-[(cyclopropylmethyl)(3,4-dicyanophenyl)amino]- (CA INDEX NAME)




RN 864285-77-8 HCAPLUS

CN Alanine, N-(cyclopropylmethyl)-N-(3,4-dicyanophenyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864285-79-0 HCAPLUS

CN Alanine, N-(cyclopropylmethyl)-N-(3,4-dicyanophenyl)- (CA INDEX NAME)




RN 864285-85-8 HCAPLUS

CN Butanoic acid, 2-[(cyclopropylmethyl)(3,4-dicyanophenyl)amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 864285-87-0 HCAPLUS

CN Butanoic acid, 2-[(cyclopropylmethyl)(3,4-dicyanophenyl)amino]- (CA INDEX NAME)



IT 864283-37-4P 864283-38-5P 864283-49-8P
 864283-50-1P 864283-51-2P 864283-52-3P
 864283-53-4P 864283-54-5P 864283-55-6P
 864283-56-7P 864283-60-3P 864283-62-5P
 864283-65-8P 864283-74-9P 864283-77-2P
 864283-80-7P 864283-83-0P 864284-16-2P
 864284-19-5P 864284-25-3P 864284-27-5P
 864284-29-7P 864284-31-1P 864284-33-3P
 864284-35-5P 864284-37-7P 864284-42-4P
 864284-48-0P 864284-50-4P 864284-57-1P
 864284-59-3P 864284-62-8P 864284-78-6P
 864284-80-0P 864284-82-2P 864284-87-7P
 864284-89-9P 864284-91-3P 864284-93-5P
 864284-97-9P 864284-99-1P 864285-01-8P
 864285-05-2P 864285-07-4P 864285-09-6P
 864285-11-0P 864285-19-8P 864285-21-2P
 864285-23-4P 864285-27-8P 864285-29-0P
 864285-31-4P 864285-33-6P 864285-35-8P
 864285-39-2P 864285-41-6P 864285-43-8P

Serial No.:10/598,508


864285-49-4P 864285-51-8P 864285-53-0P
 864285-59-6P 864285-61-0P 864285-63-2P
 864285-71-2P 864285-73-4P 864285-75-6P
 864285-81-4P 864285-83-6P 864285-89-2P
 864285-91-6P 864285-93-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of aniline amino acid derivs. as selective androgen receptor
 modulators)


RN 864283-37-4 HCAPLUS

CN Acetamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](cyclopropylmethyl)amino]-
 N-methyl- (CA INDEX NAME)




RN 864283-38-5 HCAPLUS

CN Acetamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](cyclopropylmethyl)amino]-
 (CA INDEX NAME)




RN 864283-49-8 HCAPLUS

CN Glycine, N-[4-cyano-3-(trifluoromethyl)phenyl]-N-(2,2,2-trifluoroethyl)-,
 methyl ester (CA INDEX NAME)




RN 864283-50-1 HCAPLUS

CN Glycine, N-[4-cyano-3-(trifluoromethyl)phenyl]-N-(2,2,2-trifluoroethyl)-,
 1-methylethyl ester (CA INDEX NAME)




RN 864283-51-2 HCAPLUS

CN Acetamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl]-(2,2,2-trifluoroethyl)amino]-N-methyl- (CA INDEX NAME)




RN 864283-52-3 HCAPLUS

CN Acetamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl]-(2,2,2-trifluoroethyl)amino]-N-ethyl- (CA INDEX NAME)




RN 864283-53-4 HCAPLUS

CN Acetamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl]-(2,2,2-trifluoroethyl)amino]-N-cyclohexyl- (CA INDEX NAME)




RN 864283-54-5 HCAPLUS

CN Acetamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-N,N-dimethyl- (CA INDEX NAME)




RN 864283-55-6 HCAPLUS

CN Glycine, N-[4-cyano-3-(trifluoromethyl)phenyl]-N-(2,2,2-trifluoroethyl)-, 1-methylhydrazide (CA INDEX NAME)




RN 864283-56-7 HCAPLUS

CN Glycine, N-[4-cyano-3-(trifluoromethyl)phenyl]-N-(2,2,2-trifluoroethyl)-, 2,2-dimethylhydrazide (CA INDEX NAME)




RN 864283-60-3 HCAPLUS

CN Propanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-N-methyl- (CA INDEX NAME)




RN 864283-62-5 HCAPLUS

CN Propanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl] (2,2,2-trifluoroethyl)amino]-N-ethyl- (CA INDEX NAME)




RN 864283-65-8 HCAPLUS

CN Propanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl] (2,2,2-trifluoroethyl)amino]-N,N-dimethyl- (CA INDEX NAME)




RN 864283-74-9 HCAPLUS

CN Butanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl] (2,2,2-trifluoroethyl)amino]- (CA INDEX NAME)




RN 864283-77-2 HCAPLUS

CN Butanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-N-methyl- (CA INDEX NAME)




RN 864283-80-7 HCAPLUS

CN Butanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-N-ethyl- (CA INDEX NAME)




RN 864283-83-0 HCAPLUS

CN Butanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-N,N-dimethyl- (CA INDEX NAME)




RN 864284-16-2 HCAPLUS

CN Acetamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](cyclopropylmethyl)amino]-N-ethyl- (CA INDEX NAME)




RN 864284-19-5 HCAPLUS

CN Acetamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl]-(cyclopropylmethyl)amino]-N-(cyclopropylmethyl)- (CA INDEX NAME)




RN 864284-25-3 HCAPLUS

CN Alanine, N-[4-cyano-3-(trifluoromethyl)phenyl]-N-(cyclopropylmethyl)- (CA INDEX NAME)




RN 864284-27-5 HCAPLUS

CN Propanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl]-(cyclopropylmethyl)amino]-N-methyl- (CA INDEX NAME)




RN 864284-29-7 HCAPLUS

CN Propanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl]-(cyclopropylmethyl)amino]-N-methyl- (CA INDEX NAME)




RN 864284-31-1 HCAPLUS

CN Propanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl] (cyclopropylmethyl) amino]-N-ethyl- (CA INDEX NAME)




RN 864284-33-3 HCAPLUS

CN Propanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl] (cyclopropylmethyl) amino]-N,N-dimethyl- (CA INDEX NAME)



RN 864284-35-5 HCAPLUS


CN Benzonitrile, 4-[(cyanomethyl) (2,2,2-trifluoroethyl) amino]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 864284-37-7 HCAPLUS


CN Benzonitrile, 4-[(1-cyanoethyl) (2,2,2-trifluoroethyl) amino]-2-

(trifluoromethyl)- (CA INDEX NAME)




RN 864284-42-4 HCAPLUS

CN Benzonitrile, 4-[(2-cyanopropyl)(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 864284-48-0 HCAPLUS

CN Acetamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoro-1-methylethyl)amino]- (CA INDEX NAME)




RN 864284-50-4 HCAPLUS

CN Acetamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl][1-(trifluoromethyl)propyl]amino]- (CA INDEX NAME)




RN 864284-57-1 HCAPLUS

CN Benzonitrile, 4-[(cyanomethyl) (3,3,3-trifluoropropyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 864284-59-3 HCAPLUS

CN Propanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl] (3,3,3-trifluoropropyl)amino]- (CA INDEX NAME)




RN 864284-62-8 HCAPLUS

CN Propanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl] (3,3,3-trifluoropropyl)amino]-N-methyl- (CA INDEX NAME)




RN 864284-78-6 HCAPLUS

CN Acetamide, 2-[(3-chloro-4-cyanophenyl)(2,2,2-trifluoroethyl)amino]- (CA INDEX NAME)




RN 864284-80-0 HCAPLUS

CN Acetamide, 2-[(3-chloro-4-cyanophenyl)(2,2,2-trifluoroethyl)amino]-N-methyl- (CA INDEX NAME)




RN 864284-82-2 HCAPLUS

CN Acetamide, 2-[(3-chloro-4-cyanophenyl)(2,2,2-trifluoroethyl)amino]-N-ethyl- (CA INDEX NAME)




RN 864284-87-7 HCAPLUS

CN Alanine, N-(3-chloro-4-cyanophenyl)-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 864284-89-9 HCAPLUS

CN Propanamide, 2-[(3-chloro-4-cyanophenyl)(2,2,2-trifluoroethyl)amino]- (CA INDEX NAME)




RN 864284-91-3 HCAPLUS

CN Propanamide, 2-[(3-chloro-4-cyanophenyl)(2,2,2-trifluoroethyl)amino]-N-methyl- (CA INDEX NAME)




RN 864284-93-5 HCAPLUS

CN Propanamide, 2-[(3-chloro-4-cyanophenyl)(2,2,2-trifluoroethyl)amino]-N-ethyl- (CA INDEX NAME)




RN 864284-97-9 HCAPLUS

CN Butanamide, 2-[(3-chloro-4-cyanophenyl)(2,2,2-trifluoroethyl)amino]- (CA INDEX NAME)




RN 864284-99-1 HCAPLUS

CN Butanamide, 2-[(3-chloro-4-cyanophenyl)(2,2,2-trifluoroethyl)amino]-N-methyl- (CA INDEX NAME)




RN 864285-01-8 HCAPLUS

CN Butanamide, 2-[(3-chloro-4-cyanophenyl)(2,2,2-trifluoroethyl)amino]-N-ethyl- (CA INDEX NAME)




RN 864285-05-2 HCAPLUS

CN Glycine, N-(3-chloro-4-cyanophenyl)-N-(cyclopropylmethyl)- (CA INDEX NAME)




RN 864285-07-4 HCAPLUS

CN Acetamide, 2-[(3-chloro-4-cyanophenyl)(cyclopropylmethyl)amino]- (CA INDEX NAME)




RN 864285-09-6 HCAPLUS

CN Acetamide, 2-[(3-chloro-4-cyanophenyl)(cyclopropylmethyl)amino]-N-methyl- (CA INDEX NAME)




RN 864285-11-0 HCAPLUS

CN Acetamide, 2-[(3-chloro-4-cyanophenyl)(cyclopropylmethyl)amino]-N-ethyl- (CA INDEX NAME)




RN 864285-19-8 HCAPLUS

CN Propanamide, 2-[(3-chloro-4-cyanophenyl)(cyclopropylmethyl)amino]- (CA INDEX NAME)




RN 864285-21-2 HCAPLUS

CN Propanamide, 2-[(3-chloro-4-cyanophenyl)(cyclopropylmethyl)amino]-N-methyl-
(CA INDEX NAME)




RN 864285-23-4 HCAPLUS

CN Propanamide, 2-[(3-chloro-4-cyanophenyl)(cyclopropylmethyl)amino]-N-ethyl-
(CA INDEX NAME)




RN 864285-27-8 HCAPLUS

CN Butanoic acid, 2-[(3-chloro-4-cyanophenyl)(cyclopropylmethyl)amino]- (CA
INDEX NAME)




RN 864285-29-0 HCAPLUS

CN Butanamide, 2-[(3-chloro-4-cyanophenyl)(cyclopropylmethyl)amino]- (CA
INDEX NAME)




RN 864285-31-4 HCAPLUS

CN Butanamide, 2-[(3-chloro-4-cyanophenyl)(cyclopropylmethyl)amino]-N-methyl-
(CA INDEX NAME)




RN 864285-33-6 HCAPLUS

CN Butanamide, 2-[(3-chloro-4-cyanophenyl)(cyclopropylmethyl)amino]-N-ethyl-
(CA INDEX NAME)




RN 864285-35-8 HCAPLUS

CN Glycine, N-(3,4-dicyanophenyl)-N-(2,2,2-trifluoroethyl)-, methyl ester
(CA INDEX NAME)




RN 864285-39-2 HCAPLUS

CN Acetamide, 2-[(3,4-dicyanophenyl)(2,2,2-trifluoroethyl)amino]- (CA INDEX NAME)




RN 864285-41-6 HCAPLUS

CN Acetamide, 2-[(3,4-dicyanophenyl)(2,2,2-trifluoroethyl)amino]-N-methyl-
(CA INDEX NAME)




RN 864285-43-8 HCAPLUS

CN Acetamide, 2-[(3,4-dicyanophenyl)(2,2,2-trifluoroethyl)amino]-N-ethyl-
(CA INDEX NAME)




RN 864285-49-4 HCAPLUS

CN Propanamide, 2-[(3,4-dicyanophenyl)(2,2,2-trifluoroethyl)amino]- (CA
INDEX NAME)




RN 864285-51-8 HCAPLUS

CN Propanamide, 2-[(3,4-dicyanophenyl)(2,2,2-trifluoroethyl)amino]-N-methyl-
(CA INDEX NAME)




RN 864285-53-0 HCAPLUS

CN Propanamide, 2-[(3,4-dicyanophenyl)(2,2,2-trifluoroethyl)amino]-N-ethyl-
(CA INDEX NAME)




RN 864285-59-6 HCAPLUS

CN Butanamide, 2-[(3,4-dicyanophenyl)(2,2,2-trifluoroethyl)amino]- (CA INDEX NAME)




RN 864285-61-0 HCAPLUS

CN Butanamide, 2-[(3,4-dicyanophenyl)(2,2,2-trifluoroethyl)amino]-N-methyl-
(CA INDEX NAME)




RN 864285-63-2 HCAPLUS

CN Butanamide, 2-[(3,4-dicyanophenyl)(2,2,2-trifluoroethyl)amino]-N-ethyl- (CA INDEX NAME)




RN 864285-71-2 HCAPLUS

CN Acetamide, 2-[(cyclopropylmethyl)(3,4-dicyanophenyl)amino]-N-methyl- (CA INDEX NAME)




RN 864285-73-4 HCAPLUS

CN Acetamide, 2-[(cyclopropylmethyl)(3,4-dicyanophenyl)amino]-N-ethyl- (CA INDEX NAME)




RN 864285-75-6 HCAPLUS

CN 1,2-Benzenedicarbonitrile, 4-[(cyanomethyl)(cyclopropylmethyl)amino]- (CA INDEX NAME)




RN 864285-81-4 HCAPLUS

CN Propanamide, 2-[(cyclopropylmethyl)(3,4-dicyanophenyl)amino]-N-methyl- (CA INDEX NAME)




RN 864285-83-6 HCAPLUS

CN Propanamide, 2-[(cyclopropylmethyl)(3,4-dicyanophenyl)amino]-N-ethyl- (CA INDEX NAME)




RN 864285-89-2 HCAPLUS

CN Butanamide, 2-[(cyclopropylmethyl)(3,4-dicyanophenyl)amino]- (CA INDEX NAME)




RN 864285-91-6 HCAPLUS

CN Butanamide, 2-[(cyclopropylmethyl)(3,4-dicyanophenyl)amino]-N-methyl- (CA INDEX NAME)



RN 864285-93-8 HCAPLUS

CN Butanamide, 2-[(cyclopropylmethyl)(3,4-dicyanophenyl)amino]-N-ethyl- (CA INDEX NAME)



IT 864286-08-3P 864286-10-2P 864286-12-4P

864286-19-1P 864286-21-5P 864286-23-7P

864286-27-1P 864286-29-3P 864286-31-7P

864286-34-0P 864286-36-2P 864286-38-4P


864286-55-5P 864286-61-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aniline amino acid derivs. as selective androgen receptor modulators)


RN 864286-08-8 HCAPLUS

CN 2-Propenoic acid, 2-[[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]methyl]-, methyl ester (CA INDEX NAME)




RN 864286-10-2 HCAPLUS

CN Propanoic acid, 3-[[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-2-methyl- (CA INDEX NAME)




RN 864286-12-4 HCAPLUS

CN Propanamide, 3-[[4-cyano-3-(trifluoromethyl)phenyl] (2,2,2-trifluoroethyl)amino]-2-methyl- (CA INDEX NAME)




RN 864286-19-1 HCAPLUS

CN Benzonitrile, 4-[2-propen-1-yl (2,2,2-trifluoro-1-methylethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 864286-21-5 HCAPLUS

CN Benzonitrile, 4-[(2-oxoethyl) (2,2,2-trifluoro-1-methylethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 864286-23-7 HCAPLUS

CN Glycine, N-[4-cyano-3-(trifluoromethyl)phenyl]-N-(2,2,2-trifluoro-1-methylethyl)- (CA INDEX NAME)




RN 864286-27-1 HCAPLUS

CN Benzonitrile, 4-[2-propen-1-yl[1-(trifluoromethyl)propyl]amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 864286-29-3 HCAPLUS

CN Benzonitrile, 4-[(2-oxoethyl)[1-(trifluoromethyl)propyl]amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 864286-31-7 HCAPLUS

CN Glycine, N-[4-cyano-3-(trifluoromethyl)phenyl]-N-[1-(trifluoromethyl)propyl]- (CA INDEX NAME)




RN 864286-34-0 HCAPLUS

CN Glycine, N-[4-cyano-3-(trifluoromethyl)phenyl]-N-(3,3,3-trifluoropropyl)-
(CA INDEX NAME)




RN 864286-36-2 HCAPLUS

CN Alanine, N-[4-cyano-3-(trifluoromethyl)phenyl]-N-(3,3,3-trifluoropropyl)-,
1,1-dimethylethyl ester (CA INDEX NAME)




RN 864286-38-4 HCAPLUS


CN Alanine, N-[4-cyano-3-(trifluoromethyl)phenyl]-N-(3,3,3-trifluoropropyl)-
(CA INDEX NAME)



RN 864286-55-5 HCAPLUS
 CN Butanoic acid, 2-[(3-chloro-4-cyanophenyl)(2,2,2-trifluoroethyl)amino]-
 (CA INDEX NAME)



RN 864286-61-3 HCAPLUS
 CN Glycine, N-(3,4-dicyanophenyl)-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:1343064 HCAPLUS Full-text
 DOCUMENT NUMBER: 146:287642
 TITLE: Design and Synthesis of an Array of Selective Androgen
 Receptor Modulators
 AUTHOR(S): Trump, Ryan P.; Blanc, Jean-Baptiste E.; Stewart,
 Eugene L.; Brown, Peter J.; Caivano, Matilde;
 Gray, David W.; Hoekstra, William J.; Willson, Timothy
 M.; Han, Bajin; Turnbull, Philip
 CORPORATE SOURCE: GlaxoSmithKline, Research Triangle Park, NC, 27709,
 USA
 SOURCE: Journal of Combinatorial Chemistry (2007), 9(1),
 107-114
 CODEN: JCCHFF; ISSN: 1520-4766
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 ED Entered STN: 24 Dec 2006
 AB We describe the design, using shape comparison and fast docking computer
 algorithms, and rapid parallel synthesis of a 1300 member array based on
 GSK7721, a 4-aminobenzonitrile androgen receptor (AR) antagonist identified by
 focused screening of the GSK compound collection. The array yielded 352
 submicromolar and 17 subnanomolar AR agonists as measured by a cell-based

Serial No.:10/598,508

reporter gene functional assay. The rapid synthesis of a large number of active compds. provided valuable information in the optimization of AR modulators, which may be useful in treating androgen deficiency in aging males.


IT 821776-43-6P 821776-44-7P 821776-58-3P
927693-16-1P 927693-77-4P 927699-39-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Design and Synthesis of an Array of Selective Androgen Receptor Modulators)


RN 821776-43-6 HCAPLUS

CN Benzonitrile, 4-[(cyclopropylmethyl)propylamino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 821776-44-7 HCAPLUS

CN Benzonitrile, 4-[(cyclopropylmethyl)propylamino]-2-nitro- (CA INDEX NAME)




RN 821776-58-3 HCAPLUS

CN Benzonitrile, 2-chloro-4-[(cyclopropylmethyl)propylamino]- (CA INDEX NAME)




RN 927693-16-1 HCAPLUS

CN Benzonitrile, 2-chloro-4-[(1,3-dioxolan-2-ylmethyl)methylamino]- (CA INDEX NAME)




RN 927693-77-4 HCAPLUS

CN Benzonitrile, 4-[(1,3-dioxolan-2-ylmethyl)methylamino]-2-nitro- (CA INDEX NAME)



RN 927699-39-6 HCAPLUS

CN Benzonitrile, 4-[(1,3-dioxolan-2-ylmethyl)methylamino]- (CA INDEX NAME)



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:1312622 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 146:62449

TITLE: Nonsteroidal tertiary arylamines as modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors and their preparation and use for treatment of diseases

INVENTOR(S): Turnbull, Philip Stewart; Cadilla, Rodolfo; Larkin, Andrew Lamont; Stewart, Eugene Lee; Stetson, Katherine

PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 191pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2006133216	A2	20061214	WO 2006-US21966	20060606
WO 2006133216	A3	20070426		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

EP 1888512 A2 20080220 EP 2006-772327 20060606


R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR

PRIORITY APPLN. INFO.: US 2005-687895P P 20050606
WO 2006-US21966 W 20060606

OTHER SOURCE(S): MARPAT 146:62449

ED Entered STN: 15 Dec 2006

GI



AB This invention relates to non-steroidal compds. of formula I that are modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of such compds. Compds. of formula I wherein R1 is CN, NO2 and halo; n is 0, 1, and 2; each R3 is independently CN, NO2, halo, (halo)alkyl, alkenyl, alkynyl, OH, (halo)alkoxy, and aryl; R3 is (Rx)aR7; Rx is (un)substituted C1-4 alkylene; a is 0 and 1; R7 is H, (halo)alkyl, cycloalkyl, alkenyl, alkynyl, CN; R4 and R5 are independently H, (halo)alkyl, and cycloalkyl; R6 is (un)substituted aryl and (un)substituted heterocyclyl; and their pharmaceutically acceptable salts, and solvates thereof are claimed. Example compound II was prepared by substitution of 4-fluoro-2- trifluoromethylbenzonitrile with (R)-(+)-1-(2-naphthyl)ethylamine; the resulting 4-[[[(1R)-1-(2-naphthyl)ethyl]amino]-2-trifluoromethylbenzonitrile underwent N-alkylation with cyclopropanemethyl bromide to give compound II. All the invention compds. were evaluated for their androgen, glucocorticoid, mineralocorticoid, and progesterone receptor modulatory activity. From the assay, it was determined that some of the compds. exhibited pIC50 values of ≥ 5.0 .

IT 916807-89-1P 916808-25-8P 916808-26-9P
916808-52-1P 916808-53-2P 916808-58-7P
916808-60-1P 916808-67-8P 916808-71-4P
916809-17-1P 916809-19-3P 916809-37-5P
916809-38-6P 916809-83-1P 916809-89-7P
916809-99-9P 916810-00-9P 916810-05-4P


916810-24-7P 916810-35-0P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate and intermediate; preparation of nonsteroidal tertiary arylamines as modulators of androgen, glucocorticoid, mineralocorticoid and progesterone receptors useful in therapy)


RN 916807-89-1 HCAPLUS

CN Benzonitrile, 4-[[[3-bromophenyl)methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-25-8 HCAPLUS

CN 2-Furancarboxylic acid, 5-[[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]methyl]-, ethyl ester (CA INDEX NAME)




RN 916808-26-9 HCAPLUS

CN 2-Furancarboxamide, 5-[[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]methyl]- (CA INDEX NAME)




RN 916808-52-1 HCAPLUS

CN 3-Furancarboxylic acid, 2-[[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]methyl]-, methyl ester (CA INDEX NAME)




RN 916808-53-2 HCAPLUS

CN 3-Furancarboxamide, 2-[[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]methyl]- (CA INDEX NAME)




RN 916808-58-7 HCAPLUS

CN Benzonitrile, 4-[[[5-chloro-2-thienyl)methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-60-1 HCAPLUS

CN Benzonitrile, 4-[[[5-bromo-2-thienyl)methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-67-8 HCAPLUS

CN 1H-Imidazole-1-carboxylic acid, 4-[[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 916808-71-4 HCAPLUS

CN Benzonitrile, 4-[[[4-(hydroxymethyl)-2-oxazolyl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-17-1 HCAPLUS

CN Carbamic acid, N-[[[3-[[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]methyl]-1,2,4-oxadiazol-5-yl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 916809-19-3 HCAPLUS

CN Benzonitrile, 4-[[[5-(aminomethyl)-1,2,4-oxadiazol-3-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-37-5 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-[[[4-cyano-3-


Serial No.:10/598,508

(trifluoromethyl)phenyl][2,2,2-trifluoroethyl amino)methyl]-1,2,4-oxadiazol-5-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 916809-38-6 HCAPLUS

CN Benzonitrile, 4-[[[5-(3-piperidinyl)-1,2,4-oxadiazol-3-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-83-1 HCAPLUS

CN Benzonitrile, 4-[[[5-(5-bromo-3-pyridinyl)-1,3,4-oxadiazol-2-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-89-7 HCAPLUS

CN Benzonitrile, 4-[[[5-(4-fluorophenyl)-1,3,4-oxadiazol-2-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-99-9 HCAPLUS

CN Benzonitrile, 4-[[[5-(4-nitrophenyl)-1,3,4-oxadiazol-2-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916810-00-9 HCAPLUS

CN Benzonitrile, 4-[[[5-(4-aminophenyl)-1,3,4-oxadiazol-2-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916810-05-4 HCAPLUS

CN Benzonitrile, 4-[[[5-[4-(methylthio)phenyl]-1,3,4-oxadiazol-2-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916810-24-7 HCAPLUS

CN Benzonitrile, 4-[[[5-(4,5-dihydro-5-oxo-1,3,4-oxadiazol-2-yl)methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 916810-35-0 HCAPLUS

CN Benzonitrile, 4-[[[5-(4-fluorophenyl)-4-(phenylmethyl)-4H-1,2,4-triazol-3-yl)methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)



IT 916807-39-1P 916807-59-5P 916807-71-1P
 916807-75-5P 916807-78-8P 916807-81-3P
 916807-83-5P 916807-86-8P 916807-87-9P
 916807-88-0P 916807-90-4P 916807-91-5P
 916807-92-6P 916807-93-7P 916807-95-9P
 916807-96-0P 916807-97-1P 916807-98-2P
 916807-99-3P 916808-00-9P 916808-01-0P
 916808-02-1P 916808-03-2P 916808-04-3P
 916808-05-4P 916808-06-5P 916808-07-6P
 916808-08-7P 916808-09-8P 916808-10-1P
 916808-11-2P 916808-12-3P 916808-13-4P
 916808-14-5P 916808-15-6P 916808-16-7P
 916808-17-8P 916808-18-9P 916808-19-0P
 916808-20-3P 916808-21-4P 916808-22-5P
 916808-23-6P 916808-24-7P 916808-27-0P
 916808-28-1P 916808-29-2P 916808-30-5P

Serial No.:10/598,508

916808-31-6P 916808-32-7P 916808-33-8P
 916808-34-9P 916808-35-0P 916808-36-1P
 916808-37-2P 916808-38-3P 916808-39-4P
 916808-40-7P 916808-41-8P 916808-42-9P
 916808-43-0P 916808-44-1P 916808-45-2P
 916808-46-3P 916808-47-4P 916808-48-5P
 916808-49-6P 916808-50-9P 916808-51-0P
 916808-54-3P 916808-55-4P 916808-56-5P
 916808-57-6P 916808-59-8P 916808-61-2P
 916808-62-3P 916808-63-4P 916808-64-5P
 916808-65-6P 916808-66-7P 916808-68-9P
 916808-69-0P 916808-70-3P 916808-72-5P
 916808-73-6P 916808-74-7P 916808-75-8P
 916808-76-9P 916808-77-0P 916808-78-1P
 916808-79-2P 916808-80-5P 916808-81-6P
 916808-82-7P 916808-83-8P 916808-84-9P
 916808-85-0P 916808-86-1P 916808-87-2P
 916808-88-3P 916808-89-4P 916808-90-7P
 916808-91-8P 916808-92-9P 916808-93-0P
 916808-94-1P 916808-95-2P 916808-96-3P
 916808-97-4P 916808-98-5P 916808-99-6P
 916809-00-2P 916809-01-3P 916809-02-4P
 916809-03-5P 916809-04-6P 916809-05-7P
 916809-06-8P 916809-07-9P 916809-08-0P
 916809-09-1P 916809-10-4P 916809-11-5P
 916809-12-6P 916809-13-7P 916809-15-9P
 916809-20-6P 916809-21-7P 916809-22-8P
 916809-23-9P 916809-24-0P 916809-25-1P
 916809-26-2P 916809-27-3P 916809-28-4P
 916809-29-5P 916809-30-8P 916809-31-9P
 916809-32-0P 916809-33-1P 916809-34-2P
 916809-35-3P 916809-36-4P 916809-39-7P
 916809-40-0P 916809-41-1P 916809-42-2P
 916809-43-3P 916809-44-4P 916809-46-6P
 916809-50-2P 916809-51-3P 916809-53-5P
 916809-54-6P 916809-57-9P 916809-60-4P
 916809-63-7P 916809-65-9P 916809-68-2P
 916809-71-7P 916809-72-8P 916809-73-9P
 916809-74-0P 916809-75-1P 916809-76-2P
 916809-77-3P 916809-78-4P 916809-79-5P
 916809-80-8P 916809-81-9P 916809-82-0P
 916809-84-2P 916809-85-3P 916809-86-4P
 916809-87-5P 916809-88-6P 916809-90-0P
 916809-91-1P 916809-92-2P 916809-93-3P
 916809-94-4P 916809-95-5P 916809-96-6P
 916809-97-7P 916809-98-8P 916810-01-0P
 916810-02-1P 916810-03-2P 916810-04-3P
 916810-06-5P 916810-07-6P 916810-08-7P
 916810-09-8P 916810-10-1P 916810-11-2P
 916810-12-3P 916810-13-4P 916810-14-5P
 916810-15-6P 916810-16-7P 916810-17-8P
 916810-18-9P 916810-19-0P 916810-20-3P
 916810-21-4P 916810-22-5P 916810-23-6P
 916810-25-8P 916810-26-9P 916810-27-0P
 916810-28-1P 916810-29-2P 916810-30-5P
 916810-31-6P 916810-32-7P 916810-33-8P
 916810-34-9P 916810-36-1P 916810-37-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)


Serial No.:10/598,508

(drug candidate; preparation of nonsteroidal tertiary arylamines as modulators of androgen, glucocorticoid, mineralocorticoid and progesterone receptors useful in therapy)

RN 916807-39-1 HCAPLUS


CN Benzonitrile, 4-[(cyclopropylmethyl) [(1R)-1-(2-naphthalenyl)ethyl]amino]-2-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 916807-59-5 HCAPLUS

CN Benzonitrile, 4-[(1-cyclopropylethyl) (phenylmethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916807-71-1 HCAPLUS

CN Benzonitrile, 4-[(phenylmethyl) (2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916807-75-5 HCAPLUS

CN Benzonitrile, 4-[[(2-methylphenyl)methyl] (2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916807-78-8 HCAPLUS

CN Benzonitrile, 4-[(2,2,2-trifluoroethyl)[[2-(trifluoromethyl)phenyl]methyl]amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916807-81-3 HCAPLUS

CN Benzonitrile, 4-[[[2-(fluorophenyl)methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916807-83-5 HCAPLUS

CN Benzonitrile, 4-[[[3-methylphenyl)methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916807-86-8 HCAPLUS

CN Benzonitrile, 4-[(2,2,2-trifluoroethyl)[[3-(trifluoromethyl)phenyl]methyl]amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916807-87-9 HCAPLUS

CN Benzonitrile, 4-[[[(3-fluorophenyl)methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916807-88-0 HCAPLUS

CN Benzonitrile, 4-[[[(3-chlorophenyl)methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916807-90-4 HCAPLUS

CN Benzonitrile, 4-[[[(1,1'-biphenyl)-3-ylmethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916807-91-5 HCAPLUS

CN Benzonitrile, 4-[[[(3-methoxyphenyl)methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916807-92-6 HCAPLUS

CN Benzonitrile, 4-[(2,2,2-trifluoroethyl)[[3-(trifluoromethoxy)phenyl]methyl]amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916807-93-7 HCAPLUS

CN Benzonitrile, 4-[[[3-(4-fluorophenoxy)phenyl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916807-95-9 HCAPLUS

CN Benzonitrile, 4-[[[3-(2-fluorophenoxy)phenyl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916807-96-0 HCAPLUS

CN Benzonitrile, 4-[(2,2,2-trifluoroethyl)[[3-[(trifluoromethyl)thio]phenyl]methyl]amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916807-97-1 HCAPLUS

CN Benzonitrile, 4-[[[3-(cyanophenyl)methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916807-98-2 HCAPLUS

CN Benzoic acid, 3-[[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]methyl]-, methyl ester (CA INDEX NAME)




RN 916807-99-3 HCAPLUS

CN Benzamide, 3-[[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]methyl]- (CA INDEX NAME)




RN 916808-00-9 HCAPLUS

CN Benzonitrile, 4-[[[(3-nitrophenyl)methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-01-0 HCAPLUS

CN Benzonitrile, 4-[[[(4-methylphenyl)methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-02-1 HCAPLUS

CN Benzonitrile, 4-[[[4-(1,1-dimethylethyl)phenyl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-03-2 HCAPLUS

CN Benzonitrile, 4-[(2,2,2-trifluoroethyl)[[4-(trifluoromethyl)phenyl]methyl]amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-04-3 HCAPLUS

CN Benzonitrile, 4-[[[4-(4-fluorophenyl)methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-05-4 HCAPLUS

CN Benzonitrile, 4-[[[4-(4-methoxyphenyl)methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-06-5 HCAPLUS

CN Benzonitrile, 4-[(2,2,2-trifluoroethyl)[[4-(trifluoromethoxy)phenyl]methyl]amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-07-6 HCAPLUS

CN Benzonitrile, 4-[[[4-(methylsulfonyl)phenyl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-08-7 HCAPLUS

CN Benzonitrile, 4-[[[4-(4-cyanophenyl)methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-09-8 HCAPLUS

CN Benzoic acid, 4-[[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]methyl]-, methyl ester (CA INDEX NAME)




RN 916808-10-1 HCAPLUS

CN Benzonitrile, 4-[[[4-(4-nitrophenyl)methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-11-2 HCAPLUS

CN Benzonitrile, 4-[[[3,5-dimethylphenyl)methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-12-3 HCAPLUS

CN Benzonitrile, 4-[[[3,5-bis(trifluoromethyl)phenyl)methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-13-4 HCAPLUS

CN Benzonitrile, 4-[[[3,5-dimethoxyphenyl)methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-14-5 HCAPLUS

CN Benzonitrile, 4-[[[3,5-dichlorophenyl)methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-15-6 HCAPLUS

CN Benzonitrile, 4-[[(3,5-difluorophenyl)methyl] (2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-16-7 HCAPLUS

CN Benzonitrile, 4-[[(2,6-difluorophenyl)methyl] (2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-17-8 HCAPLUS

CN Benzonitrile, 4-[[(2,4-difluorophenyl)methyl] (2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-18-9 HCAPLUS

CN Benzonitrile, 4-[[(3,4-difluorophenyl)methyl] (2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-19-0 HCAPLUS

CN Benzonitrile, 4-[[(2,3-difluorophenyl)methyl] (2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-20-3 HCAPLUS

CN Benzonitrile, 4-[[[3-fluoro-4-(trifluoromethyl)phenyl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-21-4 HCAPLUS

CN Benzonitrile, 4-[(2-naphthalenylmethyl)(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-22-5 HCAPLUS

CN Benzonitrile, 4-[(1-phenylethyl)(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-23-6 HCAPLUS

CN Benzonitrile, 4-[(3-furanylmethyl)(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-24-7 HCAPLUS

CN Benzonitrile, 4-[(2-furanylmethyl)(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-27-0 HCAPLUS

CN 2-Furancarboxonitrile, 5-[[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]methyl]- (CA INDEX NAME)




RN 916808-28-1 HCAPLUS

CN Benzonitrile, 4-[[[(5-methyl-2-furanyl)methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-29-2 HCAPLUS

CN Benzonitrile, 4-[(2,2,2-trifluoroethyl)[[5-(trifluoromethyl)-2-furanyl]methyl]amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-30-5 HCAPLUS

CN 2-Furanacetonitrile, 5-[[[4-cyano-3-(trifluoromethyl)phenyl] (2,2,2-trifluoroethyl)amino]methyl]- (CA INDEX NAME)




RN 916808-31-6 HCAPLUS

CN Benzonitrile, 4-[[[5-(methoxymethyl)-2-furanyl]methyl] (2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-32-7 HCAPLUS

CN Benzonitrile, 4-[[[5-[(2,2,2-trifluoroethoxy)methyl]-2-furanyl]methyl] (2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-33-8 HCAPLUS

CN Benzonitrile, 4-[[[5-[(methylthio)methyl]-2-furanyl]methyl] (2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-34-9 HCAPLUS

CN Benzonitrile, 4-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-35-0 HCAPLUS

CN Benzonitrile, 4-[[[5-(1H-imidazol-1-ylmethyl)-2-furanyl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-36-1 HCAPLUS

CN Benzonitrile, 4-[[[5-(1H-1,2,4-triazol-1-ylmethyl)-2-furanyl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-37-2 HCAPLUS

CN 2-Furanpropanenitrile, 5-[[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]methyl]- (CA INDEX NAME)




RN 916808-38-3 HCAPLUS

CN Benzonitrile, 4-[[[5-(3,5-difluorophenyl)-2-furanyl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-39-4 HCAPLUS

CN Benzonitrile, 4-[[[5-phenyl-2-furanyl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-40-7 HCAPLUS

CN Benzonitrile, 4-[[[5-(4-fluorophenyl)-2-furanyl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-41-8 HCAPLUS

CN Benzonitrile, 4-[[[5-(3,4-difluorophenyl)-2-furanyl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-42-9 HCAPLUS

CN Benzonitrile, 4-[[[5-(2,4-difluorophenyl)-2-furanyl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-43-0 HCAPLUS

CN Benzonitrile, 4-[(2,2,2-trifluoroethyl)[[5-[4-(trifluoromethoxy)phenyl]-2-furanyl]methyl]amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-44-1 HCAPLUS

CN Acetamide, N-[4-[5-[[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]methyl]-2-furanyl]phenyl]- (CA INDEX NAME)




RN 916808-45-2 HCAPLUS

CN Benzonitrile, 4-[[[5-(4-cyanophenyl)-2-furanyl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-46-3 HCAPLUS

CN Benzonitrile, 4-[[[5-[4-(methylsulfonyl)phenyl]-2-furanyl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-47-4 HCAPLUS

CN Benzonitrile, 4-[[[5-(3-cyanophenyl)-2-furanyl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-48-5 HCAPLUS

CN 2-Thiophenecarbonitrile, 5-[5-[[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]methyl]-2-furanyl]- (CA INDEX NAME)




RN 916808-49-6 HCAPLUS

CN Benzonitrile, 4-[[[5-(5-pyrimidinyl)-2-furanyl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-50-9 HCAPLUS

CN Benzonitrile, 4-[[[5-(3,5-dimethyl-4-isoxazolyl)-2-furanyl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-51-0 HCAPLUS

CN Benzonitrile, 4-[[[4-(4-cyanophenyl)-2-furanyl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-54-3 HCAPLUS

CN 3-Furancarbonitrile, 2-[[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]methyl]- (CA INDEX NAME)




RN 916808-55-4 HCAPLUS

CN Benzonitrile, 4-[[[3-(hydroxymethyl)-2-furanyl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-56-5 HCAPLUS

CN Benzonitrile, 4-[[(3-methyl-2-furanyl)methyl] (2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-57-6 HCAPLUS

CN Benzonitrile, 4-[(2-benzofuranylmethyl) (2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-59-8 HCAPLUS

CN Benzonitrile, 4-[(2-thienylmethyl) (2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-61-2 HCAPLUS

CN 2-Thiophenecarbonitrile, 5-[[[4-cyano-3-(trifluoromethyl)phenyl] (2,2,2-trifluoroethyl)amino]methyl]- (CA INDEX NAME)




RN 916808-62-3 HCAPLUS

CN Benzonitrile, 4-[[[5-(4-fluorophenyl)-2-thienyl]methyl] (2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-63-4 HCAPLUS

CN Benzonitrile, 4-[[[5-(4-cyanophenyl)-2-thienyl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-64-5 HCAPLUS

CN Benzonitrile, 4-[(3-thienylmethyl)(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-65-6 HCAPLUS

CN Benzonitrile, 4-[[[5-(5-chlorobenzo[b]thien-3-yl)methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-66-7 HCAPLUS

CN Benzonitrile, 4-[(1H-imidazol-2-ylmethyl)(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-68-9 HCAPLUS

CN Benzonitrile, 4-[(1H-imidazol-5-ylmethyl)(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-69-0 HCAPLUS

CN Benzonitrile, 4-[(2-oxazolylmethyl)(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-70-3 HCAPLUS

CN Benzonitrile, 4-[(4-oxazolylmethyl)(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-72-5 HCAPLUS

CN 4-Oxazolecarbonitrile, 2-[[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]methyl]- (CA INDEX NAME)




RN 916808-73-6 HCAPLUS

CN 5-Oxazolecarbonitrile, 2-[[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]methyl]- (CA INDEX NAME)




RN 916808-74-7 HCAPLUS

CN Benzonitrile, 4-[[[5-[(phenylmethoxy)methyl]-2-oxazolyl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-75-8 HCAPLUS

CN Benzonitrile, 4-[[[2-(4-fluorophenyl)-4-oxazolyl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-76-9 HCAPLUS

CN Benzonitrile, 4-[[[4-phenyl-2-oxazolyl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-77-0 HCAPLUS

CN 2-Oxazolecarbonitrile, 5-[[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]methyl]- (CA INDEX NAME)




RN 916808-78-1 HCAPLUS

CN Benzonitrile, 4-[[[2-(4-fluorophenyl)-5-oxazolyl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-79-2 HCAPLUS

CN Benzonitrile, 4-[[[5-(4-fluorophenyl)-2-oxazolyl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-80-5 HCAPLUS

CN Benzonitrile, 4-[(5-oxazolylmethyl)(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-81-6 HCAPLUS

CN Benzonitrile, 4-[(3,5-dimethyl-4-isoxazolyl)methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-82-7 HCAPLUS

CN Benzonitrile, 4-[(5-methyl-3-isoxazolyl)methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-83-8 HCAPLUS

CN Benzonitrile, 4-[(5-isoxazolylmethyl)(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-84-9 HCAPLUS

CN Benzonitrile, 4-[(cyclopropylmethyl)(4-thiazolylmethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 916808-85-0 HCAPLUS


CN Benzonitrile, 4-[(4-thiazolylmethyl)(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 916808-86-1 HCAPLUS


Serial No.:10/598,508

CN Benzonitrile, 4-[[[(2-methyl-4-thiazolyl)methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-87-2 HCAPLUS

CN Benzonitrile, 4-[[[(2-phenyl-4-thiazolyl)methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-88-3 HCAPLUS

CN Benzonitrile, 4-[(2,2,2-trifluoroethyl)[[2-[4-(trifluoromethyl)phenyl]-4-thiazolyl]methyl]amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-89-4 HCAPLUS

CN Benzonitrile, 4-[[[2-(2-thienyl)-4-thiazolyl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-90-7 HCAPLUS

CN Benzonitrile, 4-[(2-benzothiazolylmethyl)(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-91-8 HCAPLUS

CN Benzonitrile, 4-[(5-thiazolylmethyl)(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)





RN 916808-92-9 HCAPLUS

CN Benzonitrile, 4-[(2-thiazolylmethyl)(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-93-0 HCAPLUS

CN Benzonitrile, 4-[[1-(2-thiazolyl)ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-94-1 HCAPLUS

CN Benzonitrile, 2-chloro-4-[(4-thiazolylmethyl)(2,2,2-trifluoroethyl)amino]-
(CA INDEX NAME)




RN 916808-95-2 HCAPLUS

CN 1,2-Benzenedicarbonitrile, 4-[(cyclopropylmethyl)(4-thiazolylmethyl)amino]-
(CA INDEX NAME)



RN 916808-96-3 HCAPLUS


CN 1,2-Benzenedicarbonitrile, 4-[(4-thiazolylmethyl)(2,2,2-trifluoroethyl)amino]-
(CA INDEX NAME)



RN 916808-97-4 HCAPLUS


CN Benzonitrile, 4-[[[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)-
(CA INDEX NAME)

NAME)




RN 916808-98-5 HCAPLUS

CN Benzonitrile, 4-[[5-phenyl-1,2,4-oxadiazol-3-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916808-99-6 HCAPLUS

CN Benzonitrile, 4-[[[5-(2-methoxyphenyl)-1,2,4-oxadiazol-3-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 916809-00-2 HCAPLUS


CN Benzonitrile, 4-[(2,2,2-trifluoroethyl)[[5-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]methyl]amino]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 916809-01-3 HCAPLUS


CN 1-Piperidinesulfonamide, 4-[3-[[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-

trifluoroethyl)amino]methyl]-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)




RN 916809-02-4 HCAPLUS

CN Benzonitrile, 4-[(1,2,4-oxadiazol-3-ylmethyl)(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-03-5 HCAPLUS

CN Benzonitrile, 4-[[[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 916809-04-6 HCAPLUS

CN Benzonitrile, 4-[[[5-methyl-1,2,4-oxadiazol-3-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-05-7 HCAPLUS

CN Benzonitrile, 4-[[[5-(1-methylpropyl)-1,2,4-oxadiazol-3-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)


Serial No.:10/598,508

trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-06-8 HCAPLUS

CN Benzonitrile, 4-[(2,2,2-trifluoroethyl)[[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]methyl]amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-07-9 HCAPLUS

CN Benzonitrile, 4-[[[(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-08-0 HCAPLUS

CN Benzonitrile, 4-[[[5-(4-fluorophenyl)-1,2,4-oxadiazol-3-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-09-1 HCAPLUS

CN Benzonitrile, 4-[(2,2,2-trifluoroethyl)[[5-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-3-yl]methyl]amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-10-4 HCAPLUS

CN Benzonitrile, 4-[(2,2,2-trifluoroethyl)[[5-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]methyl]amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-11-5 HCAPLUS

CN Benzonitrile, 4-[(2,2,2-trifluoroethyl)[[5-[3-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-3-yl]methyl]amino]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 916809-12-6 HCAPLUS


CN Benzonitrile, 4-[[[5-(5-isoxazolyl)-1,2,4-oxadiazol-3-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 916809-13-7 HCAPLUS


CN Benzonitrile, 4-[[[5-(2-thienyl)-1,2,4-oxadiazol-3-yl]methyl](2,2,2-

trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-15-9 HCAPLUS

CN Benzonitrile, 4-[[[5-(3,5-dimethyl-4-isoxazolyl)-1,2,4-oxadiazol-3-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-20-6 HCAPLUS

CN Acetamide, N-[[[3-[[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]methyl]-1,2,4-oxadiazol-5-yl]methyl]- (CA INDEX NAME)




RN 916809-21-7 HCAPLUS

CN Methanesulfonamide, N-[[[3-[[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]methyl]-1,2,4-oxadiazol-5-yl]methyl]- (CA INDEX NAME)




RN 916809-22-8 HCAPLUS

CN Urea, N-[3-[[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]methyl]-1,2,4-oxadiazol-5-yl]methyl]- (CA INDEX NAME)




RN 916809-23-9 HCAPLUS

CN Urea, N-(aminocarbonyl)-N'-[3-[[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]methyl]-1,2,4-oxadiazol-5-yl]methyl]- (CA INDEX NAME)




RN 916809-24-0 HCAPLUS

CN Carbamic acid, N-[2-[3-[[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]methyl]-1,2,4-oxadiazol-5-yl]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 916809-25-1 HCAPLUS

CN Benzonitrile, 4-[[[5-(2-aminoethyl)-1,2,4-oxadiazol-3-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-26-2 HCAPLUS

CN Acetamide, N-[2-[3-[[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]methyl]-1,2,4-oxadiazol-5-yl]ethyl]- (CA INDEX NAME)




RN 916809-27-3 HCAPLUS

CN Methanesulfonamide, N-[2-[3-[[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]methyl]-1,2,4-oxadiazol-5-yl]ethyl]- (CA INDEX NAME)



RN 916809-28-4 HCAPLUS

CN Urea, N-[2-[3-[[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]methyl]-1,2,4-oxadiazol-5-yl]ethyl]- (CA INDEX NAME)




RN 916809-29-5 HCAPLUS

CN Urea, N-(aminocarbonyl)-N'-[2-[3-[[[4-cyano-3-


Serial No.:10/598,508

(trifluoromethyl)phenyl] (2,2,2-trifluoroethyl amino)methyl]-1,2,4-oxadiazol-5-yl]ethyl]- (CA INDEX NAME)




RN 916809-30-8 HCAPLUS

CN Benzonitrile, 4-[[[5-(1-acetyl-4-piperidiny)-1,2,4-oxadiazol-3-yl]methyl] (2,2,2-trifluoroethyl amino)-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-31-9 HCAPLUS

CN Benzonitrile, 4-[[[5-[1-(5-isoxazolylcarbonyl)-4-piperidiny]-1,2,4-oxadiazol-3-yl]methyl] (2,2,2-trifluoroethyl amino)-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-32-0 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-[[[4-cyano-3-(trifluoromethyl)phenyl] (2,2,2-trifluoroethyl amino)methyl]-1,2,4-oxadiazol-5-yl]-, methyl ester (CA INDEX NAME)




RN 916809-33-1 HCAPLUS

CN 1-Piperidinecarboxamide, 4-[3-[[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]methyl]-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)




RN 916809-34-2 HCAPLUS

CN 1-Piperidinecarboxamide, 4-[3-[[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]methyl]-1,2,4-oxadiazol-5-yl]-N-methyl- (CA INDEX NAME)




RN 916809-35-3 HCAPLUS

CN Benzonitrile, 4-[[[5-[1-(methylsulfonyl)-4-piperidiny]-1,2,4-oxadiazol-3-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-36-4 HCAPLUS

CN Benzonitrile, 4-[[[5-(1-methyl-4-piperidiny)-1,2,4-oxadiazol-3-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-39-7 HCAPLUS

CN Benzonitrile, 4-[[[5-(1-acetyl-3-piperidiny1)-1,2,4-oxadiazol-3-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-40-0 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-[[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]methyl]-1,2,4-oxadiazol-5-yl]-, methyl ester (CA INDEX NAME)




RN 916809-41-1 HCAPLUS

CN 1-Piperidinecarboxamide, 3-[3-[[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]methyl]-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)




RN 916809-42-2 HCAPLUS

CN 1-Piperidinecarboxamide, 3-[3-[[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]methyl]-1,2,4-oxadiazol-5-yl]-N-methyl- (CA INDEX NAME)




RN 916809-43-3 HCAPLUS

CN Benzonitrile, 4-[[[5-[1-(methylsulfonyl)-3-piperidiny]l]-1,2,4-oxadiazol-3-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-44-4 HCAPLUS

CN Benzonitrile, 4-[[[5-benzoyl-1,2,4-oxadiazol-3-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 916809-46-6 HCAPLUS


CN Benzonitrile, 4-[[[5-(2-furanylcarbonyl)-1,2,4-oxadiazol-3-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 916809-50-2 HCAPLUS


Serial No.:10/598,508

CN Benzonitrile, 4-[[[5-(2-pyridinyl)-1,2,4-oxadiazol-3-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-51-3 HCAPLUS

CN Benzonitrile, 4-[[[5-(cyclopropylmethyl)-1,2,4-oxadiazol-3-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-53-5 HCAPLUS

CN Benzonitrile, 4-[(2,2,2-trifluoroethyl)[[5-(2,2,2-trifluoroethyl)-1,2,4-oxadiazol-3-yl]methyl]amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-54-6 HCAPLUS


CN Benzonitrile, 4-[[[5-[(dimethylamino)methyl]-1,2,4-oxadiazol-3-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-57-9 HCAPLUS
 CN Benzonitrile, 4-[(2,2,2-trifluoroethyl)[[5-[6-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]methyl]amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-60-4 HCAPLUS
 CN Benzonitrile, 4-[[[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 916809-63-7 HCAPLUS
 CN Benzonitrile, 4-[[[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-65-9 HCAPLUS
 CN Benzonitrile, 4-[[[3-phenyl-1,2,4-oxadiazol-5-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)



Serial No.:10/598,508


RN 916809-68-2 HCAPLUS

CN Benzonitrile, 4-[(2,2,2-trifluoroethyl)[[3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]methyl]amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-71-7 HCAPLUS

CN Benzonitrile, 4-[(2,2,2-trifluoroethyl)[[3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl]methyl]amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-72-8 HCAPLUS

CN Benzonitrile, 4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1,2,4-oxadiazol-5-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 916809-73-9 HCAPLUS


CN Benzonitrile, 4-[(2,2,2-trifluoroethyl)[[3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]methyl]amino]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 916809-74-0 HCAPLUS


Serial No.:10/598,508

CN Benzonitrile, 4-[[[3-(3-pyridinyl)-1,2,4-oxadiazol-5-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-75-1 HCAPLUS

CN Benzonitrile, 4-[[[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-76-2 HCAPLUS

CN Benzonitrile, 4-[[[3-(3-nitrophenyl)-1,2,4-oxadiazol-5-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 916809-77-3 HCAPLUS


CN Benzonitrile, 4-[[[3-[[[4-(4-fluorophenyl)sulfonyl]methyl]-1,2,4-oxadiazol-5-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 916809-78-4 HCAPLUS


CN Benzonitrile, 4-[(2,2,2-trifluoroethyl)[[3-[6-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-5-yl]methyl]amino]-2-(trifluoromethyl)- (CA INDEX NAME)

INDEX NAME)




RN 916809-79-5 HCAPLUS

CN Benzonitrile, 4-[[[3-(2,4-dichlorophenyl)-1,2,4-oxadiazol-5-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-80-8 HCAPLUS

CN Benzonitrile, 4-[[[3-(2,3-dichlorophenyl)-1,2,4-oxadiazol-5-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-81-9 HCAPLUS

CN Benzonitrile, 4-[[[5-(4-methylphenyl)-1,3,4-oxadiazol-2-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-82-0 HCAPLUS

CN Benzonitrile, 4-[[[5-(2-pyridinyl)-1,3,4-oxadiazol-2-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-84-2 HCAPLUS

CN Benzonitrile, 4-[[[5-(2-chloro-4-pyridinyl)-1,3,4-oxadiazol-2-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 916809-85-3 HCAPLUS

CN Benzonitrile, 4-[[[5-(6-chloro-3-pyridinyl)-1,3,4-oxadiazol-2-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-86-4 HCAPLUS

CN Benzonitrile, 4-[(2,2,2-trifluoroethyl)[[5-[6-(trifluoromethyl)-3-


Serial No.:10/598,508

pyridinyl]-1,3,4-oxadiazol-2-yl)methyl]amino]-2-(trifluoromethyl)- (CA
INDEX NAME)




RN 916809-87-5 HCAPLUS

CN Benzonitrile, 4-[[[5-(6-chloro-2-pyridinyl)-1,3,4-oxadiazol-2-yl)methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX
NAME)




RN 916809-88-6 HCAPLUS

CN Benzonitrile, 4-[[[5-(6-fluoro-2-pyridinyl)-1,3,4-oxadiazol-2-yl)methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX
NAME)




RN 916809-90-0 HCAPLUS

CN Benzonitrile, 4-[[[5-(3-methylphenyl)-1,3,4-oxadiazol-2-yl)methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-91-1 HCAPLUS

CN Benzonitrile, 4-[[[5-(3-pyridinyl)-1,3,4-oxadiazol-2-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-92-2 HCAPLUS

CN Benzonitrile, 4-[[[5-(phenyl)-1,3,4-oxadiazol-2-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-93-3 HCAPLUS

CN Benzonitrile, 4-[[[5-(2-furanyl)-1,3,4-oxadiazol-2-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-94-4 HCAPLUS

CN Benzonitrile, 4-[[[5-(3-furanyl)-1,3,4-oxadiazol-2-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-95-5 HCAPLUS

CN Benzonitrile, 4-[[[5-(4-pyridinyl)-1,3,4-oxadiazol-2-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-96-6 HCAPLUS

CN Benzonitrile, 4-[[[5-[4-(dimethylamino)phenyl]-1,3,4-oxadiazol-2-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-97-7 HCAPLUS

CN Benzonitrile, 4-[[[5-(1,3-benzodioxol-5-yl)-1,3,4-oxadiazol-2-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916809-98-8 HCAPLUS

CN Benzonitrile, 4-[[[5-(3-thienyl)-1,3,4-oxadiazol-2-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916810-01-0 HCAPLUS

CN Acetamide, N-[4-[5-[[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]methyl]-1,3,4-oxadiazol-2-yl]phenyl]- (CA INDEX NAME)




RN 916810-02-1 HCAPLUS

CN Benzonitrile, 4-[[[5-(2-methylphenyl)-1,3,4-oxadiazol-2-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916810-03-2 HCAPLUS

CN Benzonitrile, 4-[[[5-(3-fluorophenyl)-1,3,4-oxadiazol-2-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916810-04-3 HCAPLUS

CN Benzonitrile, 4-[[[5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916810-06-5 HCAPLUS

CN Benzonitrile, 4-[[[5-[4-(methoxymethyl)phenyl]-1,3,4-oxadiazol-2-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916810-07-6 HCAPLUS

CN Benzonitrile, 4-[[[5-[4-(methylsulfonyl)phenyl]-1,3,4-oxadiazol-2-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916810-08-7 HCAPLUS

CN Benzonitrile, 4-[[[5-(5-bromo-2-furanyl)-1,3,4-oxadiazol-2-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916810-09-8 HCAPLUS

CN Benzonitrile, 4-[(2,2,2-trifluoroethyl)[[5-[4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2-yl]methyl]amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916810-10-1 HCAPLUS

CN Benzonitrile, 4-[[[5-(3,4-difluorophenyl)-1,3,4-oxadiazol-2-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916810-11-2 HCAPLUS

CN Carbamic acid, N-[[[5-[[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]methyl]-1,3,4-oxadiazol-2-yl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 916810-12-3 HCAPLUS

CN Benzonitrile, 4-[[[5-(3,5-difluorophenyl)-1,3,4-oxadiazol-2-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916810-13-4 HCAPLUS

CN Benzonitrile, 4-[[[5-(6-bromo-2-pyridinyl)-1,3,4-oxadiazol-2-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916810-14-5 HCAPLUS


CN Benzonitrile, 4-[[[5-(2,4-difluorophenyl)-1,3,4-oxadiazol-2-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916810-15-6 HCAPLUS
 CN Benzonitrile, 4-[(2,2,2-trifluoroethyl)[[5-[2-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-yl]methyl]amino]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 916810-16-7 HCAPLUS
 CN Benzonitrile, 4-[(2,2,2-trifluoroethyl)[[5-[3-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-yl]methyl]amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916810-17-8 HCAPLUS
 CN Benzonitrile, 4-[[[5-(2-fluorophenyl)-1,3,4-oxadiazol-2-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916810-18-9 HCAPLUS

CN Benzonitrile, 4-[(2,2,2-trifluoroethyl)[[5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-yl]methyl]amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916810-19-0 HCAPLUS

CN Benzonitrile, 4-[[[5-(2-chloro-6-methoxy-4-pyridinyl)-1,3,4-oxadiazol-2-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916810-20-3 HCAPLUS

CN Benzonitrile, 4-[[[5-(1,3-dimethyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol-2-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916810-21-4 HCAPLUS

CN Benzonitrile, 4-[[[5-(2-pyrazinyl)-1,3,4-oxadiazol-2-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916810-22-5 HCAPLUS

CN Benzonitrile, 4-[[[5-(5-pyrimidinyl)-1,3,4-oxadiazol-2-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916810-23-6 HCAPLUS

CN Benzonitrile, 4-[[[5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916810-25-8 HCAPLUS

CN Benzonitrile, 4-[[[4,5-dihydro-4-methyl-5-oxo-1,3,4-oxadiazol-2-yl)methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916810-26-9 HCAPLUS

CN Benzonitrile, 4-[[[5-(dimethylamino)-1,3,4-oxadiazol-2-yl)methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916810-27-0 HCAPLUS

CN Benzonitrile, 4-[[[5-(4-morpholinyl)-1,3,4-oxadiazol-2-yl)methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916810-28-1 HCAPLUS

CN Benzonitrile, 4-[[[5-(1-piperidinyl)-1,3,4-oxadiazol-2-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916810-29-2 HCAPLUS

CN Benzonitrile, 4-[[[5-(1-piperidinyl)-1,3,4-oxadiazol-2-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916810-30-5 HCAPLUS

CN Benzonitrile, 2-chloro-4-[(cyclopropylmethyl)[[5-(2-pyridinyl)-1,3,4-oxadiazol-2-yl]methyl]amino]- (CA INDEX NAME)




RN 916810-31-6 HCAPLUS

CN Benzonitrile, 2-chloro-4-[[[5-(2-pyridinyl)-1,3,4-oxadiazol-2-yl]methyl](2,2,2-trifluoroethyl)amino]- (CA INDEX NAME)




RN 916810-32-7 HCAPLUS

CN 1,2-Benzenedicarbonitrile, 4-[(cyclopropylmethyl)[[5-(2-pyridinyl)-1,3,4-oxadiazol-2-yl]methyl]amino]- (CA INDEX NAME)




RN 916810-33-8 HCAPLUS

CN Benzonitrile, 4-[[[5-(2-pyridinyl)-1H-1,2,4-triazol-3-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916810-34-9 HCAPLUS

CN Benzonitrile, 4-[[[3-(5-bromo-3-pyridinyl)-1H-1,2,4-triazol-5-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916810-36-1 HCAPLUS

CN Benzonitrile, 4-[[[3-(4-fluorophenyl)-1H-1,2,4-triazol-5-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 916810-37-2 HCAPLUS

CN Benzonitrile, 4-[[[2-methyl-2H-tetrazol-5-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




IT 864283-46-5P 864283-47-6P 864283-48-7P
 864284-35-5P 864284-74-2P 864284-76-4P
 864285-03-0P 864285-05-2P 864285-65-4P
 864285-67-6P 916810-42-9P 916810-43-0P
 916810-44-1P 916810-45-2P 916810-46-3P
 916810-47-4P 916810-48-5P 916810-49-6P
 916810-50-9P 916810-53-2P 916810-58-7P
 916810-72-5P 916810-73-6P 916810-74-7P
 916810-75-8P 916810-76-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of nonsteroidal tertiary arylamines as modulators of androgen, glucocorticoid, mineralocorticoid and progesterone receptors useful in therapy)


RN 864283-46-5 HCAPLUS

CN Glycine, N-[4-cyano-3-(trifluoromethyl)phenyl]-N-(2,2,2-trifluoroethyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864283-47-6 HCAPLUS

CN Glycine, N-[4-cyano-3-(trifluoromethyl)phenyl]-N-(2,2,2-trifluoroethyl)-
(CA INDEX NAME)




RN 864283-48-7 HCAPLUS

CN Acetamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl]-(2,2,2-trifluoroethyl)amino]- (CA INDEX NAME)




RN 864284-35-5 HCAPLUS

CN Benzonitrile, 4-[(cyanomethyl)-(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 864284-74-2 HCAPLUS

CN Glycine, N-(3-chloro-4-cyanophenyl)-N-(2,2,2-trifluoroethyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864284-76-4 HCAPLUS

CN Glycine, N-(3-chloro-4-cyanophenyl)-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 864285-03-0 HCAPLUS

CN Glycine, N-(3-chloro-4-cyanophenyl)-N-(cyclopropylmethyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864285-05-2 HCAPLUS

CN Glycine, N-(3-chloro-4-cyanophenyl)-N-(cyclopropylmethyl)- (CA INDEX NAME)




RN 864285-65-4 HCAPLUS

CN Glycine, N-(cyclopropylmethyl)-N-(3,4-dicyanophenyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864285-67-6 HCAPLUS

CN Glycine, N-(cyclopropylmethyl)-N-(3,4-dicyanophenyl)- (CA INDEX NAME)




RN 916810-42-9 HCAPLUS

CN 2-Furancarboxylic acid, 5-[[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]methyl]- (CA INDEX NAME)




RN 916810-43-0 HCAPLUS

CN Benzonitrile, 4-[[[5-(hydroxymethyl)-2-furanyl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916810-44-1 HCAPLUS

CN Benzonitrile, 4-[[[5-[(acetyloxy)methyl]-2-furanyl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916810-45-2 HCAPLUS

CN Benzonitrile, 4-[[[5-(chloromethyl)-2-furanyl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916810-46-3 HCAPLUS

CN Benzonitrile, 4-[[[5-(formyl-2-furanyl)methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916810-47-4 HCAPLUS

CN Benzonitrile, 4-[[[5-(2-cyanoethenyl)-2-furanyl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916810-48-5 HCAPLUS

CN Benzonitrile, 4-[[[5-(5-bromo-2-furanyl)methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)





RN 916810-49-6 HCAPLUS

CN Benzonitrile, 4-[[(4-bromo-2-furanyl)methyl] (2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916810-50-9 HCAPLUS

CN Benzonitrile, 4-[[[1-(phenylmethyl)-1H-imidazol-2-yl]methyl] (2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916810-53-2 HCAPLUS

CN 4-Oxazolecarboxylic acid, 2-[[[4-cyano-3-(trifluoromethyl)phenyl] (2,2,2-trifluoroethyl)amino]methyl]-, methyl ester (CA INDEX NAME)




RN 916810-58-7 HCAPLUS

CN Benzonitrile, 4-[[[5-(hydroxymethyl)-2-oxazolyl]methyl] (2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 916810-72-5 HCAPLUS

CN Ethanimidamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-N-hydroxy- (CA INDEX NAME)




RN 916810-73-6 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-[[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]methyl]-1,2,4-oxadiazol-5-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 916810-74-7 HCAPLUS


CN Benzonitrile, 4-[[[5-(4-piperidinyl)-1,2,4-oxadiazol-3-yl]methyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 916810-75-8 HCAPLUS


CN Carbamic acid, N-[[4-[3-[[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]methyl]-1,2,4-oxadiazol-5-yl]-1-piperidinyl]sulfonyl]-

, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 916810-76-9 HCAPLUS

CN Acetic acid, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-, hydrazide (CA INDEX NAME)




IT 916810-77-0

RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of nonsteroidal tertiary arylamines as modulators of androgen, glucocorticoid, mineralocorticoid and progesterone receptors useful in therapy)

RN 916810-77-0 HCAPLUS

CN Benzonitrile, 4-[(2H-tetrazol-5-ylmethyl)(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)



L41 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:383697 HCAPLUS Full-text

DOCUMENT NUMBER: 144:432552

TITLE: Preparation of substituted anilines as selective androgen receptor modulators

INVENTOR(S): Turnbull, Philip Stewart; Larkin, Andrew Lamont; Kaldor, Istvan; Cadilla, Rodolfo; Cowan, David John; Stewart, Eugene Lee

PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 134 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent



LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006044707	A1	20060427	WO 2005-US37094	20051013
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM EP 1809275 A1 20070725 EP 2005-812180 20051013 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR JP 2008515998 T 20080515 JP 2007-536962 20051013 PRIORITY APPLN. INFO.: US 2004-618480P P 20041013 WO 2005-US37094 W 20051013 OTHER SOURCE(S): CASREACT 144:432552; MARPAT 144:432552 ED Entered STN: 27 Apr 2006 GI				




AB This invention relates to non-steroidal compds. I [R₁ = CN or NO₂; R₂ = independently CN, NO₂, halo, etc.; R₃ = H, (cyclo)alkyl, alkoxycarbonylalkyl, etc.; R₄, R₅ = independently H, (cyclo)alkyl, halo, etc., or R₄R₅ = (un)substituted (hetero)cyclyl; Y = (un)substituted methylene(oxy), methylenethio, carbonylamino, etc.; A = (hetero)aryl or heterocyclyl; m = 0-2; n = 0-5; R₆ = independently (halo)alkyl, halo, hydroxy, etc.] which are or are believed to be modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of such compds. For example, II was provided in a multi-step synthesis starting from the reaction of 4-fluoro-2-(trifluoromethyl)benzonitrile with 1-

cyclopropylmethanamine. The compds. I are claimed to be useful in the treatment or prophylaxis of conditions or disorders that respond to selective androgen receptor modulation (no data given).


- IT 884854-00-6P, 1,1-Dimethylethyl [4-[[2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]ethyl]oxy]phenyl]carbamate 884854-06-2P, Methyl 4-[[2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]ethyl]oxy]benzoate 884854-07-3P, 4-[[2-[[4-Cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]ethyl]oxy]benzoic acid 884854-14-2P, 4-[[2-[[4-(Trifluoroacetyl)phenyl]oxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 884854-57-3P, 4-[[2-(Phenylthio)ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 884854-58-4P, N-[4-[[2-[[4-Cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]ethyl]thio]phenyl]acetamide 884854-66-4P, 4-[[2-[[4-(Pyrimidin-2-yl)amino]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile
- RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
- (preparation of substituted aniline derivs. as selective androgen receptor modulators)
- RN 884854-00-6 HCAPLUS
- CN Carbamic acid, [4-[2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]ethoxy]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



- RN 884854-06-2 HCAPLUS
- CN Benzoic acid, 4-[2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]ethoxy]-, methyl ester (CA INDEX NAME)




- RN 884854-07-3 HCAPLUS
- CN Benzoic acid, 4-[2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]ethoxy]- (CA INDEX NAME)




RN 884854-14-2 HCAPLUS

CN Benzonitrile, 4-[[2-[4-(2,2,2-trifluoroacetyl)phenoxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884854-57-3 HCAPLUS

CN Benzonitrile, 4-[[2-(phenylthio)ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884854-58-4 HCAPLUS

CN Acetamide, N-[4-[[2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]ethyl]thio]phenyl]- (CA INDEX NAME)



RN 884854-66-4 HCAPLUS

CN Benzonitrile, 4-[[2-(2-pyrimidinylamino)ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)



IT 884853-73-0P, 4-[(Cyclopropylmethyl)[2-[[4-(1,1-dimethylethyl)phenyl]oxy]ethyl]amino]-2-(trifluoromethyl)benzonitrile

884853-74-1P, N-[4-[[2-[[4-Cyano-3-(trifluoromethyl)phenyl](cyclopropylmethyl)amino]ethyl]oxy]phenyl]acetamide 884853-75-2P,
 4-[(Cyclopropylmethyl)[2-[[4-(methyloxy)phenyl]oxy]ethyl]amino]-2-(trifluoromethyl)benzonitrile 884853-76-3P, 4-
 [(Cyclopropylmethyl)[2-[[4-fluorophenyl]oxy]ethyl]amino]-2-(trifluoromethyl)benzonitrile 884853-77-4P, 4-
 [(Cyclopropylmethyl)[2-[[4-(hydroxymethyl)phenyl]oxy]ethyl]amino]-2-(trifluoromethyl)benzonitrile 884853-78-5P, N-[4-[[3-[[4-Cyano-3-(trifluoromethyl)phenyl](cyclopropylmethyl)amino]propyl]oxy]phenyl]acetamide 884853-80-9P, 4-[(Cyclopropylmethyl)[3-[[4-(1,1-dimethylethyl)phenyl]oxy]propyl]amino]-2-(trifluoromethyl)benzonitrile 884853-81-0P, 4-[(Cyclopropylmethyl)[3-[[4-(methyloxy)phenyl]oxy]propyl]amino]-2-(trifluoromethyl)benzonitrile 884853-82-1P, 4-[(Cyclopropylmethyl)[3-[[4-fluorophenyl]oxy]propyl]amino]-2-(trifluoromethyl)benzonitrile 884853-83-2P, 4-[(Cyclopropylmethyl)[3-[[4-(hydroxymethyl)phenyl]oxy]propyl]amino]-2-(trifluoromethyl)benzonitrile 884853-84-3P, N-[4-[[3-[[4-Cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]propyl]oxy]phenyl]acetamide 884853-85-4P, 4-[[3-[[4-(1,1-Dimethylethyl)phenyl]oxy]propyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 884853-86-5P, 4-[[3-[[4-Fluorophenyl]oxy]propyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 884853-87-6P, 4-[[3-[[4-(Methyloxy)phenyl]oxy]propyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 884853-88-7P, 4-[[2-[[4-[[2-(1-Piperidinyl)ethyl]oxy]phenyl]oxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 884853-89-8P, 4-[[2-[[4-(Methyloxy)phenyl]oxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 884853-90-1P, N-[4-[[2-[[4-Cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]ethyl]oxy]phenyl]acetamide 884853-91-2P, 4-[[2-[[4-Cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]ethyl]oxy]benzenesulfonamide 884853-92-3P, 4-[[2-[[4-Cyanophenyl]oxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 884853-93-4P, 4-[[2-[[4-Fluorophenyl]oxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 884853-94-5P, 4-[[2-[[4-(3-Oxobutyl)phenyl]oxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 884853-95-6P, 4-[[2-[[1H-Indol-5-yl]oxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 884853-96-7P, 4-[[2-[[3-Fluorophenyl]oxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 884853-97-8P, 4-[[2-[[4-Acetylphenyl]oxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 884853-98-9P, 4-[[2-[[4-(2-Oxopropyl)phenyl]oxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 884853-99-0P, N-[3-[[2-[[4-Cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]ethyl]oxy]phenyl]acetamide 884854-01-7P, N-[4-[[2-[[4-Cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]ethyl]oxy]phenyl]methanesulfonamide 884854-03-9P, 1-[4-[[2-[[4-Cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]ethyl]oxy]phenyl]urea 884854-04-0P, 4-[[2-[[4-(Methylsulfonyl)phenyl]oxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 884854-05-1P, 4-[[2,2,2-Trifluoroethyl][2-[[4-(trifluoromethyl)phenyl]oxy]ethyl]amino]-2-(trifluoromethyl)benzonitrile 884854-08-4P, 4-[[2-[[4-Cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]ethyl]oxy]benzamide 884854-09-5P, 1,1-Dimethylethyl [[4-[[2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]ethyl]oxy]phenyl]methyl]carbamate 884854-12-0P, N-[4-[[2-[[4-Cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]ethyl]oxy]phenyl]guanidine trifluoroacetate

884854-15-3P, 4-[(2,2,2-Trifluoroethyl)[2-[[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]oxy]ethyl]amino]-2-(trifluoromethyl)benzonitrile 884854-16-4P, 4-[[2-[[4-(2-Oxo-1-pyrrolidinyl)phenyl]oxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 884854-17-5P, 4-[[2-[[4-(1,3-Thiazol-2-yl)phenyl]oxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 884854-19-7P, 4-[[2-[[4-(1,3-Oxazol-2-yl)phenyl]oxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 884854-20-0P, 4-[[2-[(2-Oxo-1,2,3,4-tetrahydro-6-quinolinyl)oxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 884854-21-1P, 4-[[2-(2-Pyridinyloxy)ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 884854-22-2P, 4-[[2-(3-Pyridinyloxy)ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 884854-23-3P, 4-[[2-(4-Pyridinyloxy)ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 884854-24-4P, 4-[(2,2,2-Trifluoroethyl)[2-[[5-(trifluoromethyl)-2-pyridinyl]oxy]ethyl]amino]-2-(trifluoromethyl)benzonitrile 884854-25-5P, 4-[[2-[(5-Methyl-2-pyridinyl)oxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 884854-26-6P, 4-[[2-[(6-Chloro-3-pyridinyl)oxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 884854-27-7P, 4-[[2-[(6-Methyl-3-pyridinyl)oxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 884854-28-8P, 4-[[2-[(5-Bromo-2-pyridinyl)oxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 884854-29-9P, 4-[[2-[(6-Fluoro-3-pyridinyl)oxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 884854-30-2P, 4-[[2-[(5-Fluoro-2-pyridinyl)oxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 884854-31-3P, N-[6-[[2-[[4-Cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]ethyl]oxy]-3-pyridinyl]acetamide 884854-33-5P 884854-36-8P, 4-[[2-(3-Pyridazinyloxy)ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 884854-37-9P, 4-[[2-(4-Pyrimidinyloxy)ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 884854-60-8P, N-[4-[[2-[[4-Cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]ethyl]thio]phenyl]-N-methylacetamide 884854-61-9P, 4-[[2-(Phenylsulfinyl)ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 884854-62-0P, N-[4-[[2-[[4-Cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]ethyl]sulfinyl]phenyl]acetamide 884854-63-1P, 4-[[2-(Phenylsulfonyl)ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 884854-64-2P, N-[4-[[2-[[4-Cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]ethyl]sulfonyl]phenyl]acetamide 884854-65-3P, N-[4-[[2-[[4-Cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]ethyl]thio]phenyl]methanesulfonamide 884854-67-5P, 4-[[2-[Methyl(pyrimidin-2-yl)amino]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 884854-68-6P, N-[2-[[4-Cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]ethyl]benzamide 884854-69-7P, 4-[[3-(4-Fluorophenyl)propyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 884854-71-1P, N-[4-[3-[[4-Cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]propyl]phenyl]acetamide 884854-72-2P, 4-[[3-Phenylpropyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 884854-74-4P 884854-88-0P 884854-89-1P 884854-90-4P 884854-91-5P 884854-92-6P 884854-93-7P 884854-96-0P 884854-97-1P 884854-98-2P 884854-99-3P,

Serial No.:10/598,508


2-[[4-Cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-N-phenylbutanamide 884855-00-9P, 2-[[4-Cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-N-(4-fluorophenyl)butanamide 884855-01-0P, 4-[[2-(1H-1,2,4-Triazol-1-yl)ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 884855-07-6P 884855-11-2P 884856-05-7P 884856-06-8P 884856-07-9P 884856-08-0P 885050-04-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted aniline derivs. as selective androgen receptor modulators)


RN 884853-73-0 HCAPLUS

CN Benzonitrile, 4-[(cyclopropylmethyl)[2-[4-(1,1-dimethylethyl)phenoxy]ethyl]amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884853-74-1 HCAPLUS

CN Acetamide, N-[4-[2-[4-cyano-3-(trifluoromethyl)phenyl](cyclopropylmethyl)amino]ethoxy]phenyl]- (CA INDEX NAME)




RN 884853-75-2 HCAPLUS

CN Benzonitrile, 4-[(cyclopropylmethyl)[2-(4-methoxyphenoxy)ethyl]amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884853-76-3 HCAPLUS

CN Benzonitrile, 4-[(cyclopropylmethyl)[2-(4-fluorophenoxy)ethyl]amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884853-77-4 HCAPLUS

CN Benzonitrile, 4-[(cyclopropylmethyl)[2-[4-(hydroxymethyl)phenoxy]ethyl]amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884853-78-5 HCAPLUS

CN Acetamide, N-[4-[3-[[4-cyano-3-(trifluoromethyl)phenyl](cyclopropylmethyl)amino]propoxy]phenyl]- (CA INDEX NAME)




RN 884853-80-9 HCAPLUS

CN Benzonitrile, 4-[(cyclopropylmethyl)[3-[4-(1,1-dimethylethyl)phenoxy]propyl]amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884853-81-0 HCAPLUS

CN Benzonitrile, 4-[(cyclopropylmethyl)[3-(4-methoxyphenoxy)propyl]amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884853-82-1 HCAPLUS

CN Benzonitrile, 4-[(cyclopropylmethyl)[3-(4-fluorophenoxy)propyl]amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884853-83-2 HCAPLUS

CN Benzonitrile, 4-[(cyclopropylmethyl)[3-[4-(hydroxymethyl)phenoxy]propyl]amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884853-84-3 HCAPLUS

CN Acetamide, N-[4-[3-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]propoxy]phenyl]- (CA INDEX NAME)




RN 884853-85-4 HCAPLUS

CN Benzonitrile, 4-[[3-[4-(1,1-dimethylethyl)phenoxy]propyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884853-86-5 HCAPLUS

CN Benzonitrile, 4-[[3-(4-fluorophenoxy)propyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884853-87-6 HCAPLUS

CN Benzonitrile, 4-[[3-(4-methoxyphenoxy)propyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884853-88-7 HCAPLUS

CN Benzonitrile, 4-[[2-[4-[2-(1-piperidinyl)ethoxy]phenoxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884853-89-8 HCAPLUS

CN Benzonitrile, 4-[[2-(4-methoxyphenoxy)ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884853-90-1 HCAPLUS

CN Acetamide, N-[4-[2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]ethoxy]phenyl]- (CA INDEX NAME)




RN 884853-91-2 HCAPLUS

CN Benzenesulfonamide, 4-[2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]ethoxy]- (CA INDEX NAME)




RN 884853-92-3 HCAPLUS

CN Benzonitrile, 4-[[2-(4-cyanophenoxy)ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884853-93-4 HCAPLUS

CN Benzonitrile, 4-[[2-(4-fluorophenoxy)ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884853-94-5 HCAPLUS

CN Benzonitrile, 4-[[2-[2-(4-(3-oxobutyl)phenoxy)ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884853-95-6 HCAPLUS

CN Benzonitrile, 4-[[2-(1H-indol-5-yloxy)ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884853-96-7 HCAPLUS

CN Benzonitrile, 4-[[2-(3-fluorophenoxy)ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884853-97-8 HCAPLUS

CN Benzonitrile, 4-[[2-(4-acetylphenoxy)ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884853-98-9 HCAPLUS

CN Benzonitrile, 4-[[2-[4-(2-oxopropyl)phenoxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884853-99-0 HCAPLUS

CN Acetamide, N-[3-[2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]ethoxy]phenyl]- (CA INDEX NAME)




RN 884854-01-7 HCAPLUS

CN Methanesulfonamide, N-[4-[2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]ethoxy]phenyl]- (CA INDEX NAME)




RN 884854-03-9 HCAPLUS

CN Urea, N-[4-[2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]ethoxy]phenyl]- (CA INDEX NAME)




RN 884854-04-0 HCAPLUS

CN Benzonitrile, 4-[[2-[4-(methanesulfonyl)phenoxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884854-05-1 HCAPLUS

CN Benzonitrile, 4-[[2-[4-(trifluoromethyl)phenoxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884854-08-4 HCAPLUS

CN Benzonitrile, 4-[[2-[4-(trifluoromethyl)phenoxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 884854-09-5 HCAPLUS


CN Carbamic acid, [[4-[2-[4-(trifluoromethyl)phenoxy]ethyl](2,2,2-trifluoroethyl)amino]ethoxy]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 884854-12-0 HCAPLUS
 CN Guanidine, N-[4-[2-[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]ethoxy]phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 884854-11-9
 CMF C19 H17 F6 N5 O




CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 884854-15-3 HCAPLUS
 CN Benzonitrile, 4-[(2,2,2-trifluoroethyl)[2-[4-(2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenoxy]ethyl]amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884854-16-4 HCAPLUS
 CN Benzonitrile, 4-[[2-[4-(2-oxo-1-pyrrolidinyl)phenoxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884854-17-5 HCAPLUS

CN Benzonitrile, 4-[[2-[4-(2-thiazolyl)phenoxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884854-19-7 HCAPLUS

CN Benzonitrile, 4-[[2-[4-(2-oxazolyl)phenoxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884854-20-0 HCAPLUS

CN Benzonitrile, 4-[[2-[(1,2,3,4-tetrahydro-2-oxo-6-quinolinyl)oxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884854-21-1 HCAPLUS

CN Benzonitrile, 4-[[2-(2-pyridinyloxy)ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884854-22-2 HCAPLUS

CN Benzonitrile, 4-[[2-(3-pyridinyloxy)ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884854-23-3 HCAPLUS

CN Benzonitrile, 4-[[2-(4-pyridinyloxy)ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884854-24-4 HCAPLUS

CN Benzonitrile, 4-[(2,2,2-trifluoroethyl)[2-[[5-(trifluoromethyl)-2-pyridinyl]oxy]ethyl]amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884854-25-5 HCAPLUS

CN Benzonitrile, 4-[[2-[(5-methyl-2-pyridinyl)oxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884854-26-6 HCAPLUS

CN Benzonitrile, 4-[[2-[(6-chloro-3-pyridinyl)oxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884854-27-7 HCAPLUS

CN Benzonitrile, 4-[[2-[(6-methyl-3-pyridinyl)oxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884854-28-8 HCAPLUS

CN Benzonitrile, 4-[[2-[(5-bromo-2-pyridinyl)oxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884854-29-9 HCAPLUS

CN Benzonitrile, 4-[[2-[(6-fluoro-3-pyridinyl)oxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884854-30-2 HCAPLUS

CN Benzonitrile, 4-[[2-[(5-fluoro-2-pyridinyl)oxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884854-31-3 HCAPLUS

CN Acetamide, N-[6-[2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]ethoxy]-3-pyridinyl]- (CA INDEX NAME)




RN 884854-33-5 HCAPLUS

CN Benzonitrile, 4-[[2-[(1,6-dihydro-6-oxo-3-pyridinyl)oxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884854-36-8 HCAPLUS

CN Benzonitrile, 4-[[2-(3-pyridazinyl)oxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884854-37-9 HCAPLUS

CN Benzonitrile, 4-[[2-(4-pyrimidinyloxy)ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884854-60-8 HCAPLUS

CN Acetamide, N-[4-[[2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]ethyl]thio]phenyl]-N-methyl- (CA INDEX NAME)




RN 884854-61-9 HCAPLUS

CN Benzonitrile, 4-[[2-(phenylsulfinyl)ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 884854-62-0 HCAPLUS


CN Acetamide, N-[4-[[2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]ethyl]sulfinyl]phenyl]- (CA INDEX NAME)



RN 884854-63-1 HCAPLUS


CN Benzonitrile, 4-[[2-(phenylsulfonyl)ethyl](2,2,2-trifluoroethyl)amino]-2-

(trifluoromethyl)- (CA INDEX NAME)




RN 884854-64-2 HCAPLUS

CN Acetamide, N-[4-[[2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]ethyl]sulfonyl]phenyl]- (CA INDEX NAME)




RN 884854-65-3 HCAPLUS

CN Methanesulfonamide, N-[4-[[2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]ethyl]thio]phenyl]- (CA INDEX NAME)




RN 884854-67-5 HCAPLUS

CN Benzonitrile, 4-[[2-(methyl-2-pyrimidinylamino)ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884854-68-6 HCAPLUS

CN Benzamide, N-[2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]ethyl]- (CA INDEX NAME)




RN 884854-69-7 HCAPLUS

CN Benzonitrile, 4-[[3-(4-fluorophenyl)propyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884854-71-1 HCAPLUS

CN Acetamide, N-[4-[3-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]propyl]phenyl]- (CA INDEX NAME)



RN 884854-72-2 HCAPLUS

CN Benzonitrile, 4-[(3-phenylpropyl)(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884854-74-4 HCAPLUS

CN Benzonitrile, 4-[[3-(3-pyridinyl)propyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 884854-73-3


CMF C18 H15 F6 N3



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 884854-88-0 HCAPLUS

CN Acetamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](cyclopropylmethyl)amino]-N-(4-fluorophenyl)- (CA INDEX NAME)



RN 884854-89-1 HCAPLUS


CN Acetamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](cyclopropylmethyl)amino]-N-[(4-fluorophenyl)methyl]- (CA INDEX NAME)



RN 884854-90-4 HCAPLUS


CN Acetamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl] (cyclopropylmethyl) amino]-N-[(1S)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 884854-91-5 HCAPLUS

CN Acetamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl] (cyclopropylmethyl) amino]-N-(2-phenylethyl)- (CA INDEX NAME)




RN 884854-92-6 HCAPLUS

CN Acetamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl] (cyclopropylmethyl) amino]-N-[2-(4-fluorophenyl)ethyl]- (CA INDEX NAME)




RN 884854-93-7 HCAPLUS

CN Propanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](cyclopropylmethyl)amino]-N-(4-fluorophenyl)- (CA INDEX NAME)




RN 884854-96-0 HCAPLUS

CN Acetamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-N-phenyl- (CA INDEX NAME)




RN 884854-97-1 HCAPLUS

CN Acetamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-N-(4-fluorophenyl)- (CA INDEX NAME)




RN 884854-98-2 HCAPLUS


CN Acetamide, N-[4-(acetamino)phenyl]-2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]- (CA INDEX NAME)




RN 884854-99-3 HCAPLUS
 CN Butanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-N-phenyl- (CA INDEX NAME)



RN 884855-00-9 HCAPLUS
 CN Butanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]-N-(4-fluorophenyl)- (CA INDEX NAME)




RN 884855-01-0 HCAPLUS
 CN Benzonitrile, 4-[[2-(1H-1,2,4-triazol-1-yl)ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 884855-07-6 HCAPLUS
 CN Benzonitrile, 4-[(cyclopropylmethyl)[2-(4-morpholinyl)ethyl]amino]-2-(trifluoromethyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 884855-06-5
 CMF C18 H22 F3 N3 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 884855-11-2 HCAPLUS

CN Benzonitrile, 4-[[2-(1-pyrrolidinyl)ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 884855-10-1


CMF C16 H17 F6 N3



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 884856-05-7 HCAPLUS

CN Acetamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](cyclopropylmethyl)amino]-N-phenyl- (CA INDEX NAME)




RN 884856-06-8 HCAPLUS

CN Acetamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](cyclopropylmethyl)amino]-N-(phenylmethyl)- (CA INDEX NAME)



RN 884856-07-9 HCAPLUS


CN Propanamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](cyclopropylmethyl)amino]-N-phenyl- (CA INDEX NAME)



RN 884856-08-0 HCAPLUS

CN Acetamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-


trifluoroethyl)amino]-N-(2-phenylethyl)- (CA INDEX NAME)



RN 885050-04-4 HCAPLUS

CN Acetamide, 2-[[4-cyano-3-(trifluoromethyl)phenyl]-(cyclopropylmethyl)amino]-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 821777-25-7P, 4-[(Cyclopropylmethyl)(3-hydroxypropyl)amino]-2-(trifluoromethyl)benzonitrile 821777-26-8P, 4-[(Cyclopropylmethyl)(2-hydroxyethyl)amino]-2-(trifluoromethyl)benzonitrile 821777-52-0P, 4-[(3-Hydroxypropyl)(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 821777-58-6P, 4-[(2-Hydroxyethyl)(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 821777-73-5P 821777-85-9P, 2-[[4-Cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]ethyl methanesulfonate 821777-86-0P, 4-[(2-Aminoethyl)(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 864283-36-3P, N-[4-Cyano-3-(trifluoromethyl)phenyl]-N-(cyclopropylmethyl)glycine 864283-47-6P, N-[4-Cyano-3-(trifluoromethyl)phenyl]-N-(2,2,2-trifluoroethyl)glycine 864283-49-8P, Methyl N-[4-cyano-3-(trifluoromethyl)phenyl]-N-(2,2,2-trifluoroethyl)glycinate 864283-71-6P, 2-[[4-Cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]butanoic acid 864284-25-3P, N-[4-Cyano-3-(trifluoromethyl)phenyl]-N-(cyclopropylmethyl)alanine 884854-02-8P, 4-[[2-[(4-Aminophenyl)oxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 884854-10-8P, 4-[[2-[(4-Formylphenyl)oxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 884854-13-1P 884854-18-6P, 4-[[2-[[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]oxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 884854-35-7P, 4-[[2-[[6-[[[4-(Methyloxy)phenyl]methyl]oxy]-3-pyridinyl]oxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 884854-59-5P, 4-[[2-[(4-Aminophenyl)thio]ethyl](2,2,2-trifluoroethyl)amino]-2-


Serial No.:10/598,508

(trifluoromethyl)benzonitrile 884854-70-0P, 4-[(2-Propen-1-yl)(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of substituted aniline derivs. as selective androgen receptor modulators)


RN 821777-25-7 HCAPLUS

CN Benzonitrile, 4-[(cyclopropylmethyl)(3-hydroxypropyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 821777-26-8 HCAPLUS

CN Benzonitrile, 4-[(cyclopropylmethyl)(2-hydroxyethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 821777-52-0 HCAPLUS

CN Benzonitrile, 4-[(3-hydroxypropyl)(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 821777-58-6 HCAPLUS

CN Benzonitrile, 4-[(2-hydroxyethyl)(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 821777-73-5 HCAPLUS

CN Benzonitrile, 4-[(2-azidoethyl)(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 821777-85-9 HCAPLUS

CN Benzonitrile, 4-[[2-[(methylsulfonyl)oxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 821777-86-0 HCAPLUS

CN Benzonitrile, 4-[(2-aminoethyl)(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 864283-36-3 HCAPLUS

CN Glycine, N-[4-cyano-3-(trifluoromethyl)phenyl]-N-(cyclopropylmethyl)- (CA INDEX NAME)




RN 864283-47-6 HCAPLUS

CN Glycine, N-[4-cyano-3-(trifluoromethyl)phenyl]-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 864283-49-8 HCAPLUS

CN Glycine, N-[4-cyano-3-(trifluoromethyl)phenyl]-N-(2,2,2-trifluoroethyl)-, methyl ester (CA INDEX NAME)




RN 864283-71-6 HCAPLUS

CN Butanoic acid, 2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]- (CA INDEX NAME)




RN 864284-25-3 HCAPLUS

CN Alanine, N-[4-cyano-3-(trifluoromethyl)phenyl]-N-(cyclopropylmethyl)- (CA INDEX NAME)




RN 884854-02-8 HCAPLUS

CN Benzonitrile, 4-[[2-(4-aminophenoxy)ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884854-10-8 HCAPLUS

CN Benzonitrile, 4-[[2-(4-formylphenoxy)ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884854-13-1 HCAPLUS

CN Carbamic acid, [[4-[2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]ethoxy]phenyl]carbonimidoyl]bis-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)




RN 884854-18-6 HCAPLUS

CN Benzonitrile, 4-[[2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884854-35-7 HCAPLUS

CN Benzonitrile, 4-[[2-[[6-[(4-methoxyphenyl)methoxy]-3-pyridinyl]oxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 884854-59-5 HCAPLUS

CN Benzonitrile, 4-[[2-[(4-aminophenyl)thio]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 884854-70-0 HCAPLUS

CN Benzonitrile, 4-[2-propen-1-yl(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:14359 HCAPLUS Full-text
 DOCUMENT NUMBER: 142:113710
 TITLE: Preparation of substituted anilines as androgen receptor modulators
 INVENTOR(S): Blanc, Jean-Baptiste E.; Cadilla, Rodolfo; Cowan, David John; Kaldor, Istvan; Larkin, Andrew L.; Stewart, Eugene Lee; Turnbull, Philip Stewart; Trump, Ryan Paul
 PATENT ASSIGNEE(S): SmithKline Beecham Corporation, USA
 SOURCE: PCT Int. Appl., 86 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005000795	A2	20050106	WO 2004-US18252	20040609
WO 2005000795	A3	20050310		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1654221	A2	20060510	EP 2004-776383	20040609
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR			
JP 2007500245	T	20070111	JP 2006-533629	20040609
US 20060148893	A1	20060706	US 2005-560012	20051208
PRIORITY APPLN. INFO.:			US 2003-477252P	P 20030610
			WO 2004-US18252	W 20040609

OTHER SOURCE(S): MARPAT 142:113710
 ED Entered STN: 07 Jan 2005
 GI




AB This invention relates to non-steroidal compds. I [R1, R2, R4, R5 = H, CN, NO2, halo, etc. (at least one of R1, R2, R4, R5 is not H); R3 = CN, NO2, halo, etc.; R6, R7 = H, (Ra)xR9 (Ra = alkylene; x = 0-1; R9 = alkyl, haloalkyl, hydroxyalkyl, etc.)] that are or are believed to be modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of such compds. Thus, reacting 4-fluoro-2-trifluoromethylbenzonitrile with N-(cyclopropylmethyl)-N-propylamine afforded 81% I [R1, R2, R5 = H; R3 = CN; R4 = CF3; R6 = CH2(cyclopropyl); R7 = Pr]. The compds. I are claimed to be useful in the treatment or prophylaxis of conditions or disorders that respond to selective androgen receptor modulation (no data given). The pharmaceutical composition comprising the compound I is disclosed.

IT 821777-58-6P 821777-66-6P 821777-68-8P
821777-73-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of substituted anilines as androgen receptor modulators)


RN 821777-58-6 HCAPLUS

CN Benzonitrile, 4-[(2-hydroxyethyl)(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 821777-66-6 HCAPLUS


CN Benzonitrile, 4-[(2-methyl-2-propen-1-yl)(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 821777-68-8 HCAPLUS
 CN Benzonitrile, 4-[(3-methyl-2-buten-1-yl)(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 821777-73-5 HCAPLUS
 CN Benzonitrile, 4-[(2-azidoethyl)(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




IT 821776-43-6P 821776-44-7P 821776-58-3P
 821777-25-7P 821777-26-8P 821777-33-7P
 821777-52-0P 821777-55-3P 821777-56-4P
 821777-59-7P 821777-60-0P 821777-61-1P
 821777-62-2P 821777-63-3P 821777-64-4P
 821777-65-5P 821777-67-7P 821777-69-9P
 821777-70-2P 821777-71-3P 821777-72-4P
 821777-74-6P 821777-75-7P 821777-76-8P
 821777-77-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted anilines as androgen receptor modulators)


RN 821776-43-6 HCAPLUS
 CN Benzonitrile, 4-[(cyclopropylmethyl)propylamino]-2-(trifluoromethyl)- (CA

INDEX NAME)




RN 821776-44-7 HCAPLUS

CN Benzonitrile, 4-[(cyclopropylmethyl)propylamino]-2-nitro- (CA INDEX NAME)




RN 821776-58-3 HCAPLUS

CN Benzonitrile, 2-chloro-4-[(cyclopropylmethyl)propylamino]- (CA INDEX NAME)




RN 821777-25-7 HCAPLUS

CN Benzonitrile, 4-[(cyclopropylmethyl)(3-hydroxypropyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 821777-26-8 HCAPLUS

CN Benzonitrile, 4-[(cyclopropylmethyl)(2-hydroxyethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 821777-33-7 HCAPLUS

CN Benzonitrile, 4-[(1-cyclopropylethyl)-2-propen-1-ylamino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 821777-52-0 HCAPLUS

CN Benzonitrile, 4-[(3-hydroxypropyl)(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 821777-55-3 HCAPLUS

CN Benzonitrile, 4-[bis(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 821777-56-4 HCAPLUS

CN Benzonitrile, 4-[(2,2-difluoroethyl)(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 821777-59-7 HCAPLUS

CN Benzonitrile, 4-[(2-methoxyethyl)(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 821777-60-0 HCAPLUS

CN Benzonitrile, 4-[(2-ethoxyethyl)(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 821777-61-1 HCAPLUS

CN Benzonitrile, 4-[[2-(2,2,2-trifluoroethoxy)ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 821777-62-2 HCAPLUS

CN Benzonitrile, 4-[methyl(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)-
(CA INDEX NAME)




RN 821777-63-3 HCAPLUS

CN Benzonitrile, 4-[ethyl(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)-
(CA INDEX NAME)




RN 821777-64-4 HCAPLUS

CN Benzonitrile, 4-[propyl(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)-
(CA INDEX NAME)




RN 821777-65-5 HCAPLUS

CN Benzonitrile, 4-[butyl(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)-
(CA INDEX NAME)




RN 821777-67-7 HCAPLUS

CN Benzonitrile, 4-[(2-methylpropyl)(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 821777-69-9 HCAPLUS

CN Benzonitrile, 4-[(3-methylbutyl)(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 821777-70-2 HCAPLUS

CN Benzonitrile, 4-[2-propyn-1-yl(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 821777-71-3 HCAPLUS

CN Benzonitrile, 4-[(2-fluoroethyl)(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 821777-72-4 HCAPLUS

CN Benzonitrile, 4-[[2-(methylthio)ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 821777-74-6 HCAPLUS

CN Acetamide, N-[2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]ethyl]- (CA INDEX NAME)




RN 821777-75-7 HCAPLUS

CN Carbamic acid, [2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 821777-76-8 HCAPLUS

CN Carbamic acid, [2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 821777-77-9 HCAPLUS

CN Methanesulfonamide, N-[2-[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]ethyl]- (CA INDEX NAME)




IT 821777-79-1P 821777-85-9P 821777-86-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of substituted anilines as androgen receptor modulators)


RN 821777-79-1 HCAPLUS

CN Benzonitrile, 4-[(cyclopropylmethyl)[3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]propyl]amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 821777-85-9 HCAPLUS

CN Benzonitrile, 4-[[2-[(methylsulfonyl)oxy]ethyl](2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 821777-86-0 HCAPLUS

CN Benzonitrile, 4-[(2-aminoethyl)(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)



Serial No.:10/598,508
Author Search

=> FILE HCAPLUS
FILE 'HCAPLUS' ENTERED AT 10:22:18 ON 26 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Sep 2008 VOL 149 ISS 14
FILE LAST UPDATED: 25 Sep 2008 (20080925/ED)


HCAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.
'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

=> D STAT QUE L4
L1 STR

G2³ Cy¹
Ak²G1



G1 CF3, [01]
G2 CF3, [01]
G3 [02], [03]
G4
G5
G6 CN,NO2,X

Structure attributes must be viewed using STN Express query preparation.
L3 774 SEA FILE=REGISTRY SSS FUL L1

L4 37 SEA FILE=HCAPLUS ABB=ON PLU=ON L3

=> D STAT QUE L7
L5 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


Structure attributes must be viewed using STN Express query preparation.

L6 (189)SEA FILE=REGISTRY SSS FUL L5
L7 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L6

=> D STAT QUE L13
L1 STR

G2³ Cy¹

Ak²G1




G1 CF3, [01]
G2 CF3, [01]
G3 [02], [03]
G4
G5
G6 CN,NO2, X

Structure attributes must be viewed using STN Express query preparation.

L3 774 SEA FILE=REGISTRY SSS FUL L1
L10 STR

G2³ Cy¹

Ak²G1



G1 CF3, [01]
 G2 CF3, [01]
 G3 [02], [03]
 G4
 G5
 G6 CN, NO2, X
 G7 O, S, N

Structure attributes must be viewed using STN Express query preparation.

L12 395 SEA FILE=REGISTRY SUB=L3 SSS FUL L10

L13 16 SEA FILE=HCAPLUS ABB=ON PLU=ON L12

=> S L13, L7, L4 NOT L34

L42 31 (L13 OR L7 OR L4) NOT L34

=> FILE WPIX

FILE 'WPIX' ENTERED AT 10:23:24 ON 26 SEP 2008

COPYRIGHT (C) 2008 THOMSON REUTERS

FILE LAST UPDATED: 20 SEP 2008 <20080920/UP>

MOST RECENT UPDATE: 200860 <200860/DW>

DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> Now containing more than 1.1 million chemical structures in DCR <<<

>>> IPC Reform backfile reclassifications have been loaded to the end of June 2008. No update date (UP) has been created for the reclassified documents, but they can be identified by 20060101/UPIC and 20061231/UPIC, 20070601/UPIC, 20071001/UPIC, 20071130/UPIC, 20080401/UPIC and 20080701/UPIC. ECLA reclassifications to June and US national classifications to the end of April 2008 have also been loaded. Update dates 20080401 and 20080701/UPEC and /UPNC have been assigned to these. <<<

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE, PLEASE VISIT:

http://www.stn-international.de/training_center/patents/stn_guide.pdf

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE

<http://scientific.thomsonreuters.com/support/patents/coverage/latestupdates/>

EXPLORE DERWENT WORLD PATENTS INDEX IN STN ANAVIST, VERSION 2.0:

http://www.stn-international.com/archive/presentations/DWPIAnaVist2_0608.pdf

>>> HELP for European Patent Classifications see HELP ECLA, HELP ICO <<<

'BI,ABEX' IS DEFAULT SEARCH FIELD FOR 'WPIX' FILE

=> D STAT QUE L37
L8 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

L36 109 SEA FILE=WPIX SSS FUL L8
L37 2 SEA FILE=WPIX ABB=ON PLU=ON L36/DCR

=> S L37 NOT L38
L43 0 L37 NOT L38

=> FILE BEILSTEIN

FILE 'BEILSTEIN' ENTERED AT 10:24:26 ON 26 SEP 2008
COPYRIGHT (c) 2008 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein GmbH and MDL Information Systems GmbH

FILE LAST UPDATED ON April 1, 2008

FILE COVERS 1771 TO 2008.

*** FILE CONTAINS 10.322,808 SUBSTANCES ***

>>>PLEASE NOTE: Reaction Data and substance data are stored in
separate documents and can not be searched together in one query.
Reaction data for BEILSTEIN compounds may be displayed
immediately with the display codes PRE (preparations) and REA
(reactions). A substance answer set retrieved after the search
for a chemical name, a compounds with available reaction
information by combining with PRE/FA, REA/FA or more generally
with RX/FA. The BEILSTEIN Registry Number (BRN) is the link
between a BEILSTEIN compound and belonging reactions. For mo
detailed reaction searches BRNs can be searched as reaction
partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE <<<

* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST. *
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE *
* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE *
* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS. *
* FOR PRICE INFORMATION SEE HELP COST *

>>> Price change as of January 1st, 2008: Connect Time and Structure
Search fees re-introduced. See NEWS and HELP COST <<<

=> D STAT QUE L40
L8 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

L9 189 SEA FILE=REGISTRY SSS FUL L8

L40 0 SEA FILE=BEILSTEIN ABB=ON PLU=ON L9

=> DUP REM L42 L43 L40
 L43 HAS NO ANSWERS
 L40 HAS NO ANSWERS
 DUPLICATE IS NOT AVAILABLE IN 'BEILSTEIN'.
 ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
 FILE 'HCAPLUS' ENTERED AT 10:24:44 ON 26 SEP 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Sep 2008 VOL 149 ISS 14
 FILE LAST UPDATED: 25 Sep 2008 (20080925/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE
 PROCESSING COMPLETED FOR L42
 PROCESSING COMPLETED FOR L43
 PROCESSING COMPLETED FOR L40
 L44 31 DUP REM L42 L43 L40 (0 DUPLICATES REMOVED)
 ANSWERS '1-31' FROM FILE HCAPLUS

=> D IBIB ED ABS HITSTR L44 1-31

L44 ANSWER 1 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2008:962643 HCAPLUS Full-text
 TITLE: Potent, Plasmodium-Selective Farnesyltransferase Inhibitors That Arrest the Growth of Malaria Parasites: Structure-Activity Relationships of Ethylenediamine-Analogue Scaffolds and Homology Model Validation
 AUTHOR(S): Fletcher, Steven; Cummings, Christopher G.; Rivas, Kasey; Katt, William P.; Horney, Carrie; Buckner, Frederick S.; Chakrabarti, Debopam; Sebti, Said M.; Gelb, Michael H.; Van Voorhis, Wesley C.; Hamilton, Andrew D.
 CORPORATE SOURCE: Department of Chemistry, Yale University, New Haven, CT, 06511, USA
 SOURCE: Journal of Medicinal Chemistry (2008), 51(17), 5176-5197
 CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 ED Entered STN: 11 Aug 2008

AB New chemotherapeutics are urgently needed to combat malaria. We previously reported on a novel series of antimalarial, ethylenediamine-based inhibitors of protein farnesyltransferase (PFT). In the current study, we designed and synthesized a series of second generation inhibitors, wherein the core ethylenediamine scaffold was varied in order to examine both the homol. model of Plasmodium falciparum PFT (PfPFT) and our predicted inhibitor binding mode. We identified several PfPFT inhibitors (PfPFTIs) that are selective for PfPFT vs. the mammalian isoform of the enzyme (up to 136-fold selectivity), that inhibit the malarial enzyme with IC50 values down to 1 nM, and that block the growth of P. falciparum in infected whole cells (erythrocytes) with ED50 values down to 55 nM. The structure-activity data for these second generation, ethylenediamine-inspired PFT inhibitors were rationalized by consideration of the X-ray crystal structure of mammalian PFT and the homol. model of the malarial enzyme.


IT 910910-63-3P 1052099-95-2P 1052099-96-3P
 1052099-97-4P 1052099-98-5P 1052099-99-6P
 1052100-00-1P 1052100-01-2P 1052100-02-3P
 1052100-03-4P 1052100-04-5P

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(plasmodium-selective farnesyltransferase inhibitors that arrest malaria parasites growth: SAR of ethylenediamine analog scaffolds and homol. model validation)


RN 910910-63-3 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl-N-[[1-(2-pyrimidinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 1052099-95-2 HCAPLUS


CN INDEX NAME NOT YET ASSIGNED




RN 1052099-96-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1052099-97-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1052099-98-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1052099-99-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1052100-00-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1052100-01-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1052100-02-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1052100-03-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1052100-04-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




IT 865788-27-8 865788-35-8 910910-62-2
1052099-94-1

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(plasmodium-selective farnesyltransferase inhibitors that arrest malaria parasites growth: SAR of ethylenediamine analog scaffolds and homol. model validation)

RN 865788-27-8 HCAPLUS


CN 1H-Imidazole-4-sulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl-N-(phenylmethyl)- (CA INDEX NAME)



Serial No.:10/598,508


RN 865788-35-8 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl-N-[(2-methylphenyl)methyl]- (CA INDEX NAME)




RN 910910-62-2 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl][(1-methyl-1H-imidazol-4-yl)sulfonyl]amino]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 1052099-94-1 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED



IT 1052100-30-7P 1052100-31-8P 1052100-40-9P
1052100-41-0P 1052100-44-3P 1052100-45-4P
1052100-46-5P 1052100-47-6P 1052100-48-7P

Serial No.:10/598,508


1052100-49-8P 1052100-50-1P 1052100-51-2P
1052100-52-3P 1052100-54-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(plasmodium-selective farnesyltransferase inhibitors that arrest
malaria parasites growth: SAR of ethylenediamine analog scaffolds and
homol. model validation)


RN 1052100-30-7 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1052100-31-8 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1052100-40-9 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1052100-41-0 HCAPLUS


CN INDEX NAME NOT YET ASSIGNED




RN 1052100-44-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1052100-45-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1052100-46-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1052100-47-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1052100-48-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1052100-49-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1052100-50-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1052100-51-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1052100-52-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1052100-54-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L44 ANSWER 2 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:761566 HCAPLUS Full-text
DOCUMENT NUMBER: 147:166201
TITLE: Preparation of 3,5-Substituted Piperidine Compounds as Renin Inhibitors

Serial No.:10/598,508

INVENTOR(S): Ehara, Takeru; Grosche, Philipp; Irie, Osamu; Iwaki, Yuki; Kanazawa, Takanori; Kawakami, Shimpei; Konishi, Kazuhide; Mogi, Muneto; Suzuki, Masaki; Yokokawa, Fumiaki

PATENT ASSIGNEE(S): Novartis AG, Switz.; Novartis Pharma GmbH

SOURCE: PCT Int. Appl., 692pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007077005	A1	20070712	WO 2006-EP12581	20061228
<p>W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW</p> <p>RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM</p>				
AU 2006332124	A1	20070712	AU 2006-332124	20061228
EP 1968940	A1	20080917	EP 2006-829892	20061228
<p>R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BA, HR</p>				
PRIORITY APPLN. INFO.:			EP 2005-28771	A 20051230
			GB 2006-4223	A 20060302
			GB 2006-11390	A 20060608
			WO 2006-EP12581	W 20061228

OTHER SOURCE(S): MARPAT 147:166201

ED Entered STN: 13 Jul 2007

GI



AB Title compds. I [R1 = H, (un)substituted alkyl, alkenyl, alkynyl, etc.; R2 = (un)substituted alkyl, alkenyl, alkynyl, aryl, etc.; R3 = H, (un)substituted aryl or alkyl; R4 = (un)substituted alkyl, alkenyl, aryl, heterocyclyl, etc.; or R3 and R4 may together form (un)substituted nitrogen heterocycle; R6 = H, halo, alkyl or alkoxy; R7 and R8 independently = H or halo; T = methylene or carbonyl], and their pharmaceutically acceptable salts, are disclosed as renin inhibitors and as such are useful for the treatment of a disease (= disorder) that depends on activity of renin. Thus, e.g., II was prepared in a multistep synthesis from indole-3-carboxaldehyde via N-alkylation with toluene-4-sulfonic acid 3-methoxypropyl ester followed by reductive amination with cyclopropyl amine, reaction with 2,4-dioxo-3-oxa-7-aza- bicyclo[3.3.1]nonane-7-carboxylic acid tert Bu ester, amidation with isobutylamine and deprotection. I in assays for inhibition of recombinant human renin will preferably possess IC50 values in the range from 1 nM to 20 μ M (no data). Further disclosed are methods for preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin.

IT 944137-09-1P 944137-10-4P 944137-29-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted piperidine compds. as renin inhibitors)

RN 944137-09-1 HCAPLUS

CN 3,5-Piperidinedicarboxamide, N3-[4-cyano-3-(3-methoxypropoxy)phenyl]-N3-cyclopropyl-N5-[3-methyl-1-(2-methylpropyl)butyl]-, (3R,5S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 944137-10-4 HCAPLUS

CN 3,5-Piperidinedicarboxamide, N3-[4-cyano-3-(3-methoxypropoxy)phenyl]-N3-cyclopropyl-N5-(2-methoxy-6-methylphenyl)-, (3R,5S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 944137-29-5 HCAPLUS

CN 3,5-Piperidinedicarboxamide, N3-[4-cyano-3-(3-methoxypropoxy)phenyl]-N3-cyclopropyl-N5-[1-(4-pyridinyl)cyclopentyl]-, (3R,5S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 944142-31-8P 944142-32-9P 944142-34-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of substituted piperidine compds. as renin inhibitors)

RN 944142-31-8 HCAPLUS


CN 1-Piperidinecarboxylic acid, 3-[[[4-cyano-3-(3-methoxypropoxy)phenyl]cyclopropylamino]carbonyl]-5-[[[1-(4-pyridinyl)cyclopentyl]amino]carbonyl]-, 1,1-dimethylethyl ester, (3R,5S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 944142-32-9 HCAPLUS
 CN 1,3-Piperidinedicarboxylic acid, 5-[[[4-cyano-3-(3-methoxypropoxy)phenyl]cyclopropylamino]carbonyl]-, 1-(1,1-dimethylethyl) ester, (3S,5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 944142-34-1 HCAPLUS
 CN 1,3-Piperidinedicarboxylic acid, 5-[[[4-cyano-3-(3-methoxypropoxy)phenyl]cyclopropylamino]carbonyl]-, 1-(1,1-dimethylethyl) 3-methyl ester, (3S,5R)- (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L44 ANSWER 3 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:538978 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 146:521801
 TITLE: Preparation of 1-N-phenyl-amino-1H-imidazole derivatives as aromatase, steroid sulfatase, and carbonic anhydrase inhibitors and pharmaceutical compositions containing them
 INVENTOR(S): Lafay, Jean; Rondot, Benoit; Bonnet, Paule; Clerc, Thierry; Shields, Jacqueline; Duc, Igor; Duranti, Eric; Puccio, Francois; Blot, Christian; Maillos, Philippe
 PATENT ASSIGNEE(S): Fr.
 SOURCE: U.S. Pat. Appl. Publ., 32pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070112009	A1	20070517	US 2006-582778	20060817
EP 1544195	A1	20050622	EP 2003-293152	20031215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
WO 2005058842	A1	20050630	WO 2004-EP14847	20041215
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			EP 2003-293152	A 20031215
			EP 2004-292681	A 20041112
			WO 2004-EP14847	W 20041215
OTHER SOURCE(S): MARPAT 146:521801				
ED Entered STN: 18 May 2007				
GI				



AB The invention relates to the compds. of formula I: in which R1 and R2 are H, (C1-C6)alkyl, (C3-C8)cycloalkyl, or together form a (un)saturated 5-7-membered carbocyclic ring; Q is (CH2)m-X-(CH2)n-A; A is a direct link, O, S, SO, SO2, NR5; X is a direct link, CF2, O, S, SO, SO2, C(O), NR5 or CR6R7; Z is (un)substituted Ph or heterocycle; m and n are 0-4; R3 is H, OH, (C1-C6)alkyl, etc.; R4 is H, OH, CN, halo, (C1-C6)alkoxy, etc.; R3 and R4 together with the Ph ring bearing them can also form a benzofuran or a N-methylbenzotriazole; R6 and R7 are H, halo, (C1-C6)alkyl or (C3-C8) cycloalkyl; R5, is H, OH, (C1-C6)alkyl, or (C3-C8)cycloalkyl;. I are inhibitors of the enzymes aromatase and/ or steroid sulfatase and/or carbonic anhydrase and can be used alone or in combination with other active ingredients for the treatment or the prevention of any hormone or non hormone-dependent cancer, in humans as well as in wild or domestic animals. Because of their inhibition activity of aromatase and/or steroid sulfatase, the compds. of the invention are suitable for the management of estrogen-regulated reproductive functions, in humans as well as in wild or domestic animals. The invention also relates to the pharmaceutical compns. containing these compds. Example compound, 4-[N-(4-hydroxyphenylmethyl)- N-(1H-imidazol-1-yl)amino]benzonitrile (II) , was

Serial No.:10/598,508

prepared by reacting 4-hydroxybenzyl bromide and 4-[N-(1H-imidazol-1-yl)amino]benzonitrile. II inhibited human aromatase with IC50 = 0.17 nM.

IT 936575-69-8P

RL: BYP (Byproduct); PREP (Preparation)

(drug candidate; preparation of 1-N-Ph-amino-1H-imidazole derivs. as aromatase, steroid sulfatase, and carbonic anhydrase inhibitors and pharmaceutical compns. containing them)


RN 936575-69-8 HCAPLUS

CN Sulfamic acid, N-(aminosulfonyl)-, compd. with 4-[[(3-bromophenyl)methyl]-1H-imidazol-1-ylamino]benzonitrile (1:1) (CA INDEX NAME)

CM 1

CRN 936575-68-7


CMF C17 H13 Br N4



CM 2

CRN 13776-65-3

CMF H4 N2 O5 S2




IT 854602-62-3P, 4-[N-(4-Hydroxyphenylmethyl)-N-(1H-imidazol-1-yl)amino]benzonitrile 854602-63-4P, 4-[N-(3-Chloro-4-hydroxyphenylmethyl)-N-(1H-imidazol-1-yl)amino]benzonitrile 854602-64-5P, 4-[N-(3-Bromo-4-hydroxyphenylmethyl)-N-(1H-imidazol-1-yl)amino]benzonitrile 854602-65-6P, 4-[N-[(4-Hydroxy-3-methoxyphenyl)methyl]-N-(1H-imidazol-1-yl)amino]benzonitrile 854602-67-8P, 4-[N-(3-Formyl-4-hydroxyphenylmethyl)-N-(1H-imidazol-1-yl)amino]benzonitrile 854602-76-9P, 4-[N-[(2,2-Dioxido-1,2,3-benzoxathiazin-6-yl)methyl]-N-(1H-imidazol-1-yl)amino]benzonitrile 936575-31-4P, 4-[N-[2-(4-Benzoyloxyphenoxy)ethyl]-N-(1H-imidazol-1-yl)amino]benzonitrile 936575-34-7P, 4-[N-(4-Hydroxy-3-nitrophenylmethyl)-N-(1H-imidazol-1-yl)amino]benzonitrile 936575-38-1P, N-(1H-Imidazol-1-yl)-N-(4-cyanophenyl)-2-(4-hydroxyphenyl)acetamide 936575-39-2P, N-(4-Cyanophenyl)-3-(4-

hydroxyphenyl)-N-(1H-imidazol-1-yl)propanamide 936575-41-6P,
 5-Nitro-N-(4-cyanophenyl)-N-(1H-imidazol-1-yl)benzothiophene-2-carboxamide
 936575-42-7P, N-(4-Cyanophenyl)-N-(1H-imidazol-1-yl)-2-(6-
 methoxybenzo[b]thien-3-yl)acetamide 936575-43-8P,
 4-[N-(1H-Imidazol-1-yl)-N-[(6-methoxybenzo[b]thien-3-
 yl)methyl]amino]benzonitrile 936575-45-0P, 4-[N-[(6-
 Benzyloxybenzo[b]thien-2-yl)methyl]-N-(1H-imidazol-1-yl)amino]benzonitrile
 936575-46-1P, 4-[N-[(6-Hydroxybenzo[b]thien-3-yl)methyl]-N-(1H-
 imidazol-1-yl)amino]benzonitrile 936575-49-4P,
 4-[N-[2-(4-Hydroxyphenoxy)ethyl]-N-(1H-imidazol-1-yl)amino]benzonitrile
 936575-52-9P, 4-[N-[(6-Hydroxybenzo[b]thien-2-yl)methyl]-N-(1H-
 imidazol-1-yl)amino]benzonitrile 936575-54-1P,
 5-Amino-N-(4-cyanophenyl)-N-(1H-imidazol-1-yl)benzothiophene-2-carboxamide
 936575-73-4P, 4-[N-[(2,2-Dioxido-3-tosyl-3H-1,2,3-benzoxathiazol-5-
 yl)methyl]-N-(1H-imidazol-1-yl)amino]benzonitrile
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of 1-N-Ph-amino-1H-imidazole derivs. as
 aromatase, steroid sulfatase, and carbonic anhydrase inhibitors and
 pharmaceutical compns. containing them)


RN 854602-62-3 HCAPLUS

CN Benzonitrile, 4-[[[(4-hydroxyphenyl)methyl]-1H-imidazol-1-ylamino]- (CA
 INDEX NAME)




RN 854602-63-4 HCAPLUS

CN Benzonitrile, 4-[[[(3-chloro-4-hydroxyphenyl)methyl]-1H-imidazol-1-ylamino]- (CA
 INDEX NAME)




RN 854602-64-5 HCAPLUS

CN Benzonitrile, 4-[[(3-bromo-4-hydroxyphenyl)methyl]-1H-imidazol-1-ylamino]-
(CA INDEX NAME)




RN 854602-65-6 HCAPLUS

CN Benzonitrile, 4-[[(4-hydroxy-3-methoxyphenyl)methyl]-1H-imidazol-1-ylamino]-
(CA INDEX NAME)



RN 854602-67-8 HCAPLUS


CN Benzonitrile, 4-[[(3-formyl-4-hydroxyphenyl)methyl]-1H-imidazol-1-ylamino]-
(CA INDEX NAME)



RN 854602-76-9 HCAPLUS


Serial No.:10/598,508

CN Benzonitrile, 4-[[(2,2-dioxido-1,2,3-benzoxathiazin-6-yl)methyl]-1H-imidazol-1-ylamino]- (CA INDEX NAME)




RN 936575-31-4 HCAPLUS

CN Benzonitrile, 4-[1H-imidazol-1-yl[2-[4-(phenylmethoxy)phenoxy]ethyl]amino]- (CA INDEX NAME)




RN 936575-34-7 HCAPLUS

CN Benzonitrile, 4-[[(4-hydroxy-3-nitrophenyl)methyl]-1H-imidazol-1-ylamino]- (CA INDEX NAME)




RN 936575-38-1 HCAPLUS

CN Benzenacetamide, N-(4-cyanophenyl)-4-hydroxy-N-1H-imidazol-1-yl- (CA INDEX NAME)




RN 936575-39-2 HCAPLUS

CN Benzenepropanamide, N-(4-cyanophenyl)-4-hydroxy-N-1H-imidazol-1-yl- (CA INDEX NAME)




RN 936575-41-6 HCAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(4-cyanophenyl)-N-1H-imidazol-1-yl-5-nitro- (CA INDEX NAME)




RN 936575-42-7 HCAPLUS

CN Benzo[b]thiophene-3-acetamide, N-(4-cyanophenyl)-N-1H-imidazol-1-yl-6-methoxy- (CA INDEX NAME)




RN 936575-43-8 HCAPLUS

CN Benzonitrile, 4-[1H-imidazol-1-yl] [(6-methoxybenzo[b]thien-3-yl)methyl]amino]- (CA INDEX NAME)




RN 936575-45-0 HCAPLUS

CN Benzonitrile, 4-[1H-imidazol-1-yl] [[6-(phenylmethoxy)benzo[b]thien-2-yl]methyl]amino]- (CA INDEX NAME)




RN 936575-46-1 HCAPLUS

CN Benzonitrile, 4-[[(6-hydroxybenzo[b]thien-3-yl)methyl]-1H-imidazol-1-ylamino]- (CA INDEX NAME)




RN 936575-49-4 HCAPLUS

CN Benzonitrile, 4-[[2-(4-hydroxyphenoxy)ethyl]-1H-imidazol-1-ylamino]- (CA INDEX NAME)




RN 936575-52-9 HCAPLUS

CN Benzonitrile, 4-[[(6-hydroxybenzo[b]thien-2-yl)methyl]-1H-imidazol-1-ylamino]- (CA INDEX NAME)



RN 936575-54-1 HCAPLUS


CN Benzo[b]thiophene-2-carboxamide, 5-amino-N-(4-cyanophenyl)-N-1H-imidazol-1-yl- (CA INDEX NAME)



RN 936575-73-4 HCAPLUS

CN Benzonitrile, 4-[1H-imidazol-1-yl[[3-[(4-methylphenyl)sulfonyl]-2,2-

dioxido-3H-1,2,3-benzoxathiazol-5-yl)methyl]amino]- (CA INDEX NAME)




IT 854602-71-4P, Sulfamic acid 4-[[N-(4-cyanophenyl)-N-(1H-imidazol-1-yl)amino]methyl]phenyl ester 854602-72-5P, Sulfamic acid 2-chloro-4-[[N-(4-cyanophenyl)-N-(1H-imidazol-1-yl)amino]methyl]phenyl ester 854602-74-7P, Sulfamic acid 2-methoxy-4-[[N-(4-cyanophenyl)-N-(1H-imidazol-1-yl)amino]methyl]phenyl ester 854602-75-8P, Sulfamic acid 2,3,5,6-tetrafluoro-4-[[N-(4-cyanophenyl)-N-(1H-imidazol-1-yl)amino]methyl]phenyl ester 854602-78-1P, 4-[N-[(2,2-Dioxido-3,4-dihydro-1,2,3-benzoxathiazin-6-yl)methyl]-N-(1H-imidazol-1-yl)amino]benzonitrile 936575-32-5P, 4-[N-[(6-Chloropyridin-3-yl)methyl]-N-(1H-imidazol-1-yl)amino]benzonitrile 936575-33-6P, 4-[[N-(4-Cyanophenyl)-N-(1H-imidazol-1-yl)amino]methyl]benzenesulfonamide 936575-35-8P, 5-[[N-(4-Cyanophenyl)-N-(1H-imidazol-1-yl)amino]methyl]-2-methoxybenzoic acid 936575-36-9P, 6-Chloro-N-(4-cyanophenyl)-N-(1H-imidazol-1-yl)nicotinamide 936575-37-0P, N-(1H-Imidazol-1-yl)-N-(4-cyanophenyl)-2-(4-fluorophenyl)acetamide 936575-47-2P, N-(4-Cyanophenyl)-N-(1H-imidazol-1-yl)-2-(6-hydroxybenzo[b]thien-3-yl)acetamide 936575-48-3P, 4-[N-(3-Amino-4-hydroxyphenylmethyl)-N-(1H-imidazol-1-yl)amino]benzonitrile 936575-57-4P 936575-59-6P, Sulfamic acid 4-[2-[N-(4-cyanophenyl)-N-(1H-imidazol-1-yl)amino]ethoxy]phenyl ester 936575-60-9P, Sulfamic acid 4-[[N-(4-cyanophenyl)-N-(1H-imidazol-1-yl)carbamoyl]methyl]phenyl ester 936575-61-0P 936575-62-1P, Sulfamic acid 3-[(aminosulfonyl)amino]-4-[[N-(4-cyanophenyl)-N-(1H-imidazol-1-yl)amino]methyl]phenyl ester 936575-63-2P, 5-[(Aminosulfonyl)amino]-N-(4-cyanophenyl)-N-(1H-imidazol-1-yl)benzothiophene-2-carboxamide 936575-65-4P, Sulfamic acid 3-[2-[N-(4-cyanophenyl)-N-(1H-imidazol-1-yl)amino]-2-oxoethyl]benzo[b]thien-6-yl ester 936575-66-5P, Sulfamic acid 3-[[N-(4-cyanophenyl)-N-(1H-imidazol-1-yl)amino]methyl]benzo[b]thien-6-yl ester 936575-67-6P, Sulfamic acid 2-[[N-(4-cyanophenyl)-N-(1H-imidazol-1-yl)amino]methyl]benzo[b]thien-6-yl ester 936575-70-1P, 5-[[N-(4-Cyanophenyl)-N-(1H-imidazol-1-yl)amino]methyl]-2-hydroxybenzoic acid 936575-72-3P, 4-[N-[3-(Tosylamino)-4-hydroxybenzyl]-N-(1H-imidazol-1-yl)amino]benzonitrile 936575-74-5P, 4-[N-[(2,2-Dioxido-3H-1,2,3-benzoxathiazol-5-yl)methyl]-N-(1H-imidazol-1-yl)amino]benzonitrile 936575-75-6P, 1-(4-Cyanophenyl)-1-(1H-imidazol-1-yl)-3-phenylurea

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of 1-N-Ph-amino-1H-imidazole derivs. as aromatase, steroid sulfatase, and carbonic anhydrase inhibitors and pharmaceutical compns. containing them)


RN 854602-71-4 HCAPLUS

CN Sulfamic acid, 4-[[[(4-cyanophenyl)-1H-imidazol-1-ylamino]methyl]phenyl ester (CA INDEX NAME)




RN 854602-72-5 HCAPLUS

CN Sulfamic acid, 2-chloro-4-[[[(4-cyanophenyl)-1H-imidazol-1-ylamino]methyl]phenyl ester (CA INDEX NAME)




RN 854602-74-7 HCAPLUS

CN Sulfamic acid, 4-[[[(4-cyanophenyl)-1H-imidazol-1-ylamino]methyl]-2-methoxyphenyl ester (CA INDEX NAME)




RN 854602-75-8 HCAPLUS

CN Sulfamic acid, 4-[[[4-cyanophenyl)-1H-imidazol-1-ylamino]methyl]-2,3,5,6-tetrafluorophenyl ester (CA INDEX NAME)




RN 854602-78-1 HCAPLUS

CN Benzonitrile, 4-[[[(3,4-dihydro-2,2-dioxido-1,2,3-benzoxathiazin-6-yl)methyl]-1H-imidazol-1-ylamino]- (CA INDEX NAME)




RN 936575-32-5 HCAPLUS

CN Benzonitrile, 4-[[[(6-chloro-3-pyridinyl)methyl]-1H-imidazol-1-ylamino]- (CA INDEX NAME)




RN 936575-33-6 HCAPLUS

CN Benzenesulfonamide, 4-[[(4-cyanophenyl)-1H-imidazol-1-ylamino]methyl]-
(CA INDEX NAME)




RN 936575-35-8 HCAPLUS

CN Benzoic acid, 5-[[(4-cyanophenyl)-1H-imidazol-1-ylamino]methyl]-2-methoxy-
(CA INDEX NAME)




RN 936575-36-9 HCAPLUS

CN 3-Pyridinecarboxamide, 6-chloro-N-(4-cyanophenyl)-N-1H-imidazol-1-yl- (CA
INDEX NAME)




RN 936575-37-0 HCAPLUS

CN Benzeneacetamide, N-(4-cyanophenyl)-4-fluoro-N-1H-imidazol-1-yl- (CA INDEX NAME)




RN 936575-47-2 HCAPLUS

CN Benzo[b]thiophene-3-acetamide, N-(4-cyanophenyl)-6-hydroxy-N-1H-imidazol-1-yl- (CA INDEX NAME)



RN 936575-48-3 HCAPLUS

CN Benzonitrile, 4-[[(3-amino-4-hydroxyphenyl)methyl]-1H-imidazol-1-ylamino]- (CA INDEX NAME)




RN 936575-57-4 HCAPLUS

CN Sulfamic acid, 2-bromo-4-[[(4-cyanophenyl)-1H-imidazol-1-

Serial No.:10/598,508


ylamino]methyl]phenyl ester, hydrochloride (1:?) (CA INDEX NAME)



●x HCl


RN 936575-59-6 HCAPLUS

CN Sulfamic acid, 4-[2-[(4-cyanophenyl)-1H-imidazol-1-ylamino]ethoxy]phenyl ester (CA INDEX NAME)




RN 936575-60-9 HCAPLUS

CN Sulfamic acid, 4-[2-[(4-cyanophenyl)-1H-imidazol-1-ylamino]-2-oxoethyl]phenyl ester (CA INDEX NAME)




RN 936575-61-0 HCAPLUS

CN Sulfamic acid, 4-[3-[(4-cyanophenyl)-1H-imidazol-1-ylamino]-3-oxopropyl]phenyl ester (CA INDEX NAME)




RN 936575-62-1 HCAPLUS

CN Sulfamic acid, 3-[(aminosulfonyl)amino]-4-[[[(4-cyanophenyl)-1H-imidazol-1-ylamino]methyl]phenyl ester (CA INDEX NAME)




RN 936575-63-2 HCAPLUS

CN Benzo[b]thiophene-2-carboxamide, 5-[(aminosulfonyl)amino]-N-(4-cyanophenyl)-N-1H-imidazol-1-yl- (CA INDEX NAME)




RN 936575-65-4 HCAPLUS

CN Sulfamic acid, 3-[2-[(4-cyanophenyl)-1H-imidazol-1-ylamino]-2-oxoethyl]benzo[b]thien-6-yl ester (CA INDEX NAME)




RN 936575-66-5 HCAPLUS

CN Sulfamic acid, 3-[[(4-cyanophenyl)-1H-imidazol-1-ylamino]methyl]benzo[b]thien-6-yl ester (CA INDEX NAME)




RN 936575-67-6 HCAPLUS

CN Sulfamic acid, 2-[[(4-cyanophenyl)-1H-imidazol-1-ylamino]methyl]benzo[b]thien-6-yl ester (CA INDEX NAME)




RN 936575-70-1 HCAPLUS

CN Benzoic acid, 5-[[[4-cyanophenyl]-1H-imidazol-1-ylamino]methyl]-2-hydroxy-
(CA INDEX NAME)




RN 936575-72-3 HCAPLUS

CN Benzenesulfonamide, N-[5-[[[4-cyanophenyl]-1H-imidazol-1-ylamino]methyl]-2-hydroxyphenyl]-4-methyl- (CA INDEX NAME)




RN 936575-74-5 HCAPLUS

CN Benzonitrile, 4-[[[2,2-dioxido-3H-1,2,3-benzoxathiazol-5-yl)methyl]-1H-imidazol-1-ylamino]- (CA INDEX NAME)



RN 936575-75-6 HCAPLUS

CN Urea, N-(4-cyanophenyl)-N-1H-imidazol-1-yl-N'-phenyl- (CA INDEX NAME)




IT 854602-66-7, 4-[N-(2,3,5,6-Tetrafluoro-4-hydroxyphenylmethyl)-N-(1H-imidazol-1-yl)amino]benzonitrile 936575-56-3,
N-(4-Cyanophenyl)-N-(1H-imidazol-1-yl)-2-(6-hydroxybenzo[b]thien-2-yl)acetamide

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 1-N-Ph-amino-1H-imidazole derivs. as aromatase, steroid sulfatase, and carbonic anhydrase inhibitors and pharmaceutical comps. containing them)


RN 854602-66-7 HCAPLUS

CN Benzonitrile, 4-[1H-imidazol-1-yl]-(2,3,5,6-tetrafluoro-4-hydroxyphenyl)methyl]amino]- (CA INDEX NAME)



RN 936575-56-3 HCAPLUS



CN Benzo[b]thiophene-2-acetamide, N-(4-cyanophenyl)-6-hydroxy-N-1H-imidazol-1-yl- (CA INDEX NAME)



L44 ANSWER 4 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:1010090 HCAPLUS Full-text
 DOCUMENT NUMBER: 145:376919
 TITLE: Aminoethyl sulfonamide compounds and their
 preparation, pharmaceutical composition,
 structure-activity relationship, pharmacokinetics and
 methods for the treatment of malaria and cancer
 INVENTOR(S): Hamilton, Andrew; Buckner, Frederick; Glenn, Matthew;
 Van Voorhis, Wesley
 PATENT ASSIGNEE(S): Yale University, USA; University of South Florida;
 University of Washington; Sebti, Said
 SOURCE: PCT Int. Appl., 72pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006102159	A2	20060928	WO 2006-US9861	20060317
WO 2006102159	A3	20070215		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2005-663370P P 20050317
 OTHER SOURCE(S): MARPAT 145:376919
 ED Entered STN: 29 Sep 2006
 GI



AB Compds. of formula I according to the invention are useful in one or more aspects to inhibit farnesyl transferase, or to treat malaria, neoplasia, a hyperproliferative disease state or arthritis, including rheumatoid arthritis or osteoarthritis. Compds. of formula I wherein R1 is (un)substituted C3-12 hydrocarbyl, (un)substituted heterocyclyl and (un)substituted (hetero)aryl; R is alkyl, acyl, etc.; R5-R10 and RN are independently H, (un)substituted C1-12 hydrocarbyl, (un)substituted C5-12 cycloalkyl, (un)substituted heterocyclyl, (un)substituted (hetero)aryl, etc.; A is thioalkyl, azolylalkyl, carboxyalkyl, etc.; and their pharmaceutically acceptable salts thereof are claimed. Example compound II was prepared by amidation of N'-benzyl-N-(4-bromophenyl)-N-(3-methyl-2H-imidazol-4-ylmethyl)ethane-1,2-diamine with 1-methylimidazolylsulfonyl acid derivative. All the invention compds. were evaluated for their antimalaria and anticancer activity. The tested compds. showed good activity. The structure activity relationship and some pharmacokinetics are also reported.


IT 910910-59-7P

RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate and intermediate; preparation of aminoethyl sulfonamide compds. their structure-activity relationship, pharmacokinetics, and methods for the treatment of malaria and cancer)

RN 910910-59-7 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl-N-(4-piperidinylmethyl)- (CA INDEX NAME)



IT 865788-27-8P 865788-32-5P 865788-34-7P
910910-50-8P 910910-62-2P 910910-63-3P
910910-65-5P 910910-71-3P


RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of aminoethyl sulfonamide compds. their

Serial No.:10/598,508

structure-activity relationship, pharmacokinetics, and methods for the treatment of malaria and cancer)


RN 865788-27-8 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 865788-32-5 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-N-(cyclohexylmethyl)-1-methyl- (CA INDEX NAME)




RN 865788-34-7 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-([1,1'-biphenyl]-4-ylmethyl)-N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl- (CA INDEX NAME)




RN 910910-50-8 HCAPLUS

CN 2-Pyridinesulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-N-(phenylmethyl)- (CA INDEX NAME)




RN 910910-62-2 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl][(1-methyl-1H-imidazol-4-yl)sulfonyl]amino]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 910910-63-3 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl-N-[[1-(2-pyrimidinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 910910-65-5 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl-N-[(4-methylphenyl)methyl]- (CA INDEX NAME)




RN 910910-71-3 HCAPLUS
 CN 1H-Imidazole-4-sulfonamide, N-([1,1'-biphenyl]-3-ylmethyl)-N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl- (CA INDEX NAME)



IT 865788-30-3P 865788-31-4P 865788-33-6P
 865788-35-8P 910910-49-5P 910910-51-9P
 910910-52-0P 910910-53-1P 910910-54-2P
 910910-55-3P 910910-56-4P 910910-57-5P
 910910-58-6P 910910-60-0P 910910-61-1P
 910910-64-4P 910910-66-6P 910910-67-7P
 910910-68-8P 910910-69-9P 910910-70-2P
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of aminoethyl sulfonamide compds. their structure-activity relationship, pharmacokinetics, and methods for the treatment of malaria and cancer)


RN 865788-30-3 HCAPLUS
 CN Benzenesulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-N-(phenylmethyl)- (CA INDEX NAME)



Serial No.:10/598,508


RN 865788-31-4 HCAPLUS

CN 1-Naphthalenesulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-5-(dimethylamino)-N-(phenylmethyl)- (CA INDEX NAME)




RN 865788-33-6 HCAPLUS

CN Acetamide, 2-[[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl][(1-methyl-1H-imidazol-4-yl)sulfonyl]amino]-N-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 865788-35-8 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl-N-[(2-methylphenyl)methyl]- (CA INDEX NAME)




RN 910910-49-5 HCAPLUS

CN 2-Thiophenesulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-N-(phenylmethyl)- (CA INDEX NAME)




RN 910910-51-9 HCAPLUS

CN 8-Quinolinesulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-N-(phenylmethyl)- (CA INDEX NAME)



RN 910910-52-0 HCAPLUS


CN Acetamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-N-(phenylmethyl)- (CA INDEX NAME)



RN 910910-53-1 HCAPLUS


CN Propanamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-N-(phenylmethyl)- (CA INDEX NAME)

yl)methyl]amino]ethyl]-2-methyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 910910-54-2 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl-N-2-propen-1-yl- (CA INDEX NAME)




RN 910910-55-3 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl-N-(2-methyl-2-propen-1-yl)- (CA INDEX NAME)




RN 910910-56-4 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-(2-bromo-2-propen-1-yl)-N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl- (CA INDEX NAME)




RN 910910-57-5 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl-N-[2-(1H-pyrrol-1-yl)ethyl]- (CA INDEX NAME)




RN 910910-58-6 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl-N-[(tetrahydro-2H-pyran-4-yl)methyl]- (CA INDEX NAME)




RN 910910-60-0 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[(1-acetyl-4-piperidiny)methyl]-N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl- (CA INDEX NAME)




RN 910910-61-1 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl-N-[[1-(2-methyl-1-oxopropyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 910910-64-4 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl-N-[(3-methylphenyl)methyl]- (CA INDEX NAME)




RN 910910-66-6 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl-N-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 910910-67-7 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 910910-68-8 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl-N-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 910910-69-9 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[(3-cyanophenyl)methyl]-N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl- (CA INDEX NAME)




RN 910910-70-2 HCAPLUS
 CN 1H-Imidazole-4-sulfonamide, N-[(4-cyanophenyl)methyl]-N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl- (CA INDEX NAME)




IT 865788-39-2P 865788-42-7P 865788-43-8P
 865788-44-9P 865788-45-0P 865788-46-1P
 910910-72-4P 910910-73-5P 910910-82-6P
 910910-84-8P 910910-86-0P 910910-87-1P
 910910-88-2P 910910-89-3P 910910-90-6P
 910910-91-7P 910910-92-8P 910910-93-9P
 910910-94-0P 910910-95-1P 910910-96-2P
 910910-97-3P 910910-98-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of aminoethyl sulfonamide compds. their structure-activity relationship, pharmacokinetics, and methods for the treatment of malaria and cancer)

RN 865788-39-2 HCAPLUS
 CN Carbamic acid, [2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 865788-42-7 HCAPLUS
 CN Benzonitrile, 4-[[[(1-methyl-1H-imidazol-5-yl)methyl][2-[(phenylmethyl)amino]ethyl]amino]- (CA INDEX NAME)




RN 865788-43-8 HCAPLUS

CN Benzonitrile, 4-[[2-[(cyclohexylmethyl)amino]ethyl][(1-methyl-1H-imidazol-5-yl)methyl]amino]- (CA INDEX NAME)




RN 865788-44-9 HCAPLUS

CN Acetamide, 2-[[2-[(4-cyanophenyl][(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]amino]-N-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 865788-45-0 HCAPLUS


CN Benzonitrile, 4-[[2-[[[1,1'-biphenyl]-4-ylmethyl]amino]ethyl][(1-methyl-1H-imidazol-5-yl)methyl]amino]- (CA INDEX NAME)




RN 865788-46-1 HCAPLUS

CN Benzonitrile, 4-[[[(1-methyl-1H-imidazol-5-yl)methyl][2-[[[2-


methylphenyl)methyl]amino]ethyl]amino]- (CA INDEX NAME)




CN 1H-Imidazole-4-sulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl-N-[[3-(1H-pyrrol-1-yl)phenyl]methyl]- (CA INDEX NAME)



CN 1H-Imidazole-4-sulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl-N-[[4-(1H-pyrrol-1-yl)phenyl]methyl]- (CA INDEX NAME)




CN Benzonitrile, 4-[[(1-methyl-1H-imidazol-5-yl)methyl][2-(2-propen-1-ylamino)ethyl]amino]- (CA INDEX NAME)




RN 910910-84-8 HCAPLUS

CN Benzonitrile, 4-[[[(1-methyl-1H-imidazol-5-yl)methyl][2-[(2-methyl-2-propen-1-yl)amino]ethyl]amino]- (CA INDEX NAME)




RN 910910-86-0 HCAPLUS

CN Benzonitrile, 4-[[2-[(2-bromo-2-propen-1-yl)amino]ethyl] [(1-methyl-1H-imidazol-5-yl)methyl]amino]- (CA INDEX NAME)




RN 910910-87-1 HCAPLUS

CN Benzonitrile, 4-[[[(1-methyl-1H-imidazol-5-yl)methyl][2-[[2-(1H-pyrrol-1-yl)ethyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 910910-88-2 HCAPLUS

CN Benzonitrile, 4-[[[(1-methyl-1H-imidazol-5-yl)methyl][2-[(tetrahydro-2H-pyran-4-yl)methyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 910910-89-3 HCAPLUS

CN Benzonitrile, 4-[[[(1-methyl-1H-imidazol-5-yl)methyl][2-[[[(3-methylphenyl)methyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 910910-90-6 HCAPLUS

CN Benzonitrile, 4-[[[(1-methyl-1H-imidazol-5-yl)methyl][2-[[[(4-methylphenyl)methyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 910910-91-7 HCAPLUS

CN Benzonitrile, 4-[[[(1-methyl-1H-imidazol-5-yl)methyl][2-[(2-pyridinyl)methyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 910910-92-8 HCAPLUS

CN Benzonitrile, 4-[[[(1-methyl-1H-imidazol-5-yl)methyl][2-[(3-pyridinylmethyl)amino]ethyl]amino]- (CA INDEX NAME)




RN 910910-93-9 HCAPLUS

CN Benzonitrile, 4-[[[(1-methyl-1H-imidazol-5-yl)methyl][2-[(4-pyridinylmethyl)amino]ethyl]amino]- (CA INDEX NAME)




RN 910910-94-0 HCAPLUS

CN Benzonitrile, 3-[[[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]amino]methyl]- (CA INDEX NAME)




RN 910910-95-1 HCAPLUS

CN Benzonitrile, 4-[[2-[[[(4-cyanophenyl)methyl]amino]ethyl][(1-methyl-1H-imidazol-5-yl)methyl]amino]- (CA INDEX NAME)




RN 910910-96-2 HCAPLUS

CN Benzonitrile, 4-[[2-[[[1,1'-biphenyl]-3-ylmethyl]amino]ethyl][(1-methyl-1H-imidazol-5-yl)methyl]amino]- (CA INDEX NAME)




RN 910910-97-3 HCAPLUS

CN Benzonitrile, 4-[[[(1-methyl-1H-imidazol-5-yl)methyl][2-[[[3-(1H-pyrrol-1-yl)phenyl]methyl]amino]ethyl]amino]- (CA INDEX NAME)



RN 910910-98-4 HCAPLUS

CN Benzonitrile, 4-[[[(1-methyl-1H-imidazol-5-yl)methyl][2-[[[4-(1H-pyrrol-1-yl)phenyl]methyl]amino]ethyl]amino]- (CA INDEX NAME)



IT 910911-00-1

RL: RCT (Reactant); RACT (Reactant or reagent)

(starting material; preparation of aminoethyl sulfonamide compds. their structure-activity relationship, pharmacokinetics, and methods for the treatment of malaria and cancer)


RN 910911-00-1 HCAPLUS

CN Benzonitrile, 4-[(2-aminoethyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 910910-99-5


CMF C14 H17 N5



CM 2

CRN 76-05-1



CMF C2 H F3 O2



L44 ANSWER 5 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:655773 HCAPLUS Full-text
 DOCUMENT NUMBER: 145:124468
 TITLE: Preparation of 3,4-substituted piperidine compounds as
 renin inhibitors
 INVENTOR(S): Breitenstein, Werner; Ehara, Takeru; Ehrhardt, Claus;
 Grosche, Philipp; Hitomi, Yuko; Iwaki, Yuki; Kanazawa,
 Takanori; Konishi, Kazuhide; Maibaum, Juergen Klaus;
 Masuya, Keiichi; Nihonyanagi, Atsuko; Ostermann, Nils;
 Suzuki, Masaki; Toyao, Atsushi; Yokokawa, Fumiaki
 PATENT ASSIGNEE(S): Novartis AG, Switz.; Novartis Pharma GmbH
 SOURCE: PCT Int. Appl., 633 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006069788	A1	20060706	WO 2005-EP14102	20051228
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005321475	A1	20060706	AU 2005-321475	20051228
CA 2587348	A1	20060706	CA 2005-2587348	20051228
EP 1833816	A1	20070919	EP 2005-820552	20051228
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 101094848	A	20071226	CN 2005-80045028	20051228
JP 2008526701	T	20080724	JP 2007-548756	20051228
IN 2007DN03696	A	20070824	IN 2007-DN3696	20070517
MX 200708078	A	20070724	MX 2007-8078	20070629
KR 2007091174	A	20070907	KR 2007-715024	20070629
PRIORITY APPLN. INFO.:			GB 2004-28526	A 20041230
			WO 2005-EP14102	W 20051228

OTHER SOURCE(S): MARPAT 145:124468
 ED Entered STN: 07 Jul 2006
 GI



AB The title compds. I [R1 = H, alkyl, aryl, etc.; R2 = alkyl, aryl, heterocyclyl, etc.; W = substituted Ph, pyridyl, etc.; T = methylene or carbonyl; R11 = H, OH, halo, etc.] were prepared and formulated for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (or disorder) that depends on activity of renin. E.g., a multi-step synthesis of II, starting from 4-trifluoromethanesulfonyloxy-5,6-dihydro-2H-pyridine-1,3-dicarboxylic acid 1-tert-Bu ester 3-Me ester and 3-biphenylboronic acid, was given. Compds. I preferably show IC50 values in the range from 1 nM to 5 μ M in recombinant human renin assay (no specific data given).

IT 897945-83-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3,4-substituted piperidine compds. as renin inhibitors)

RN 897945-83-4 HCAPLUS

CN 3-Piperidinecarboxamide, 4-[1,1'-biphenyl]-3-yl-N-[4-cyano-3-(3-methoxypropoxy)phenyl]-N-cyclopropyl-, (3R,4S)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 897955-95-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 3,4-substituted piperidine compds. as renin inhibitors)

RN 897955-95-2 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[1,1'-biphenyl]-3-yl-3-[[[4-cyano-3-(3-methoxypropoxy)phenyl]cyclopropylamino]carbonyl]-, 1,1-dimethylethyl ester, (3R,4S)-rel- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L44 ANSWER 6 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:852846 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 145:410021

TITLE: Structurally Simple, Potent, Plasmodium Selective Farnesyltransferase Inhibitors That Arrest the Growth of Malaria Parasites

AUTHOR(S): Glenn, Matthew P.; Chang, Sung-Youn; Horney, Carrie; Rivas, Kasey; Yokoyama, Kohei; Pusateri, Erin E.; Fletcher, Steven; Cummings, Christopher G.; Buckner, Frederick S.; Pendyala, Prakash R.; Chakrabarti, Debopam; Sebti, Saied M.; Gelb, Michael; Van Voorhis, Wesley C.; Hamilton, Andrew D.

CORPORATE SOURCE: Department of Chemistry, Yale University, New Haven, CT, 06511, USA

SOURCE: Journal of Medicinal Chemistry (2006), 49(19), 5710-5727

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 145:410021

ED Entered STN: 25 Aug 2006

AB Third world nations require immediate access to inexpensive therapeutics to counter the high mortality inflicted by malaria. Here, the authors report a new class of antimalarial protein farnesyltransferase (PFT) inhibitors, designed with specific emphasis on simple mol. architecture, to facilitate easy access to therapies based on this recently validated antimalarial target. This novel series of compds. represents the first Plasmodium falciparum selective PFT inhibitors reported (up to 145-fold selectivity), with lead inhibitors displaying excellent in vitro activity (IC₅₀ < 1 nM) and toxicity to cultured parasites at low concns. (ED₅₀ < 100 nM). Initial studies of absorption, metabolism, and oral bioavailability are reported.

IT 865788-27-8P 865788-32-5P 865788-34-7P
865788-35-8P 910910-50-8P 910910-62-2P
910910-63-3P 910910-66-6P 910910-73-5P


RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(structurally simple, potent, Plasmodium selective farnesyltransferase inhibitors that arrest the growth of malaria parasites)

RN 865788-27-8 HCAPLUS


CN 1H-Imidazole-4-sulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-

yl)methyl]amino]ethyl]-1-methyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 865788-32-5 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-N-(cyclohexylmethyl)-1-methyl- (CA INDEX NAME)




RN 865788-34-7 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-([1,1'-biphenyl]-4-ylmethyl)-N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl- (CA INDEX NAME)




RN 865788-35-8 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl-N-[(2-methylphenyl)methyl]- (CA INDEX NAME)




RN 910910-50-8 HCAPLUS

CN 2-Pyridinesulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-N-(phenylmethyl)- (CA INDEX NAME)




RN 910910-62-2 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl][(1-methyl-1H-imidazol-4-yl)sulfonyl]amino]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 910910-63-3 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl-N-[[1-(2-pyrimidinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 910910-66-6 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl-N-(2-pyridinylmethyl)- (CA INDEX NAME)



RN 910910-73-5 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl-N-[[4-(1H-pyrrol-1-yl)phenyl]methyl]- (CA INDEX NAME)



IT 865788-30-3P 865788-31-4P 865788-33-6P
 910910-49-5P 910910-51-9P 910910-52-0P
 910910-53-1P 910910-54-2P 910910-55-3P
 910910-56-4P 910910-57-5P 910910-58-6P
 910910-59-7P 910910-60-0P 910910-61-1P
 910910-64-4P 910910-65-5P 910910-67-7P
 910910-68-8P 910910-69-9P 910910-70-2P
 910910-71-3P 910910-72-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

Serial No.:10/598,508

(structurally simple, potent, Plasmodium selective farnesyltransferase inhibitors that arrest the growth of malaria parasites)


RN 865788-30-3 HCAPLUS

CN Benzenesulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-N-(phenylmethyl)- (CA INDEX NAME)




RN 865788-31-4 HCAPLUS

CN 1-Naphthalenesulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-5-(dimethylamino)-N-(phenylmethyl)- (CA INDEX NAME)




RN 865788-33-6 HCAPLUS

CN Acetamide, 2-[[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl][(1-methyl-1H-imidazol-4-yl)sulfonyl]amino]-N-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 910910-49-5 HCAPLUS

CN 2-Thiophenesulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-N-(phenylmethyl)- (CA INDEX NAME)




RN 910910-51-9 HCAPLUS

CN 8-Quinolinesulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-N-(phenylmethyl)- (CA INDEX NAME)



RN 910910-52-0 HCAPLUS


CN Acetamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-N-(phenylmethyl)- (CA INDEX NAME)



RN 910910-53-1 HCAPLUS


Serial No.:10/598,508

CN Propanamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-2-methyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 910910-54-2 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl-N-2-propen-1-yl- (CA INDEX NAME)




RN 910910-55-3 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl-N-(2-methyl-2-propen-1-yl)- (CA INDEX NAME)




RN 910910-56-4 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-(2-bromo-2-propen-1-yl)-N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl- (CA INDEX NAME)




RN 910910-57-5 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl-N-[2-(1H-pyrrol-1-yl)ethyl]- (CA INDEX NAME)




RN 910910-58-6 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl-N-[(tetrahydro-2H-pyran-4-yl)methyl]- (CA INDEX NAME)




RN 910910-59-7 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl-N-(4-piperidinylmethyl)- (CA INDEX NAME)




RN 910910-60-0 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[(1-acetyl-4-piperidiny)methyl]-N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl- (CA INDEX NAME)




RN 910910-61-1 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl-N-[1-(2-methyl-1-oxopropyl)-4-piperidiny)methyl]- (CA INDEX NAME)




RN 910910-64-4 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl-N-[(3-methylphenyl)methyl]- (CA INDEX NAME)




RN 910910-65-5 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl-N-[(4-methylphenyl)methyl]- (CA INDEX NAME)




RN 910910-67-7 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 910910-68-8 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl-N-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 910910-69-9 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[(3-cyanophenyl)methyl]-N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl- (CA INDEX NAME)




RN 910910-70-2 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[(4-cyanophenyl)methyl]-N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl- (CA INDEX NAME)



RN 910910-71-3 HCAPLUS


CN 1H-Imidazole-4-sulfonamide, N-([1,1'-biphenyl]-3-ylmethyl)-N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl- (CA INDEX NAME)



RN 910910-72-4 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl-N-[[3-(1H-pyrrol-1-yl)phenyl]methyl]- (CA INDEX NAME)

INDEX NAME)



IT 910911-00-1

RL: RCT (Reactant); RACT (Reactant or reagent)

(structurally simple, potent, Plasmodium selective farnesyltransferase inhibitors that arrest the growth of malaria parasites)


RN 910911-00-1 HCAPLUS

CN Benzonitrile, 4-[(2-aminoethyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 910910-99-5


CMF C14 H17 N5



CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT 865788-39-2P 865788-42-7P 865788-43-8P
 865788-44-9P 865788-45-0P 865788-46-1P
 910910-82-6P 910910-84-8P 910910-86-0P
 910910-87-1P 910910-88-2P 910910-89-3P
 910910-90-6P 910910-91-7P 910910-92-8P
 910910-93-9P 910910-94-0P 910910-95-1P
 910910-96-2P 910910-97-3P 910910-98-4P


912482-46-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(structurally simple, potent, Plasmodium selective farnesyltransferase inhibitors that arrest the growth of malaria parasites)


RN 865788-39-2 HCAPLUS

CN Carbamic acid, [2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 865788-42-7 HCAPLUS

CN Benzonitrile, 4-[[[(1-methyl-1H-imidazol-5-yl)methyl][2-[(phenylmethyl)amino]ethyl]amino]- (CA INDEX NAME)




RN 865788-43-8 HCAPLUS

CN Benzonitrile, 4-[[2-[(cyclohexylmethyl)amino]ethyl][(1-methyl-1H-imidazol-5-yl)methyl]amino]- (CA INDEX NAME)




RN 865788-44-9 HCAPLUS

CN Acetamide, 2-[[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]amino]-N-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 865788-45-0 HCAPLUS

CN Benzonitrile, 4-[[2-[[[1,1'-biphenyl]-4-ylmethyl]amino]ethyl][(1-methyl-1H-imidazol-5-yl)methyl]amino]- (CA INDEX NAME)




RN 865788-46-1 HCAPLUS

CN Benzonitrile, 4-[[[(1-methyl-1H-imidazol-5-yl)methyl][2-[[[2-methylphenyl]methyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 910910-82-6 HCAPLUS

CN Benzonitrile, 4-[[[(1-methyl-1H-imidazol-5-yl)methyl][2-(2-propen-1-ylamino)ethyl]amino]- (CA INDEX NAME)




RN 910910-84-8 HCAPLUS

CN Benzonitrile, 4-[[[(1-methyl-1H-imidazol-5-yl)methyl][2-[(2-methyl-2-propen-1-yl)amino]ethyl]amino]- (CA INDEX NAME)




RN 910910-86-0 HCAPLUS

CN Benzonitrile, 4-[[2-[(2-bromo-2-propen-1-yl)amino]ethyl][(1-methyl-1H-imidazol-5-yl)methyl]amino]- (CA INDEX NAME)




RN 910910-87-1 HCAPLUS

CN Benzonitrile, 4-[[[(1-methyl-1H-imidazol-5-yl)methyl][2-[[2-(1H-pyrrol-1-yl)ethyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 910910-88-2 HCAPLUS

CN Benzonitrile, 4-[[[(1-methyl-1H-imidazol-5-yl)methyl][2-[[[(tetrahydro-2H-pyran-4-yl)methyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 910910-89-3 HCAPLUS

CN Benzonitrile, 4-[[[(1-methyl-1H-imidazol-5-yl)methyl][2-[[3-methylphenyl)methyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 910910-90-6 HCAPLUS

CN Benzonitrile, 4-[[[(1-methyl-1H-imidazol-5-yl)methyl][2-[[4-methylphenyl)methyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 910910-91-7 HCAPLUS

CN Benzonitrile, 4-[[[(1-methyl-1H-imidazol-5-yl)methyl][2-[(2-pyridinyl)methyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 910910-92-8 HCAPLUS

CN Benzonitrile, 4-[[[(1-methyl-1H-imidazol-5-yl)methyl][2-[(3-pyridinylmethyl)amino]ethyl]amino]- (CA INDEX NAME)




RN 910910-93-9 HCAPLUS

CN Benzonitrile, 4-[[[(1-methyl-1H-imidazol-5-yl)methyl][2-[(4-pyridinylmethyl)amino]ethyl]amino]- (CA INDEX NAME)




RN 910910-94-0 HCAPLUS

CN Benzonitrile, 3-[[[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]amino]methyl]- (CA INDEX NAME)




RN 910910-95-1 HCAPLUS

CN Benzonitrile, 4-[[2-[[[(4-cyanophenyl)methyl]amino]ethyl][(1-methyl-1H-imidazol-5-yl)methyl]amino]- (CA INDEX NAME)




RN 910910-96-2 HCAPLUS

CN Benzonitrile, 4-[[2-[[[1,1'-biphenyl]-3-ylmethyl]amino]ethyl][(1-methyl-1H-imidazol-5-yl)methyl]amino]- (CA INDEX NAME)




RN 910910-97-3 HCAPLUS

CN Benzonitrile, 4-[[[(1-methyl-1H-imidazol-5-yl)methyl][2-[[[3-(1H-pyrrol-1-yl)phenyl]methyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 910910-98-4 HCAPLUS

CN Benzonitrile, 4-[[[(1-methyl-1H-imidazol-5-yl)methyl][2-[[[4-(1H-pyrrol-1-yl)phenyl]methyl]amino]ethyl]amino]- (CA INDEX NAME)



RN 912482-46-3 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl- (CA INDEX NAME)



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L44 ANSWER 7 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1042201 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 143:326203

TITLE: Arylamines as androgen receptor modulators, their preparation, pharmaceutical compositions, and use in therapy

INVENTOR(S): Zhi, Lin; Higuchi, Robert I.; Kallel, E. Adam; Van Oeveren, Cornelis Arjan; Chen, Jyun-Hung; Ruppar, Daniel A.; Pedram, Bijan; Lau, Thomas Lot Stevens;

Serial No.:10/598,508

PATENT ASSIGNEE(S): Miller, Todd
 SOURCE: Ligand Pharmaceuticals Incorporated, USA
 PCT Int. Appl., 156 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005090282	A1	20050929	WO 2005-US7867	20050311
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20070254875	A1	20071101	US 2007-590119	20070611
PRIORITY APPLN. INFO.:			US 2004-552690P	P 20040312
			WO 2005-US7867	W 20050311
OTHER SOURCE(S): CASREACT 143:326203; MARPAT 143:326203				
ED Entered STN: 29 Sep 2005				
GI				


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a group of amines, e.g., I, which act as modulators of androgen receptors and/or androgen receptor binding agents. In compds. I, R1 and R2 are independently selected from H, F, Cl, Br, I, OH, (un)substituted C1-4 alkoxy, etc.; R3, R4, and R5 are independently selected from H, F, Cl, OH, (un)substituted C1-4 alkoxy, (un)substituted C1-4 alkyl, and (un)substituted C1-4 haloalkyl; R6 and R7 are independently selected from H, (un)substituted C1-6 alkyl, (un)substituted C1-6 haloalkyl, (un)substituted C1-6 heteroalkyl, (un)substituted C2-6 alkynyl, and (un)substituted C2-6 alkenyl, or R6 and R7 together form a carbonyl; R9 is selected from H, (un)substituted C1-8 alkyl, (un)substituted C2-8 alkenyl, (un)substituted C1-8 haloalkyl, (un)substituted aryl, (un)substituted heteroaryl, etc.; R10 is selected from H, (un)substituted C1-6 alkyl, (un)substituted C1-6 haloalkyl, (un)substituted C1-6 heteroalkyl, (un)substituted C2-6 alkynyl, and (un)substituted C2-6 alkenyl; R12 and R13 are independently selected from H, F, Cl, OH, (un)substituted C1-4 alkoxy, (un)substituted amino, (un)substituted C1-6 alkyl, etc.; Z is O, S, (un)substituted C, or (un)substituted N; and n is 0-2; provided that if R1 is NO2 and R3 is F, then Z is not O; including pharmaceutically acceptable salts, esters, amides or prodrugs thereof. The invention also relates to the preparation of the compds. of the invention, pharmaceutical compns. containing compds. of the invention along with a pharmaceutically acceptable carrier, as well as to the use of the compns. for treating various conditions. 3-(Trifluoromethyl)-4-nitrobromobenzene underwent palladium-mediated coupling with chiral pyrrolidinone II followed by reduction to the corresponding pyrrolidine, and desilylation to give alc. III. Oxidation of III to the corresponding aldehyde was followed by addition of

Serial No.:10/598,508

TMSCF3 to give IV along with its separable (R,R)-diastereomer. Some of the compds. of the invention act as androgen receptor agonists, others as androgen receptor antagonists, androgen receptor partial agonists, or tissue-specific modulators (no data).


IT 821777-55-3P, 4-[Bis(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of arylamines as androgen receptor modulators)
 RN 821777-55-3 HCAPLUS
 CN Benzonitrile, 4-[bis(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)- (CA INDEX NAME)



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L44 ANSWER 8 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:116451 HCAPLUS Full-text
 DOCUMENT NUMBER: 142:191223
 TITLE: Styrene derivatives as tyrosine kinase inhibitors, their preparation, their prodrugs, pharmaceuticals containing them, combination therapy using them, and use of them in manufacture of tyrosine kinase inhibitors and antitumor agents
 INVENTOR(S): Tasaka, Akihiro; Taniguchi, Takahiko; Tsujimoto, Saori; Naito, Kenichiro
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 82 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005035944	A	20050210	JP 2003-275675	20030716
PRIORITY APPLN. INFO.:			JP 2003-275675	20030716
OTHER SOURCE(S): MARPAT 142:191223				
ED Entered STN: 10 Feb 2005				
GI				



AB The derivs. I [$n = 1, 2$; $Y = O, S$; $R_1 = \text{halo, C1-2 (halo)alkyl}$; $R_2, R_3 = H, \text{halo, C1-2 (halo)alkyl}$; $R_4 = H, OH, \text{C1-4 (halo)alkyl}$; $R_5 = \text{halo, cyano, OH, C1-6 (halo)alkyl, C1-6 hydroxyalkoxy, C1-6 haloalkoxy, carboxy, C1-6 alkoxy, carbonyl}$; $R_6-R_8 = H, \text{any group given for } R_5$; $R_9 = \text{triazolylalkyl Q, imidazolylalkyl Q1 (m = 2-5; R_{10} = \text{C1-6 alkyl which may be substituted with 1-3 OH})}$] or their salts, useful for prevention/treatment of cancers, are prepared by reacting styryl(oxazoles or thiazoles) II ($R_1-R_4, n, Y = \text{same as above; } X = \text{leaving group}$) or their salts with phenols III ($R_5-R_9 = \text{same as above}$) or their salts. Also claimed are prodrugs of I, pharmaceutical compns. containing I (salts) or their prodrugs, drugs combining I (salts) or their prodrugs with antitumor agents or hormones such as leuporelin, method for inhibition of tyrosine kinase or prevention/treatment of cancers by administering I (salts) or their prodrugs to mammals, and use of I (salts) or their prodrugs in manufacture of tyrosine kinase inhibitors and antitumor agents. Administration of I (salts) or their prodrugs may be performed prior to surgery, radiotherapy, gene therapy, hyperthermia, cryotherapy, and/or laser cauterization. Thus, [1-[4-[4-[[2-[(E)-2-(4-bromo-2-fluorophenyl)ethenyl]-1,3-oxazol-4-yl]methoxy]-2-methylphenyl]butyl]-1H-imidazol-2-yl]methanol (IV; preparation given) inhibited growth of human BT-474 breast cancer cell at $IC_{50} < 0.05 \mu M$. Tablets containing IV were also formulated.


IT 568594-05-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of heterocycle-containing styrene derivs. as tyrosine kinase inhibitors for prevention/treatment of cancers, etc.)

RN 568594-05-8 HCAPLUS

CN Benzonitrile, 4-[[2-(1H-imidazol-1-yl)ethyl]methylamino]- (CA INDEX NAME)



L44 ANSWER 9 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:539693 HCAPLUS Full-text
 DOCUMENT NUMBER: 143:59983
 TITLE: Preparation of phenylaminoimidazoles as aromatase and/or steroid sulfatase and/or carbonic anhydrase inhibitors.
 INVENTOR(S): Lafay, Jean; Rondot, Benoit; Bonnet, Paule; Clerc, Thierry; Shields, Jacqueline; Duc, Igor; Duranti, Eric; Puccio, Francois; Blot, Christian; Maillos, Philippe
 PATENT ASSIGNEE(S): Laboratoire Theramex, Monaco
 SOURCE: Eur. Pat. Appl., 25 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1544195	A1	20050622	EP 2003-293152	20031215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AU 2004299286	A1	20050630	AU 2004-299286	20041215
CA 2549603	A1	20050630	CA 2004-2549603	20041215
WO 2005058842	A1	20050630	WO 2004-EP14847	20041215
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1694650	A1	20060830	EP 2004-804432	20041215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
CN 1890221	A	20070103	CN 2004-80036357	20041215
BR 2004017407	A	20070403	BR 2004-17407	20041215
JP 2007515420	T	20070614	JP 2006-544394	20041215


Serial No.:10/598,508

NO 2006002710	A	20060630	NO 2006-2710	20060612
IN 2006DN03428	A	20070420	IN 2006-DN3428	20060614
MX 2006PA06837	A	20060904	MX 2006-PA6837	20060615
US 20070112009	A1	20070517	US 2006-582778	20060817
PRIORITY APPLN. INFO.:			EP 2003-293152	A 20031215
			EP 2004-292681	A 20041112
			WO 2004-EP14847	W 20041215

OTHER SOURCE(S): CASREACT 143:59983; MARPAT 143:59983

ED Entered STN: 23 Jun 2005

GI



AB Title compds. [I; R1, R2 = H, alkyl, cycloalkyl; R1R2 = atoms to form a 5-7 membered (unsatd.) carbocyclyl; n = 0-2; 1 of R3, R4 = OH, NO2, NR7R8, OSO2NR7R8, NR7SO2NR7R8; the other of R3, R4 = H, OH, cyano, halo, NO2, alkyl, alkoxy, CF3, alkylthio, alkylsulfonyl, acyl, alkoxycarbonyl, carboxamido, NR7R8, OSO2NR7R8, NR7SO2NR7R8; R7, R8 = H, alkyl, cycloalkyl; m = 1-4; R5, R6 = OH, cyano, halo, NO2, alkyl, alkoxy, CF3, alkylthio, alkylsulfonyl, acyl, alkoxycarbonyl, carboxamido, R7R8, OSO2NR7R8, NR7SO2NR7R8; R4RR5 = atoms to form a benzoxathiazine dioxide or dihydrobenzoxathiazine dioxide ring; R3R6 = atoms to form a benzofuryl, N-methylbenzotriazole ring], were prepared Thus, a mixture of 4-hydroxybenzyl bromide, 4-[N-(1H-imidazol-1-yl)amino]benzonitrile (preparation given), and K2CO3 were stirred together for 2 h in THF to give 41% 4-[N-(4-hydroxyphenylmethyl)-N-(1H-imidazol-1-yl)amino]benzonitrile. The latter inhibited human aromatase with IC50 = 0.16 nM.


IT 854602-76-9P, 4-[N-[(2,2-Dioxido-1,2,3-benzoxathiazin-6-yl)methyl]-N-(1H-imidazol-1-yl)amino]benzonitrile

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of phenylaminoimidazoles as aromatase and/or steroid sulfatase and/or carbonic anhydrase inhibitors)

RN 854602-76-9 HCAPLUS


CN Benzonitrile, 4-[[[(2,2-dioxido-1,2,3-benzoxathiazin-6-yl)methyl]-1H-imidazol-1-ylamino]- (CA INDEX NAME)



IT 854602-62-3P, 4-[N-(4-Hydroxyphenylmethyl)-N-(1H-imidazol-1-yl)amino]benzonitrile 854602-63-4P, 4-[N-(3-Chloro-4-hydroxyphenylmethyl)-N-(1H-imidazol-1-yl)amino]benzonitrile 854602-64-5P, 4-[N-(3-Bromo-4-hydroxyphenylmethyl)-N-(1H-imidazol-1-yl)amino]benzonitrile 854602-65-6P, 4-[N-(4-Hydroxy-3-methoxyphenylmethyl)-N-(1H-imidazol-1-yl)amino]benzonitrile 854602-66-7P, 4-[N-(2,3,5,6-Tetrafluoro-4-hydroxyphenylmethyl)-N-(1H-imidazol-1-yl)amino]benzonitrile 854602-67-8P, 4-[N-(3-Formyl-4-hydroxyphenylmethyl)-N-(1H-imidazol-1-yl)amino]benzonitrile 854602-71-4P 854602-72-5P 854602-73-6P 854602-74-7P 854602-75-8P 854602-78-1P, 4-[N-[(2,2-Dioxido-3,4-dihydro-1,2,3-benzoxathiazin-6-yl)methyl]-N-(1H-imidazol-1-yl)amino]benzonitrile
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of phenylaminoimidazoles as aromatase and/or steroid sulfatase and/or carbonic anhydrase inhibitors)


RN 854602-62-3 HCAPLUS

CN Benzonitrile, 4-[[4-(4-hydroxyphenyl)methyl]-1H-imidazol-1-ylamino]- (CA INDEX NAME)




RN 854602-63-4 HCAPLUS

CN Benzonitrile, 4-[[3-chloro-4-hydroxyphenyl)methyl]-1H-imidazol-1-ylamino]- (CA INDEX NAME)




RN 854602-64-5 HCAPLUS

CN Benzonitrile, 4-[[(3-bromo-4-hydroxyphenyl)methyl]-1H-imidazol-1-ylamino]-
(CA INDEX NAME)




RN 854602-65-6 HCAPLUS

CN Benzonitrile, 4-[[(4-hydroxy-3-methoxyphenyl)methyl]-1H-imidazol-1-ylamino]-
(CA INDEX NAME)




RN 854602-66-7 HCAPLUS

CN Benzonitrile, 4-[1H-imidazol-1-yl[(2,3,5,6-tetrafluoro-4-hydroxyphenyl)methyl]amino]-
(CA INDEX NAME)




RN 854602-67-8 HCAPLUS

CN Benzonitrile, 4-[[(3-formyl-4-hydroxyphenyl)methyl]-1H-imidazol-1-ylamino]-
(CA INDEX NAME)




RN 854602-71-4 HCAPLUS

CN Sulfamic acid, 4-[[(4-cyanophenyl)-1H-imidazol-1-ylamino]methyl]phenyl
ester (CA INDEX NAME)




RN 854602-72-5 HCAPLUS

CN Sulfamic acid, 2-chloro-4-[[(4-cyanophenyl)-1H-imidazol-1-ylamino]methyl]phenyl ester
(CA INDEX NAME)




RN 854602-73-6 HCAPLUS

CN Benzonitrile, 4-[[[4-[(aminosulfonyl)oxy]-3-bromophenyl]methyl]-1H-imidazol-1-ylamino]- (CA INDEX NAME)




RN 854602-74-7 HCAPLUS

CN Sulfamic acid, 4-[[[4-(4-cyanophenyl)-1H-imidazol-1-ylamino]methyl]-2-methoxyphenyl ester (CA INDEX NAME)




RN 854602-75-8 HCAPLUS

CN Sulfamic acid, 4-[[[4-(4-cyanophenyl)-1H-imidazol-1-ylamino]methyl]-2,3,5,6-tetrafluorophenyl ester (CA INDEX NAME)



RN 854602-78-1 HCAPLUS
 CN Benzonitrile, 4-[[[(3,4-dihydro-2,2-dioxido-1,2,3-benzoxathiazin-6-yl)methyl]-1H-imidazol-1-ylamino]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L44 ANSWER 10 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:954488 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 143:338963

TITLE: Structurally simple farnesyltransferase inhibitors arrest the growth of malaria parasites

AUTHOR(S): Glenn, Matthew P.; Chang, Sung-Youn; Hucke, Oliver; Verlinde, Christophe L. M. J.; Rivas, Kasey; Horney, Carrie; Yokoyama, Kohei; Buckner, Frederick S.; Pendyala, Prakash R.; Chakrabarti, Debopam; Gelb, Michael; Van Voorhis, Wesley C.; Sebti, Said M.; Hamilton, Andrew D.

CORPORATE SOURCE: Department of Chemistry, Yale University, New Haven, CT, 06511, USA

SOURCE: Angewandte Chemie, International Edition (2005), 44(31), 4903-4906

CODEN: ACIEF5; ISSN: 1433-7851

PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 143:338963

ED Entered STN: 01 Sep 2005

AB Antimalarial compds.: Structurally simple acyclic inhibitors of protein farnesyltransferase (active-site model shown) from the malaria parasite

Serial No.:10/598,508

Plasmodium falciparum may allow third world countries access to an effective and inexpensive antimalarial therapy to counter the estimated half billion infections that occur annually.


IT 865788-35-8P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(oral farnesyltransferase inhibitors preparation as antimalarial drugs)

RN 865788-35-8 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl-N-[(2-methylphenyl)methyl]- (CA INDEX NAME)



IT 865788-27-8P 865788-30-3P 865788-31-4P


865788-32-5P 865788-33-6P 865788-34-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(oral farnesyltransferase inhibitors preparation as antimalarial drugs)


RN 865788-27-8 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 865788-30-3 HCAPLUS

CN Benzenesulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-N-(phenylmethyl)- (CA INDEX NAME)




RN 865788-31-4 HCAPLUS

CN 1-Naphthalenesulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-5-(dimethylamino)-N-(phenylmethyl)- (CA INDEX NAME)




RN 865788-32-5 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-N-(cyclohexylmethyl)-1-methyl- (CA INDEX NAME)




RN 865788-33-6 HCAPLUS

CN Acetamide, 2-[[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl][(1-methyl-1H-imidazol-4-yl)sulfonyl]amino]-N-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 865788-34-7 HCAPLUS

CN 1H-Imidazole-4-sulfonamide, N-([1,1'-biphenyl]-4-ylmethyl)-N-[2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-1-methyl- (CA INDEX NAME)



IT 865788-39-2P 865788-42-7P 865788-43-8P


865788-44-9P 865788-45-0P 865788-46-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(oral farnesyltransferase inhibitors preparation as antimalarial drugs)


RN 865788-39-2 HCAPLUS

CN Carbamic acid, [2-[(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 865788-42-7 HCAPLUS

CN Benzonitrile, 4-[[[(1-methyl-1H-imidazol-5-yl)methyl][2-[(phenylmethyl)amino]ethyl]amino]- (CA INDEX NAME)




RN 865788-43-8 HCAPLUS

CN Benzonitrile, 4-[[2-[(cyclohexylmethyl)amino]ethyl][(1-methyl-1H-imidazol-5-yl)methyl]amino]- (CA INDEX NAME)




RN 865788-44-9 HCAPLUS

CN Acetamide, 2-[[2-[(4-cyanophenyl][(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]amino]-N-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 865788-45-0 HCAPLUS

CN Benzonitrile, 4-[[2-[[[1,1'-biphenyl]-4-ylmethyl]amino]ethyl][(1-methyl-1H-imidazol-5-yl)methyl]amino]- (CA INDEX NAME)



RN 865788-46-1 HCAPLUS

CN Benzonitrile, 4-[[[(1-methyl-1H-imidazol-5-yl)methyl][2-[(2-methylphenyl)methyl]amino]ethyl]amino]- (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L44 ANSWER 11 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:402307 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 140:406807

TITLE: Preparation of 1-phenylamino-1H-imidazoles as aromatase inhibitors

INVENTOR(S): Adje, Nathalie; Bonnet, Paule; Carniato, Denis; Delansorne, Remi; Lafay, Jean; Pascal, Jean-Claude

PATENT ASSIGNEE(S): Laboratoire Theramex, Monaco

SOURCE: U.S., 13 pp.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6737433	B1	20040518	US 2002-319840	20021216
EP 1431292	A1	20040623	EP 2002-293107	20021216
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CA 2510175	A1	20040701	CA 2003-2510175	20031215
WO 2004054983	A2	20040701	WO 2003-EP15027	20031215
WO 2004054983	A3	20040805		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				

Serial No.:10/598,508

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
 NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
 TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2003298259 A1 20040709 AU 2003-298259 20031215
 EP 1572665 A2 20050914 EP 2003-795984 20031215
 EP 1572665 B1 20060503
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 BR 2003017339 A 20051108 BR 2003-17339 20031215
 CN 1720235 A 20060111 CN 2003-80105101 20031215
 JP 2006511546 T 20060406 JP 2004-560486 20031215
 AT 325102 T 20060615 AT 2003-795984 20031215
 PT 1572665 T 20060929 PT 2003-795984 20031215
 ES 2264032 T3 20061216 ES 2003-795984 20031215
 NZ 540643 A 20071130 NZ 2003-540643 20031215
 RU 2327691 C2 20080627 RU 2005-122469 20031215
 ZA 2005004570 A 20060830 ZA 2005-4570 20050603
 NO 2005002780 A 20050608 NO 2005-2780 20050608
 MX 2005PA06530 A 20060217 MX 2005-PA6530 20050616
 HK 1083218 A1 20061201 HK 2006-103250 20060314
 PRIORITY APPLN. INFO.: EP 2002-293107 A 20021216
 US 2002-319840 A 20021216
 WO 2003-EP15027 W 20031215
 OTHER SOURCE(S): CASREACT 140:406807; MARPAT 140:406807
 ED Entered STN: 18 May 2004
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein R1, R2 = independently H, cyclo/alkyl; X = (CH2)n; n = 0-2; R3, R4, R5, R6 = independently H, alkyl, cyano, alkoxy, CF3, alkylthio, alkylsulfonyl, sulfonamido, acyl, alkoxycarbonyl, carboxamido; R3CCR6 = benzofuran, N-methylbenzotriazole; their acid addition salts, solvates and stereoisomeric forms] were prepared as aromatase inhibitors, in particular for controlling and managing reproduction functions, and treatment of related tumors. For example, II was prepared, in 60%, by N-arylation of N-(1H-Imidazol-1-yl)-4-trifluoromethylaniline with 4-fluorobenzonitrile in DMSO. III•HCl displayed an IC50 = 0.18 .-+. 0.02 nM for the inhibition of human aromatase in vitro. III•HCl showed 57-59% inhibition of aromatase in vivo. Selected I are inhibitors of estrogen biosynthesis in vivo.

IT 690248-14-7P, 4-[N-(1H-Imidazol-1-yl)-N-(4-trifluoromethylphenylmethyl)amino]benzonitrile 690248-24-9P, 4-[N-(1H-Imidazol-1-yl)-N-(4-chlorophenylmethyl)amino]benzonitrile hydrochloride 690248-25-0P, 4-[N-(1H-Imidazol-1-yl)-N-(4-methoxyphenylmethyl)amino]benzonitrile hydrochloride 690248-26-1P, 4-[N-(1H-Imidazol-1-yl)-N-[(3-fluoro-4-methoxyphenyl)methyl]amino]benzonitrile hydrochloride 690248-27-2P, 4-[N-(1H-Imidazol-1-yl)-N-(4-methylphenylmethyl)amino]benzonitrile 690248-28-3P, 4-[N-(1H-Imidazol-1-yl)-N-(4-cyanophenylmethyl)amino]benzonitrile hydrochloride 690248-29-4P, 4-[N-(1H-Imidazol-1-yl)-N-[(3,4-dimethoxyphenyl)methyl]amino]benzonitrile hydrochloride 690248-31-8P 690248-32-9P, 4-[N-(1H-Imidazol-1-yl)-N-[(4-methylthiophenyl)methyl]amino]benzonitrile 690248-33-0P,

Serial No.:10/598,508


4-[N-(1H-Imidazol-1-yl)-N-[(4-methylsulfonylphenyl)methyl]amino]benzonitrile 690248-34-1P, 4-[N-(1H-Imidazol-1-yl)-N-(3,4-difluorophenylmethyl)amino]benzonitrile 690248-35-2P, 4-[N-(1H-Imidazol-1-yl)-N-(2,4-difluorophenylmethyl)amino]benzonitrile 690248-36-3P, 4-[N-(1H-Imidazol-1-yl)-N-(3,5-difluorophenylmethyl)amino]benzonitrile 690248-37-4P, 4-[N-(1H-Imidazol-1-yl)-N-(4-bromophenylmethyl)amino]benzonitrile hydrochloride 690248-41-0P, 4-[N-(1H-Imidazol-1-yl)-N-(phenylmethyl)amino]benzonitrile 690248-43-2P, 4-[N-(1H-Imidazol-1-yl)-N-(3-fluorophenylmethyl)amino]benzonitrile 690248-44-3P, Methyl 4-[[N-(4-cyanophenyl)-N-(1H-imidazol-1-yl)amino]methyl]benzoate 690248-46-5P, 4-[N-(1H-Imidazol-1-yl)-N-(3-trifluoromethylphenylmethyl)amino]benzonitrile 690248-50-1P, 4-[N-(4-Methyl-1H-imidazol-1-yl)-N-(4-bromophenylmethyl)amino]benzonitrile 690248-51-2P, 4-[N-(5-Methyl-1H-imidazol-1-yl)-N-(4-bromophenylmethyl)amino]benzonitrile 690248-52-3P, 4-[N-(4,5-Dimethyl-1H-imidazol-1-yl)-N-(4-bromophenylmethyl)amino]benzonitrile

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(aromatase inhibitor; preparation of 1-phenylamino-1H-imidazoles as aromatase inhibitors)


RN 690248-14-7 HCAPLUS

CN Benzonitrile, 4-[1H-imidazol-1-yl][[4-(trifluoromethyl)phenyl]methyl]amino]-(CA INDEX NAME)



RN 690248-24-9 HCAPLUS


CN Benzonitrile, 4-[[[(4-chlorophenyl)methyl]-1H-imidazol-1-ylamino]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 690248-25-0 HCAPLUS


CN Benzonitrile, 4-[1H-imidazol-1-yl]-(4-methoxyphenyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 690248-26-1 HCAPLUS

CN Benzonitrile, 4-[[[3-fluoro-4-methoxyphenyl)methyl]-1H-imidazol-1-ylamino]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 690248-27-2 HCAPLUS
 CN Benzonitrile, 4-[1H-imidazol-1-yl[(4-methylphenyl)methyl]amino]- (CA INDEX NAME)




RN 690248-28-3 HCAPLUS
 CN Benzonitrile, 4-[[[(4-cyanophenyl)-1H-imidazol-1-ylamino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 690248-29-4 HCAPLUS


CN Benzonitrile, 4-[[(3,4-dimethoxyphenyl)methyl]-1H-imidazol-1-ylamino]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 690248-31-8 HCAPLUS


CN Benzonitrile, 4-[[(4-fluorophenyl)methyl]-1H-imidazol-1-ylamino]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 690248-32-9 HCAPLUS

CN Benzonitrile, 4-[1H-imidazol-1-yl[[4-(methylthio)phenyl]methyl]amino]- (CA INDEX NAME)




RN 690248-33-0 HCAPLUS

CN Benzonitrile, 4-[1H-imidazol-1-yl[[4-(methylsulfonyl)phenyl]methyl]amino]-
(CA INDEX NAME)




RN 690248-34-1 HCAPLUS

CN Benzonitrile, 4-[[[3,4-difluorophenyl)methyl]-1H-imidazol-1-ylamino]-
(CA INDEX NAME)




RN 690248-35-2 HCAPLUS


CN Benzonitrile, 4-[[[2,4-difluorophenyl)methyl]-1H-imidazol-1-ylamino]-
(CA INDEX NAME)



RN 690248-36-3 HCAPLUS
 CN Benzonitrile, 4-[[[(3,5-difluorophenyl)methyl]-1H-imidazol-1-ylamino]- (CA INDEX NAME)




RN 690248-37-4 HCAPLUS
 CN Benzonitrile, 4-[[[(4-bromophenyl)methyl]-1H-imidazol-1-ylamino]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 690248-41-0 HCAPLUS
 CN Benzonitrile, 4-[1H-imidazol-1-yl(phenylmethyl)amino]- (CA INDEX NAME)




RN 690248-43-2 HCAPLUS

CN Benzonitrile, 4-[[[(3-fluorophenyl)methyl]-1H-imidazol-1-ylamino]- (CA INDEX NAME)




RN 690248-44-3 HCAPLUS

CN Benzoic acid, 4-[[[(4-cyanophenyl)-1H-imidazol-1-ylamino]methyl]-, methyl ester (CA INDEX NAME)




RN 690248-46-5 HCAPLUS

CN Benzonitrile, 4-[1H-imidazol-1-yl[[3-(trifluoromethyl)phenyl]methyl]amino]- (CA INDEX NAME)




RN 690248-50-1 HCAPLUS

CN Benzonitrile, 4-[[[(4-bromophenyl)methyl](4-methyl-1H-imidazol-1-yl)amino]-
(CA INDEX NAME)




RN 690248-51-2 HCAPLUS

CN Benzonitrile, 4-[[[(4-bromophenyl)methyl](5-methyl-1H-imidazol-1-yl)amino]-
(CA INDEX NAME)




RN 690248-52-3 HCAPLUS

CN Benzonitrile, 4-[[[(4-bromophenyl)methyl](4,5-dimethyl-1H-imidazol-1-yl)amino]-
(CA INDEX NAME)



IT 690248-15-3P, 4-[N-(2,3-Dihydro-1H-imidazol-1-yl-2-thione)-N-(4-trifluoromethylphenylmethyl)amino]benzonitrile
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of 1-phenylamino-1H-imidazoles as aromatase inhibitors)
 RN 690248-15-8 HCAPLUS
 CN Benzonitrile, 4-[(2,3-dihydro-2-thioxo-1H-imidazol-1-yl)[[4-(trifluoromethyl)phenyl]methyl]amino]- (CA INDEX NAME)




REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L44 ANSWER 12 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:570981 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 139:133571
 TITLE: Preparation of heterocyclic compounds such as oxazoles as anticancer agents
 INVENTOR(S): Tasaka, Akihiro; Taniguchi, Takahiko; Takakura, Nobuyuki; Momose, Yu; Naito, Kenichiro; Tsujimoto, Saori
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
 SOURCE: PCT Int. Appl., 274 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2003059907	A1	20030724	WO 2003-JP310	20030116
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003203170	A1	20030730	AU 2003-203170	20030116
JP 2003277379	A	20031002	JP 2003-8814	20030116
PRIORITY APPLN. INFO.:			JP 2002-9255	A 20020117
			WO 2003-JP310	W 20030116


OTHER SOURCE(S): MARPAT 139:133571
ED Entered STN: 25 Jul 2003
GI



AB The title compds. I [A is a nitrogenous heterocycle; B is an optionally substituted aromatic homocycle or an optionally substituted aromatic heterocycle; C is a 5- or 6-membered nitrogenous heterocycle which may be substituted; R is an optionally substituted aromatic homocyclic group or the like; m is an integer of 0 to 2; n is an integer of 1 to 5; X is oxygen or the like; and Y and Z may be the same or different from each other and are each a single bond, an oxygen atom, an optionally substituted carbon atom, or the like] are prepared. Compds. of this invention in vitro showed IC₅₀ values of < 0.05 μM to 0.2 μM against the growth of breast cancer cells BT-474. Formulations containing I are given.


IT 568594-05-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclic compds. such as oxazole derivs. as anticancer agents)

RN 568594-05-8 HCAPLUS
CN Benzonitrile, 4-[[2-(1H-imidazol-1-yl)ethyl]methylamino]- (CA INDEX NAME)



REFERENCE COUNT: 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L44 ANSWER 13 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:236032 HCAPLUS Full-text
 DOCUMENT NUMBER: 139:133506
 TITLE: Novel and selective imidazole-containing biphenyl inhibitors of protein farnesyltransferase
 AUTHOR(S): Curtin, Michael L.; Florjancic, Alan S.; Cohen, Jerome; Gu, Wen-Zhen; Frost, David J.; Muchmore, Steven W.; Sham, Hing L.
 CORPORATE SOURCE: Global Pharmaceutical Research and Development, Departments of Cancer Research and Advanced Technology, Abbott Laboratories, Abbott Park, IL, 60064, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(7), 1367-1371
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier Science B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 139:133506
 ED Entered STN: 27 Mar 2003
 GI



I


AB A series of imidazole-containing biphenyls was prepared and evaluated in vitro for inhibition of FTase and cellular Ras processing. Several of these analogs, e.g., I, are potent inhibitors of FTase (<1 nM), FTase/GGTase selective (>300-fold) and cellularly active (≤80 nM). An X-ray crystal structure of inhibitor I bound to rat farnesyltransferase is also presented.

IT 565451-86-7

RL: PAC (Pharmacological activity); BIOL (Biological study)
(farnesyltransferase inhibition and structure-activity relationships of biarylbenzylamines)

RN 565451-86-7 HCAPLUS

CN Benzonitrile, 4-[(1H-imidazol-5-ylmethyl)(phenylmethyl)amino]-2-(1-naphthalenyl)- (CA INDEX NAME)




IT 565451-83-4P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation, farnesyltransferase inhibition, SAR, and pharmacokinetics of N-(methylimidazolylmethyl)-N-(naphthylcyanophenyl)-benzylamine and crystal structure of complex with farnesyltransferase and hydroxyfarnesylphosphonic acid)

RN 565451-83-4 HCAPLUS

CN Benzonitrile, 4-[[[(3-cyanophenyl)methyl][(1-methyl-1H-imidazol-5-yl)methyl]amino]-2-(1-naphthalenyl)- (CA INDEX NAME)




IT 371764-01-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation, farnesyltransferase inhibition, and SAR of imidazolylbiarylamine via reductive condensation of tritylimidazolecarboxaldehyde with biarylamine followed by alkylation and deprotection)

RN 371764-01-1 HCAPLUS


CN [1,1'-Biphenyl]-2-carbonitrile, 5-[(1H-imidazol-5-ylmethyl)(phenylmethyl)amino]-2'-methyl- (CA INDEX NAME)



IT 371766-31-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation, farnesyltransferase inhibition, and SAR of imidazolylbiarylamine via reductive condensation of tritylimidazolecarboxaldehyde with biarylamine followed by alkylation and deprotection)
 RN 371766-31-3 HCAPLUS
 CN [1,1'-Biphenyl]-2-carbonitrile, 2'-methyl-5-[(phenylmethyl)[[1-(triphenylmethyl)-1H-imidazol-4-yl]methyl]amino]- (CA INDEX NAME)




IT 371763-58-5P 371763-59-6P 371763-61-0P
 371763-63-2P 371763-64-3P 371763-65-4P
 371763-67-6P 371763-69-8P 565451-84-5P
 565451-85-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation, farnesyltransferase inhibition, and SAR of imidazolylbiarylamine via Suzuki coupling of chlorobenzoate with arylboronic acids followed by hydrolysis, amination, reductive condensation with imidazolecarboxaldehyde, and alkylation)
 RN 371763-58-5 HCAPLUS
 CN [1,1'-Biphenyl]-2-carbonitrile, 2'-methyl-5-[[1-methyl-1H-imidazol-5-yl)methyl](phenylmethyl)amino]- (CA INDEX NAME)




RN 371763-59-6 HCAPLUS

CN Benzonitrile, 4-[methyl[(1-methyl-1H-imidazol-5-yl)methyl]amino]-2-(1-naphthalenyl)- (CA INDEX NAME)




RN 371763-61-0 HCAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5-[[[(4-cyanophenyl)methyl][(1-methyl-1H-imidazol-5-yl)methyl]amino]-2'-methyl]- (CA INDEX NAME)




RN 371763-63-2 HCAPLUS

CN Benzonitrile, 4-[[[(4-cyanophenyl)methyl][(1-methyl-1H-imidazol-5-yl)methyl]amino]-2-(1-naphthalenyl)- (CA INDEX NAME)




RN 371763-64-3 HCAPLUS

CN Benzonitrile, 4-[[[(1-methyl-1H-imidazol-5-yl)methyl](phenylmethyl)amino]-2-(1-naphthalenyl)- (CA INDEX NAME)




RN 371763-65-4 HCAPLUS

CN Benzonitrile, 4-[hexyl[(1-methyl-1H-imidazol-5-yl)methyl]amino]-2-(1-naphthalenyl)- (CA INDEX NAME)




RN 371763-67-6 HCAPLUS

CN Benzamide, N-[4-cyano-3-(1-naphthalenyl)phenyl]-N-[(1-methyl-1H-imidazol-5-yl)methyl]- (CA INDEX NAME)




RN 371763-69-8 HCAPLUS


CN [1,1'-Biphenyl]-2-carbonitrile, 5-[[[(3-cyanophenyl)methyl][(1-methyl-1H-imidazol-5-yl)methyl]amino]-2'-methyl]- (CA INDEX NAME)



RN 565451-84-5 HCAPLUS
 CN Benzonitrile, 4-[[[(3-chlorophenyl)methyl][(1-methyl-1H-imidazol-5-yl)methyl]amino]-2-(1-naphthalenyl)- (CA INDEX NAME)




RN 565451-85-6 HCAPLUS
 CN 2-Pyridinecarbonitrile, 4-[[[4-cyano-3-(1-naphthalenyl)phenyl][(1-methyl-1H-imidazol-5-yl)methyl]amino]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L44 ANSWER 14 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:123617 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 136:183819
 TITLE: Preparation of (imidazolylalkyl)biphenylcarbonitriles and analogs as farnesyltransferase inhibitors
 INVENTOR(S): Wang, Wei-Bo; Curtin, Michael L.; Fakhoury, Stephen A.; Gwaltney, Stephen L.; Hasvold, Lisa A.; Hutchins, Charles W.; Li, Qun; Lin, Nan-Horng; Nelson, Lissa Taka Jennings; O'Connor, Steve; Sham, Hing L.; Sullivan, Gerard M.; Wang, Gary T.; Wang, Xilu
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 189 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020019527	A1	20020214	US 2001-842391	20010425
PRIORITY APPLN. INFO.:			US 2000-200165P	P 20000427
OTHER SOURCE(S): MARPAT 136:183819				
ED Entered STN: 15 Feb 2002				
GI				



AB Title compds. (I) were prepared Thus, 2-MeC₆H₄C₆H₃(CN)(CHO)-2,5 was condensed with 1-methyl-2-triethylsilyl-1H-imidazole (preparation each given) and the product O-arylated to give title compound II. Data for biol. activity of I were given.


IT 371763-58-5P 371763-59-6P 371763-60-9P
 371763-61-0P 371763-62-1P 371763-63-2P
 371763-64-3P 371763-65-4P 371763-67-6P
 371763-68-7P 371763-69-8P 371763-99-4P
 371764-00-0P 371764-01-1P 371764-02-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of (imidazolylalkyl)biphenylcarbonitriles and analogs as farnesyltransferase inhibitors)


RN 371763-58-5 HCAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 2'-methyl-5-[[1-methyl-1H-imidazol-5-yl)methyl](phenylmethyl)amino]- (CA INDEX NAME)




RN 371763-59-6 HCAPLUS

CN Benzonitrile, 4-[methyl[(1-methyl-1H-imidazol-5-yl)methyl]amino]-2-(1-naphthalenyl)- (CA INDEX NAME)




RN 371763-60-9 HCAPLUS

CN Benzonitrile, 4-[[[(1-methyl-1H-imidazol-5-yl)methyl]-2-propen-1-ylamino]-2-(1-naphthalenyl)- (CA INDEX NAME)




RN 371763-61-0 HCAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5-[[[(4-cyanophenyl)methyl][(1-methyl-1H-imidazol-5-yl)methyl]amino]-2'-methyl- (CA INDEX NAME)




RN 371763-62-1 HCAPLUS

CN Benzonitrile, 4-[[[(1-methyl-1H-imidazol-5-yl)methyl](3-phenylpropyl)amino]-2-(1-naphthalenyl)- (CA INDEX NAME)




RN 371763-63-2 HCAPLUS

CN Benzonitrile, 4-[[[(4-cyanophenyl)methyl][(1-methyl-1H-imidazol-5-yl)methyl]amino]-2-(1-naphthalenyl)- (CA INDEX NAME)




RN 371763-64-3 HCAPLUS

CN Benzonitrile, 4-[[[(1-methyl-1H-imidazol-5-yl)methyl](phenylmethyl)amino]-2-(1-naphthalenyl)- (CA INDEX NAME)




RN 371763-65-4 HCAPLUS

CN Benzonitrile, 4-[hexyl[(1-methyl-1H-imidazol-5-yl)methyl]amino]-2-(1-naphthalenyl)- (CA INDEX NAME)




RN 371763-67-6 HCAPLUS

CN Benzamide, N-[4-cyano-3-(1-naphthalenyl)phenyl]-N-[(1-methyl-1H-imidazol-5-yl)methyl]- (CA INDEX NAME)




RN 371763-68-7 HCAPLUS

CN Benzamide, N-(6-cyano-2'-methyl[1,1'-biphenyl]-3-yl)-N-[(1-methyl-1H-imidazol-5-yl)methyl]- (CA INDEX NAME)




RN 371763-69-8 HCAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5-[[[(3-cyanophenyl)methyl][(1-methyl-1H-imidazol-5-yl)methyl]amino]-2'-methyl]- (CA INDEX NAME)




RN 371763-99-4 HCAPLUS

CN Benzoic acid, 4-[[[4-cyano-3-(1-naphthalenyl)phenyl][(1-methyl-1H-imidazol-5-yl)methyl]amino]methyl]-, methyl ester (CA INDEX NAME)




RN 371764-00-0 HCAPLUS

CN Benzoic acid, 4-[[[4-cyano-3-(1-naphthalenyl)phenyl][(1-methyl-1H-imidazol-5-yl)methyl]amino]methyl]- (CA INDEX NAME)




RN 371764-01-1 HCAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5-[(1H-imidazol-5-ylmethyl)(phenylmethyl)amino]-2'-methyl- (CA INDEX NAME)



RN 371764-02-2 HCAPLUS

CN Benzoic acid, 3-[[[4-cyano-3-(1-naphthalenyl)phenyl][(1-methyl-1H-imidazol-5-yl)methyl]amino]methyl]-, methyl ester (CA INDEX NAME)



Serial No.:10/598,508

TITLE: Preparation of substituted 4-(heteroarylmethyl)benzonitriles as farnesyltransferase inhibitors

INVENTOR(S): Wang, Wei-Bo; Curtin, Michael L.; Fakhoury, Stephen A.; Gwaltney, Stephen L., II; Hasvold, Lisa A.; Hutchins, Charles W.; Li, Qui; Lin, Nan-Horng; Jennings Nelson, Lissa Taka; O'Connor, Stephen J.; Sham, Hing L.; Sullivan, Gerald M.; Wang, Gary T.; Wang, Xilu

PATENT ASSIGNEE(S): Abbott Laboratories, USA

SOURCE: PCT Int. Appl., 305 pp.
CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001081316	A2	20011101	WO 2001-US13678	20010425
WO 2001081316	A3	20020523		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG CA 2407093 A1 20011101 CA 2001-2407093 20010425 EP 1276726 A2 20030122 EP 2001-932712 20010425 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR JP 2004509064 T 20040325 JP 2001-578410 20010425 MX 2002PA10608 A 20030514 MX 2002-PA10608 20021025 PRIORITY APPLN. INFO.: US 2000-563256 A 20000427 US 2001-822205 A 20010402 WO 2001-US13678 W 20010425 OTHER SOURCE(S): MARPAT 135:344482 ED Entered STN: 02 Nov 2001 GI				




AB The title compds. [I; A1 = (un)substituted alkylene, etc.; R1 = halo, cycloalkyl, aryl, heteroaryl; R2 = heteroaryl selected from imidazolyl, pyrazolyl, pyrrolyl, etc.] and their pharmaceutically acceptable salts which farnesyltransferase, were prepared E.g., 3-step synthesis of the benzonitrile II.HCl which 88% inhibition of farnesyltransferase at 10⁻⁶ M, was given.

IT 371763-99-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of substituted 4-(heteroarylmethyl)benzonitriles as farnesyltransferase inhibitors)

RN 371763-99-4 HCAPLUS


CN Benzoic acid, 4-[[[4-cyano-3-(1-naphthalenyl)phenyl][(1-methyl-1H-imidazol-5-yl)methyl]amino]methyl]-, methyl ester (CA INDEX NAME)



IT 371763-58-5P 371763-59-6P 371763-60-9P
 371763-61-0P 371763-62-1P 371763-63-2P
 371763-64-3P 371763-65-4P 371763-67-6P
 371763-68-7P 371763-69-8P 371764-00-0P
 371764-01-1P 371764-02-2P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of substituted 4-(heteroarylmethyl)benzonitriles as farnesyltransferase inhibitors)


RN 371763-58-5 HCAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 2'-methyl-5-[[[(1-methyl-1H-imidazol-5-yl)methyl](phenylmethyl)amino]- (CA INDEX NAME)




RN 371763-59-6 HCAPLUS

CN Benzonitrile, 4-[methyl[(1-methyl-1H-imidazol-5-yl)methyl]amino]-2-(1-naphthalenyl)- (CA INDEX NAME)




RN 371763-60-9 HCAPLUS

CN Benzonitrile, 4-[[1-methyl-1H-imidazol-5-yl)methyl]-2-((1-cyanophenyl)-1-naphthalenyl)- (CA INDEX NAME)




RN 371763-61-0 HCAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5-[[4-(4-cyanophenyl)methyl][(1-methyl-1H-imidazol-5-yl)methyl]amino]-2'-methyl- (CA INDEX NAME)




RN 371763-62-1 HCAPLUS

CN Benzonitrile, 4-[[1-methyl-1H-imidazol-5-yl)methyl](3-phenylpropyl)amino]-2-(1-naphthalenyl)- (CA INDEX NAME)




RN 371763-63-2 HCAPLUS

CN Benzonitrile, 4-[[[(4-cyanophenyl)methyl][(1-methyl-1H-imidazol-5-yl)methyl]amino]-2-(1-naphthalenyl)- (CA INDEX NAME)




RN 371763-64-3 HCAPLUS

CN Benzonitrile, 4-[[[(1-methyl-1H-imidazol-5-yl)methyl](phenylmethyl)amino]-2-(1-naphthalenyl)- (CA INDEX NAME)




RN 371763-65-4 HCAPLUS

CN Benzonitrile, 4-[hexyl[(1-methyl-1H-imidazol-5-yl)methyl]amino]-2-(1-naphthalenyl)- (CA INDEX NAME)




RN 371763-67-6 HCAPLUS

CN Benzamide, N-[4-cyano-3-(1-naphthalenyl)phenyl]-N-[(1-methyl-1H-imidazol-5-yl)methyl]- (CA INDEX NAME)




RN 371763-68-7 HCAPLUS

CN Benzamide, N-(6-cyano-2'-methyl[1,1'-biphenyl]-3-yl)-N-[(1-methyl-1H-imidazol-5-yl)methyl]- (CA INDEX NAME)




RN 371763-69-8 HCAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5-[[[(3-cyanophenyl)methyl][(1-methyl-1H-imidazol-5-yl)methyl]amino]-2'-methyl- (CA INDEX NAME)




RN 371764-00-0 HCAPLUS

CN Benzoic acid, 4-[[[4-cyano-3-(1-naphthalenyl)phenyl][(1-methyl-1H-imidazol-5-yl)methyl]amino]methyl]- (CA INDEX NAME)




RN 371764-01-1 HCAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5-[(1H-imidazol-5-ylmethyl)(phenylmethyl)amino]-2'-methyl- (CA INDEX NAME)



RN 371764-02-2 HCAPLUS

CN Benzoic acid, 3-[[[4-cyano-3-(1-naphthalenyl)phenyl][(1-methyl-1H-imidazol-5-yl)methyl]amino]methyl]-, methyl ester (CA INDEX NAME)




IT 371766-31-3

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of substituted 4-(heteroarylmethyl)benzonitriles as
farnesyltransferase inhibitors)

RN 371766-31-3 HCAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 2'-methyl-5-[(phenylmethyl)[[1-(triphenylmethyl)-1H-imidazol-4-yl]methyl]amino]- (CA INDEX NAME)




Serial No.:10/598,508

DOCUMENT NUMBER: 128:257449
ORIGINAL REFERENCE NO.: 128:50967a,50970a
TITLE: Preparation and anti-HIV activity of substituted
diamino-1,3,5-triazine derivatives
INVENTOR(S): Kukla, Michael Joseph; Ludovici, Donald W.; Janssen,
Paul Adriaan Jan; Heeres, Jan; Moereels, Henri Emiel
Lodewijk
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: Eur. Pat. Appl., 31 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 834507	A1	19980408	EP 1997-202917	19970924
EP 834507	B1	20040519		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
NO 9704368	A	19980402	NO 1997-4368	19970922
NO 311614	B1	20011217		
CZ 297333	B6	20061115	CZ 1997-2993	19970923
AT 267179	T	20040615	AT 1997-202917	19970924
PT 834507	T	20041029	PT 1997-202917	19970924
ES 2221679	T3	20050101	ES 1997-202917	19970924
CA 2216486	A1	19980401	CA 1997-2216486	19970925
IN 1997DE02740	A	20050311	IN 1997-DE2740	19970925
AU 9739266	A	19980409	AU 1997-39266	19970926
AU 740809	B2	20011115		
NZ 328854	A	20001027	NZ 1997-328854	19970926
US 6380194	B1	20020430	US 1997-938602	19970926
EE 3826	B1	20020815	EE 1997-253	19970926
JP 10114759	A	19980506	JP 1997-279387	19970929
JP 4127882	B2	20080730		
AP 914	A	20001218	AP 1997-1109	19970929
W: KE, UG, ZM, ZW				
IL 121849	A	20010826	IL 1997-121849	19970929
SK 285241	B6	20060907	SK 1997-1319	19970929
CN 1180698	A	19980506	CN 1997-121454	19970930
CN 1083438	C	20020424		
ZA 9708766	A	19990330	ZA 1997-8766	19970930
HU 9701596	A2	19990628	HU 1997-1596	19970930
HU 9701596	A3	20000428		
HU 225270	B1	20060828		
BR 9704937	A	20000606	BR 1997-4937	19970930
TW 411335	B	20001111	TW 1997-86114172	19970930
RU 2186774	C2	20020810	RU 1997-116200	19970930
HR 970526	B1	20021031	HR 1997-526	19970930
PL 190155	B1	20051130	PL 1997-322369	19970930
HK 1009676	A1	20041029	HK 1998-110540	19980909
US 20020147181	A1	20021010	US 2001-2456	20011115
US 6858609	B2	20050222		
US 20030199473	A1	20031023	US 2003-397760	20030326
US 6962916	B2	20051108		
US 20060189614	A1	20060824	US 2005-203325	20050812
PRIORITY APPLN. INFO.:				
			US 1996-27260P	P 19961001
			US 1997-938602	A3 19970926
			US 2001-2456	A3 20011115

OTHER SOURCE(S): MARPAT 128:257449
 ED Entered STN: 23 Apr 1998
 GI




AB The title compds. I [R1, R2 = hydrogen, hydroxy, amino, optionally substituted C1-6alkyl, C1-6alkyloxy, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl, Ar1, mono- or di(C1-6alkyl)amino, mono- or di(C1-6alkyl)aminocarbonyl, dihydro-2(3H)-furanone, or R1 and R2 taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C1-6alkyl)aminoC1-4alkylidene; R3 = hydrogen, Ar1, C1-6alkylcarbonyl, C1-6alkyl, C1-6alkyloxycarbonyl, C1-6alkyl substituted with C1-6alkyloxycarbonyl; R4, R5, R6, R7, R8 = hydrogen, halo, C1-6alkyl, C1-6alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl, trihalomethyloxy; L = optionally substituted C1-10alkyl, C3-10alkenyl, C3-10alkynyl, C3-7cycloalkyl; Ar1 = optionally substituted phenyl], useful for the manufacture of a medicine for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection, were prepared E.g., reaction of Ph N'-cyano-N-(4-cyanophenyl)carbamimidate, prepared from 4-cyanoaniline and di-Ph N-cyanocarbonimidate, with 2,6-dichlorobenzeneethanimidamide gave 67% 4-[[4-amino-6-[(2,6-dichlorophenyl)methyl]-1,3,5-triazin-2-yl]amino]benzonitrile.

IT 205381-44-8P 205381-45-9P 205381-46-0P
 205381-48-2P 205381-49-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation and anti-HIV activity of diaminotriazines)


RN 205381-44-8 HCAPLUS

CN Glycine, N-[4-amino-6-[(2,6-dichlorophenyl)methyl]-1,3,5-triazin-2-yl]-N-(4-cyanophenyl)-, methyl ester (CA INDEX NAME)




RN 205381-45-9 HCAPLUS

CN Acetamide, N-[4-(acetamino)-6-[(2,6-dichlorophenyl)methyl]-1,3,5-triazin-2-yl]-N-(4-cyanophenyl)- (CA INDEX NAME)




RN 205381-46-0 HCAPLUS

CN Imidodicarbonic acid, N-[4-[(4-cyanophenyl)(ethoxycarbonyl)amino]-6-[(2,6-dichlorophenyl)methyl]-1,3,5-triazin-2-yl]-, C,C'-diethyl ester (CA INDEX NAME)




RN 205381-48-2 HCAPLUS

CN Acetamide, N-acetyl-N-[4-[acetyl(4-cyanophenyl)amino]-6-[(2,6-dichlorophenyl)methyl]-1,3,5-triazin-2-yl]- (CA INDEX NAME)



RN 205381-49-3 HCAPLUS

CN Carbamic acid, (4-cyanophenyl)[4-[(2,6-dichlorophenyl)methyl]-6-[(ethoxycarbonyl)amino]-1,3,5-triazin-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L44 ANSWER 17 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:562758 HCAPLUS Full-text

DOCUMENT NUMBER: 129:244681

ORIGINAL REFERENCE NO.: 129:49817a,49820a

TITLE: A facile synthesis of trifluoromethylamines by oxidative desulfurization-fluorination of dithiocarbamates

AUTHOR(S): Kanie, Kiyoshi; Mizuno, Katsuya; Kuroboshi, Manabu; Hiyama, Tamejiro

CORPORATE SOURCE: Research Laboratory of Resources Utilization, Tokyo Institute of Technology, Midori-ku, Yokohama, Kanagawa, 226-8503, Japan

SOURCE: Bulletin of the Chemical Society of Japan (1998), 71(8), 1973-1991

CODEN: BCSJA8; ISSN: 0009-2673

PUBLISHER: Chemical Society of Japan

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 129:244681

ED Entered STN: 04 Sep 1998


AB Trifluoromethylamines are easily synthesized from dithiocarbamates by a reagent system consisting of tetrabutylammonium dihydrogen trifluoride and an N-halo imide under mild conditions. When this reaction was applied to dithiocarbamates ArN(R)CS₂Me at higher temps., the trifluoromethylation was accompanied by halogen substitution at the p-position of the Ar group. The synthesis of trifluoromethyl-substituted adenosine is also described.

IT 143490-24-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of trifluoromethylamines by oxidative desulfurization-fluorination of dithiocarbamates)

RN 143490-24-8 HCAPLUS

CN Benzonitrile, 4-[(phenylmethyl)(trifluoromethyl)amino]- (CA INDEX NAME)



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L44 ANSWER 18 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:213310 HCAPLUS Full-text

DOCUMENT NUMBER: 126:293338


ORIGINAL REFERENCE NO.: 126:56805a,56808a

TITLE: Studies on aromatase inhibitors. III. Synthesis and biological evaluation of [(4-bromobenzyl)(4-cyanophenyl)amino]azoles and their azine analogs

AUTHOR(S): Okada, Minoru; Yoden, Toru; Kawaminami, Eiji; Shimada, Yoshiaki; Kudoh, Masafumi; Isomura, Yasuo

CORPORATE SOURCE: Medicinal Chemistry Research II, Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., Tsukuba, 305, Japan

SOURCE: Chemical & Pharmaceutical Bulletin (1997), 45(3),
482-486
CODEN: CPBTAL; ISSN: 0009-2363
PUBLISHER: Pharmaceutical Society of Japan
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 126:293338
ED Entered STN: 02 Apr 1997
GI



AB A series of [(4-bromobenzyl)(4-cyanophenyl)amino]azoles and their azine
analogs I (Ar = 3-pyridazinyl, 1,3,4-thiadiazol-2-yl, 3-pyridyl, etc.), which
have the side chain of the selective aromatase inhibitor YM511, were
synthesized and evaluated for aromatase-inhibitory activity (in vitro) and for
pregnant mare serum gonadotropin (PMSG)-induced estrogen synthesis inhibitory
activity (in vivo). Among these aza-heterocycles, the pyrimidin-5-yl
derivative I (R = pyrimidin-5-yl) (II) was the most potent aromatase inhibitor
and its in vitro inhibitory activity was comparable to that of YM511. II also
showed weak inhibitory activity on aldosterone synthesis. These data
indicated that the pyrimidin-5-yl moiety is useful as a new azole fragment in
place of the 4H-1,2,4-triazol-4-yl moiety of the aromatase inhibitor YM511.


IT 157911-83-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); BIOL (Biological
study); PREP (Preparation)

(preparation, aromatase inhibition, and estrogen and aldosterone synthesis
inhibitory activity of (bromobenzyl)(cyanophenyl)amino-azoles and
-azines)

RN 157911-83-6 HCAPLUS

CN Benzonitrile, 4-[[[(4-bromophenyl)methyl]-1,2,4-triazin-3-ylamino]- (CA
INDEX NAME)



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Serial No.:10/598,508

L44 ANSWER 19 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1994:605372 HCAPLUS Full-text

DOCUMENT NUMBER: 121:205372

ORIGINAL REFERENCE NO.: 121:37397a,37400a

TITLE: Preparation of aminopyrimidines as aromatase inhibitors

INVENTOR(S): Okada, Minoru; Yoden, Toru; Kawaminami, Eiji; Shimada, Yoshiaki; Kudo, Masafumi; Isomura, Yasuo

PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 84 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9322290	A1	19931111	WO 1993-JP548	19930427
W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, PT, RO, RU, SD, SK, UA, US, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9340230	A	19931129	AU 1993-40230	19930427
EP 640595	A1	19950301	EP 1993-909428	19930427
EP 640595	B1	19990324		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AT 178056	T	19990415	AT 1993-909428	19930427
ES 2130258	T3	19990701	ES 1993-909428	19930427
CN 1079962	A	19931229	CN 1993-105330	19930428
CN 1039228	C	19980722		
US 5538976	A	19960723	US 1994-325383	19941026
PRIORITY APPLN. INFO.:			JP 1992-137762	A 19920428
			JP 1992-234298	A 19920810
			WO 1993-JP548	A 19930427

OTHER SOURCE(S): CASREACT 121:205372; MARPAT 121:205372

ED Entered STN: 29 Oct 1994

GI For diagram(s), see printed CA Issue.


AB The title compds. I [A = single bond, alkylene, etc.; ring B = pyrimidine, pyridazine, triazine ring; rings D and E = (substituted) aryl, etc.; a proviso is given] were prepared I have aromatase inhibiting activity and are useful as therapeutic agents for breast cancer, endometriosis, prostatic hypertrophy, etc. Treatment of aminopyrimidine II with NaH in DMF, followed by reaction with 4-trifluoromethylbenzyl bromide, gave, after workup, title compound III. One compound I in vitro exhibited IC50 of 0.036 nM against aromatase. Formulations containing I are given.

IT 157911-83-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as aromatase inhibitor)

RN 157911-83-6 HCAPLUS


CN Benzonitrile, 4-[[[(4-bromophenyl)methyl]-1,2,4-triazin-3-ylamino]- (CA INDEX NAME)



L44 ANSWER 20 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1993:495073 HCAPLUS Full-text
 DOCUMENT NUMBER: 119:95073
 ORIGINAL REFERENCE NO.: 119:17133a,17136a
 TITLE: Preparation of anticancer aromatic
 N-trifluoromethylamines
 INVENTOR(S): Hyama, Tamejiro; Kuroboshi, Manabu; Wakakuri, Shinobu
 PATENT ASSIGNEE(S): Sagami Chem Res, Japan
 SOURCE: Jpn. Kokai Tokyo Koho, 11 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05078286	A	19930330	JP 1991-268280	19910919
JP 3083186	B2	20000904		

PRIORITY APPLN. INFO.: JP 1991-268280 19910919
 OTHER SOURCE(S): CASREACT 119:95073; MARPAT 119:95073
 ED Entered STN: 04 Sep 1993
 AB R1NR2CF3 [R1 = (un)substituted aryl; R2 = (un)substituted linear or branched alkyl; NR1R2 may form ring] are safely and easily prepared by treatment of R1NR2CS2R3 [R1, R2 = same as above; R3 = (un)substituted aryl, (un)substituted linear or branched alkyl] with F+ sources in the presence of halonium generators. Treatment of Me N-benzyl-N-(4-methoxyphenyl)dithiocarbamate with (Bu4N+)(H2F3-) and NBS in CH2Cl2 at room temperature for 1 h gave 97% N-benzyl-N-(4-methoxyphenyl)-N-trifluoromethylamine, which inhibited murine leukemia P388 cell with IC50 of 4.9 µg/mL.
 IT 143490-24-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, by fluorination of dithiocarbamate derivative)
 RN 143490-24-8 HCAPLUS
 CN Benzonitrile, 4-[(phenylmethyl)(trifluoromethyl)amino]- (CA INDEX NAME)



L44 ANSWER 21 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1992:550619 HCAPLUS Full-text

DOCUMENT NUMBER: 117:150619
 ORIGINAL REFERENCE NO.: 117:26085a,26088a
 TITLE: A facile synthesis of trifluoromethylamines by oxidative desulfurization-fluorination of dithiocarbamates
 AUTHOR(S): Kuroboshi, Manabu; Hiyama, Tamejiro
 CORPORATE SOURCE: Sagami Chem. Res. Cent., Sagamihara, 229, Japan
 SOURCE: Tetrahedron Letters (1992), 33(29), 4177-8
 CODEN: TELEAY; ISSN: 0040-4039
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 117:150619
 ED Entered STN: 17 Oct 1992
 AB Reaction of Me dithiocarbamates R1R2NC(S)SMe (e.g., R1 = 4-MeOC6H4, R2 = PhCH2) with Bu4N+ H2F3- and N-bromosuccinimide provides trifluoromethylamines R1R2NCF3 in 62-99% yields.
 IT 143490-24-3F
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 143490-24-8 HCAPLUS
 CN Benzonitrile, 4-[(phenylmethyl)(trifluoromethyl)amino]- (CA INDEX NAME)




L44 ANSWER 22 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1990:206483 HCAPLUS Full-text
 DOCUMENT NUMBER: 112:206483
 ORIGINAL REFERENCE NO.: 112:34743a,34746a
 TITLE: Electrolytic transformation of fluoroorganic compounds. 5. Anodic cyanation of 2,2,2-trifluoroethylamines
 AUTHOR(S): Konno, Akinori; Fuchigami, Toshio; Fujita, Yasushi; Nonaka, Tsutomu
 CORPORATE SOURCE: Tokyo Inst. Technol., Grad. Sch. Nagatsuta, Yokohama, 227, Japan
 SOURCE: Journal of Organic Chemistry (1990), 55(6), 1952-4
 CODEN: JOCEAH; ISSN: 0022-3263
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 ED Entered STN: 26 May 1990
 AB Regioselectivity of the anodic cyanation reaction of various types of 2,2,2-trifluoroethylamines was investigated. A remarkable difference in the regioselectivity between the anodic cyanation and methoxylation of the trifluoroethylamines was observed. The cyano group was introduced into the α -position to the nitrogen atom other than the trifluoroethyl group. The effect of the trifluoromethyl group on the anodic substitution reactions and the reaction mechanism are discussed. The acidity of the cation radicals of the amines and the basicity of the reaction medium were proposed as main factors for controlling regioselectivity in the anodic cyanation.
 IT 126422-69-3F 126422-72-8F
 RL: FORM (Formation, nonpreparative); PREP (Preparation)

Serial No.:10/598,508

(formation of, in anodic cyanation of trifluoroethylamines,
regioselectivity in relation to)


RN 126422-69-3 HCAPLUS

CN Benzonitrile, 4-[methyl(2,2,2-trifluoroethyl)amino]- (CA INDEX NAME)



RN 126422-72-8 HCAPLUS

CN Benzonitrile, 4-[ethyl(2,2,2-trifluoroethyl)amino]- (CA INDEX NAME)



L44 ANSWER 23 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1984:191866 HCAPLUS Full-text

DOCUMENT NUMBER: 100:191866

ORIGINAL REFERENCE NO.: 100:29175a

TITLE: Fungicidal heterocyclic amines

INVENTOR(S): Krumkalns, Eriks Victor; Smiley, David Lee

PATENT ASSIGNEE(S): Eli Lilly and Co., USA

SOURCE: Brit. UK Pat. Appl., 40 pp.

CODEN: BAXXDU

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2121414	A	19831221	GB 1983-15446	19830606
GB 2121414	B	19860305		
US 4552886	A	19851112	US 1983-472439	19830307
CA 1223586	A1	19870630	CA 1983-429587	19830602
DK 8302569	A	19831208	DK 1983-2569	19830606
EP 97013	A2	19831228	EP 1983-303256	19830606
EP 97013	A3	19850102		
R: BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
JP 59001481	A	19840106	JP 1983-101597	19830606
BR 8302975	A	19840207	BR 1983-2975	19830606
HU 31956	A2	19840628	HU 1983-2019	19830606
HU 193491	B	19871028		


PRIORITY APPLN. INFO.: US 1982-385602 A 19820607

US 1983-472439 A 19830307

OTHER SOURCE(S): CASREACT 100:191866; MARPAT 100:191866

ED Entered STN: 08 Jun 1984

GI




AB The title compds. I [X = O, S; X1 = bond, (un)substituted CH₂, CH₂CH₂; R = pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl; R1 = (un)substituted alkyl, Ph, alkenyl, alkoxy, cycloalkyl; R2-R4 = H, alkyl; n = 0, 1] were prepared Thus II (R5 = H) was treated with CH₂:CHCH₂NCS to give II (R5 = CSNHCH₂CH:CH₂) which was cyclized with acid to III. At 10 ppm III gave 86% growth inhibition of *Hydrilla verticillata*. At 35 lb/acre II protected cotton against damping off by *Rhizoctonia*.

IT 89985-33-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 89985-33-1 HCAPLUS

CN Benzonitrile, 4-[(4,5-dihydro-2-thiazolyl)(3-pyridinylmethyl)amino]- (CA INDEX NAME)



L44 ANSWER 24 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1980:198402 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 92:198402

ORIGINAL REFERENCE NO.: 92:32143a,32146a

TITLE: Substituted 2-phenylamino-2-imidazolines

INVENTOR(S): Staehle, Helmut; Koeppe, Herbert; Kummer, Werner;
Hoefke, Wolfgang

PATENT ASSIGNEE(S): Boehringer, C. H., Sohn, Fed. Rep. Ger.

SOURCE: Ger. Offen., 14 pp.

CODEN: GWXXBX


DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2831143	A1	19800131	DE 1978-2831143	19780715
EP 7986	A1	19800220	EP 1979-101924	19790613
EP 7986	B1	19810916		
R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
AT 225	T	19811015	AT 1979-101924	19790613
JP 55015482	A	19800202	JP 1979-89179	19790713
US 4239764	A	19801216	US 1979-57582	19790716
PRIORITY APPLN. INFO.:			DE 1978-2831143	A 19780715
			EP 1979-101924	A 19790613
OTHER SOURCE(S): MARPAT 92:198402				
ED Entered STN: 12 May 1984				
GI				




AB The title compds. (I; R = H, Cl, Me, OMe; R1 = Cl, Me, Br, F, OMe, CN) and their salts were prepared for use as heart stimulants (no data). Thus, 2-(2,6-dichlorophenylimino)imidazolidine reacted with 2-(chloromethyl)pyridine-HCl in MeOCH₂CH₂OH to give I (R = Cl, R1 = 6-Cl, 2-pyridyl).

IT 73541-29-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 73541-29-4 HCAPLUS

CN Benzonitrile, 4-[(4,5-dihydro-1H-imidazol-2-yl)(2-pyridinylmethyl)amino]-
 (CA INDEX NAME)



L44 ANSWER 25 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1978:406323 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 89:6323

ORIGINAL REFERENCE NO.: 89:1087a,1090a

TITLE: Substituted 2-phenylaminoimidazolines

INVENTOR(S): Staehle, Helmut; Koeppe, Herbert; Kummer, Werner;
 Stockhaus, Klaus; Hoefke, Wolfgang; Kuhn, Franz Josef


PATENT ASSIGNEE(S): Boehringer, C. H., Sohn, Fed. Rep. Ger.

Serial No.:10/598,508

SOURCE: Ger. Offen., 18 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2636732	A1	19780216	DE 1976-2636732	19760814
FI 7702221	A	19780215	FI 1977-2221	19770718
FI 64147	B	19830630		
FI 64147	C	19831010		
AT 7705689	A	19791115	AT 1977-5689	19770802
AT 357152	B	19800625		
JP 53025567	A	19780309	JP 1977-94252	19770808
JP 60026112	B	19850621		
SU 660592	A3	19790430	SU 1977-2509800	19770810
DD 132964	A5	19781122	DD 1977-200535	19770811
CH 630906	A5	19820715	CH 1977-9858	19770811
BE 857778	A1	19780213	BE 1977-180163	19770812
DK 7703595	A	19780215	DK 1977-3595	19770812
DK 152042	B	19880125		
DK 152042	C	19880620		
NO 7702825	A	19780215	NO 1977-2825	19770812
NO 145275	B	19811109		
NO 145275	C	19820217		
SE 7709158	A	19780215	SE 1977-9158	19770812
SE 441184	B	19850916		
SE 441184	C	19860109		
NL 7708910	A	19780216	NL 1977-8910	19770812
FR 2361371	A1	19780310	FR 1977-24921	19770812
FR 2361371	B1	19800912		
US 4100292	A	19780711	US 1977-824044	19770812
ZA 7704875	A	19790425	ZA 1977-4875	19770812
GB 1548518	A	19790718	GB 1977-34025	19770812
HU 175055	B	19800528	HU 1977-B01676	19770812
CS 199686	B2	19800731	CS 1977-5341	19770812
CA 1085861	A1	19800916	CA 1977-284610	19770812
IL 52717	A	19801231	IL 1977-52717	19770812
ES 461598	A1	19780601	ES 1977-461598	19770813
PL 102537	B1	19790430	PL 1977-200251	19770813
PL 103477	B1	19790630	PL 1977-206252	19770813
RO 76806	A1	19810530	RO 1977-97261	19770813
AU 7727889	A	19790308	AU 1977-27889	19770815
AU 507063	B2	19800131		
ES 465225	A1	19780916	ES 1977-465225	19771220
SU 677655	A3	19790730	SU 1978-2611304	19780505
CS 199687	B2	19800731	CS 1979-903	19790209
AT 7904246	A	19801115	AT 1979-4246	19790615
AT 362787	B	19810610		
CH 631970	A5	19820915	CH 1981-5873	19810910
PRIORITY APPLN. INFO.:			DE 1976-2636732	A 19760814
			AT 1977-5689	A 19770802
			CH 1977-9858	A 19770811
			CS 1977-5341	19770812

OTHER SOURCE(S): MARPAT 89:6323
 ED Entered STN: 12 May 1984
 GI




AB The imidazoles I ($R = R_1 = R_2 = \text{halo, Me, Et, MeO, HO, CF}_3$; $n = 1-4$) and their pharmaceutically acceptable salts were prepared by treating II with cycloalkylmethyl halides or III ($R_3 = \text{CN, H}_2\text{NC:NH, MeSC:NH, etc.}$), with $\text{H}_2\text{NCHCHNH}_2$. Thus, treating II ($R = \text{H, R}_1\text{R}_2 = 2,6\text{-Cl}_2$) with (chloromethyl)cyclopropane gave 10.6% I ($R = \text{H, R}_1\text{R}_2 = 2,6\text{-Cl}_2, n = 1$). I have analgesic activity up to 100 times that of morphine.

IT 66542-11-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 66542-11-8 HCAPLUS

CN Benzonitrile, 4-[(cyclopropylmethyl)(4,5-dihydro-1H-imidazol-2-yl)amino]-
(CA INDEX NAME)



L44 ANSWER 26 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1974:120944 HCAPLUS Full-text

DOCUMENT NUMBER: 80:120944

ORIGINAL REFERENCE NO.: 80:19471a,19474a

TITLE: [(Furylmethyl)amino]imidazolines

INVENTOR(S): Stahle, Helmut; Koppe, Herbert; Kummer, Werner; Wick, Helmut

PATENT ASSIGNEE(S): Boehringer Ingelheim G.M.B.H.

SOURCE: Brit., 11 pp.
CODEN: BRXXAA

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.

KIND


DATE

APPLICATION NO.

DATE

Serial No.:10/598,508


GB 1344022 A 19740116 GB 1972-29635 19720623
 PRIORITY APPLN. INFO.: GB 1972-29635 A 19720623
 ED Entered STN: 12 May 1984
 GI For diagram(s), see printed CA Issue.
 AB Twenty-one title compds. (I; R = H, Me, Et; R1, R2, R3 = H, F, Cl, Br, Et, MeO, CF3, CN) which have analgesic and blood pressure decreasing properties and are useful in migraine treatment, were prepared by alkylation of the corresponding (phenylamino)imidazoline derivs. with (chloromethyl)furans or by treating appropriate N-phenyl-N-(furylmethyl)-S- methylisothiuronium iodides with H2N(CH2)2NH2. Thus, 2.3 g 2-(2,6-dichlorophenylamino)-2-imidazoline, 1.43 g 3-(chloromethyl)-2- methylfuran, and 3 ml Et3N were refluxed 3 hr in PhMe to give 1.95 g 2- N-(2-methyl-3-furylmethyl)-N-(2,6-dichlorophenyl)- amino%-2- imidazoline. I-containing compns. for tablets, ampuls, and drops were described.
 IT 50531-23-2F
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 50531-23-2 HCAPLUS
 CN Benzonitrile, 4-[(4,5-dihydro-1H-imidazol-2-yl)](2-methyl-3-furanyl)methyl]amino]- (CA INDEX NAME)




L44 ANSWER 27 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1974:463628 HCAPLUS Full-text
 DOCUMENT NUMBER: 81:63628
 ORIGINAL REFERENCE NO.: 81:10141a,10144a
 TITLE: Analgesic and antihypertensive 2-anilinoimidazolines
 INVENTOR(S): Staehle, Helmut; Koeppe, Herbert; Kummer, Werner; Hoefke, Wolfgang
 PATENT ASSIGNEE(S): Boehringer, C. H., Sohn
 SOURCE: Ger. Offen., 24 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2259160	A1	19740606	DE 1972-2259160	19721202
AT 7309432	A	19750215	AT 1973-9432	19731109
AT 326118	B	19751125		
NL 7316405	A	19740605	NL 1973-16405	19731130
AU 7363091	A	19750605	AU 1973-63091	19731130
JP 49086365	A	19740819	JP 1973-134831	19731201
ES 421067	A1	19760401	ES 1973-421067	19731201
ES 421068	A1	19760416	ES 1973-421068	19731201
BE 808150	A1	19740604	BE 1973-138456	19731203
FR 2208671	A1	19740628	FR 1973-43033	19731203
PRIORITY APPLN. INFO.:			DE 1972-2259160	A 19721202

ED Entered STN: 12 May 1984
 GI For diagram(s), see printed CA Issue.
 AB Fifty-five imidazolines I (Rn = e.g. 2,6-Cl₂, 2-F₃C, 4,2,6-BrCl₂, 2,4-F₂, 2,6-Et₂, or 2,4-ClMe; R₁ = R₂ = H or C₁-12alkyl, or R₁ = R₂ = C₁-12 alkyl), useful as antihypertensives and analgesics, were prepared by alkylation of I (R₁ = R₂ = H).
 IT 53292-36-7F 53292-37-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 53292-36-7 HCAPLUS
 CN Benzonitrile, 4-[butyl(1-butyl-4,5-dihydro-1H-imidazol-2-yl)amino]- (CA INDEX NAME)



RN 53292-37-8 HCAPLUS
 CN Benzonitrile, 4-[butyl(4,5-dihydro-1H-imidazol-2-yl)amino]- (CA INDEX NAME)




L44 ANSWER 28 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1974:3523 HCAPLUS Full-text
 DOCUMENT NUMBER: 80:3523
 ORIGINAL REFERENCE NO.: 80:619a,622a
 TITLE: 2-(Arylamino)-2-imidazolines
 INVENTOR(S): Merz, Herbert; Langbein, Adolf; Wick, Helmut;
 Stockhaus, Klaus
 PATENT ASSIGNEE(S): Boehringer, C. H., Sohn
 SOURCE: Ger. Offen., 22 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
DE 2208434	A1	19730830	DE 1972-2208434	19720223
DE 2208434	C2	19820916		
US 3850926	A	19741126	US 1972-282357	19720821
FR 2172948	A1	19731005	FR 1972-30915	19720831
PRIORITY APPLN. INFO.:			DE 1971-2102733	A 19710121

US 1972-219535
DE 1972-2208434A2 19720120
A 19720223


ED Entered STN: 12 May 1984
 GI For diagram(s), see printed CA Issue.
 AB Thirty-two imidazolines I ($R_n = 2,6\text{-Cl}_2$, 4,2- or 2,6- ClMe , 2- F_3C , 2,4,6- Br_3 , etc.; $R_1 = \text{CMe:CH}_2$, 2-methyl-3-furyl, etc.) and(or) their salts, e.g. hydrochlorides, useful as analgesics and antihypertensives, were prepared either by alkylation of the amines II (or their metal salts) with $R_2\text{CH}_2R_1$ ($R_1 = \text{Cl}$, etc.) in the presence of bases, e.g. Et_3N , or by condensation of $R_n\text{C}_6\text{H}_5\text{-nN}(\text{CH}_2R_1)R_3$ [$R_3 = \text{CN}$ or $\text{C}(\text{:NH})R_4$ with $R_4 = \text{alkoxy}$, alkylthio, SH , or NH_2] with $\text{H}_2\text{NCH}_2\text{CH}_2\text{NH}_2$.
 IT 50531-23-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 50531-23-2 HCAPLUS
 CN Benzonitrile, 4-[(4,5-dihydro-1H-imidazol-2-yl)][(2-methyl-3-furanyl)methyl]amino]- (CA INDEX NAME)



L44 ANSWER 29 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1974:134887 HCAPLUS Full-text
 DOCUMENT NUMBER: 80:134887
 ORIGINAL REFERENCE NO.: 80:21761a,21764a
 TITLE: Triphenylmethane dyes containing
 bis(trifluoromethyl)amino groups
 AUTHOR(S): Dronkina, M. I.; Yagupol'skii, L. M.
 CORPORATE SOURCE: Inst. Org. Khim., Kiev, USSR
 SOURCE: Zhurnal Organicheskoi Khimii (1973), 9(10), 2167-72
 CODEN: ZORKAE; ISSN: 0514-7492
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian

ED Entered STN: 12 May 1984
 AB In styryl and triphenylmethane dyes the $\text{N}(\text{CF}_3)_2$ group has a weak auxochromic effect; analogs of crystal violet with 1, 2, and 3 NMe_2 groups replaced by $\text{N}(\text{CF}_3)_2$ groups have λ_{max} (98% H_2SO_4) 466, 474, and 470 nm, resp. 2-[P-[bis(trifluoromethyl)amino]styryl]benzothiazole (I) [50978-84-2] has λ_{max} 325 nm, and its methiodide [50978-83-1] 366 nm. Amination of p-chloro-N,N-bis(trifluoromethyl)aniline (II, $R = \text{Cl}$) [10218-92-5] gave the diamine (II, $R = \text{NH}_2$) [3700-30-9], which was converted via the Sandmeyer reaction to II ($R = \text{Br}$, iodine). By Grignard reaction of these with Et formate [109-94-4] was obtained 4,4'-bis[bis(trifluoromethyl)amino]benzhydrol [50978-82-0] which was oxidized with CrO_3 to 4,4-bis[bis(trifluoromethyl)amino]benzophenone (III) [50978-81-9]. Further Grignard reaction of various combinations of III, Michlers ketone [90-94-8], II ($R = \text{halo}$), and p- $\text{BrC}_6\text{H}_4\text{NMe}_2$ gave the crystal violet analogs.
 IT 51167-57-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and hydrolysis of)

RN 51167-57-8 HCAPLUS
 CN Benzonitrile, 4-[bis(trifluoromethyl)amino]- (CA INDEX NAME)



L44 ANSWER 30 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1971:480250 HCAPLUS Full-text
 DOCUMENT NUMBER: 75:80250
 ORIGINAL REFERENCE NO.: 75:12697a,12700a
 TITLE: Pharmacologically active substituted N-aminoalkyl
 arylamino-2-imidazolines
 INVENTOR(S): Staehle, Helmut; Koeppe, Herbert; Kummer, Werner;
 Samtleben, Hans W.
 PATENT ASSIGNEE(S): Boehringer, C. H., Sohn
 SOURCE: Ger. Offen., 27 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
DE 1957722	A	19710519	DE 1969-1957722	19691117
DE 1957722	C3	19790628		
DE 1957722	B2	19781102		
CH 549575	A	19740531	CH 1973-3600	19701112
CH 550176	A	19740614	CH 1970-16781	19701112
CH 550177	A	19740614	CH 1973-3599	19701112
SU 386514	A3	19730614	SU 1970-1494776	19701113
SU 399128	A3	19730927	SU 1970-1724956	19701113
SU 402215	A3	19731012	SU 1970-1725405	19701113
SE 368010	B	19740617	SE 1970-15378	19701113
RO 58066	A1	19750615	RO 1970-67028	19701113
RO 58065	A1	19750715	RO 1970-67027	19701113
NL 7016744	A	19710519	NL 1970-16744	19701116
NL 169470	B	19820216		
NL 169470	C	19820716		
ES 385586	A1	19730316	ES 1970-385586	19701116
US 3752810	A	19730814	US 1970-90036	19701116
GB 1330887	A	19730919	GB 1970-54473	19701116
DK 130410	B	19750217	DK 1970-5817	19701116
PL 81165	B1	19750830	PL 1970-144454	19701116
FR 2073369	A1	19711001	FR 1970-41116	19701117
FR 2073369	A5	19711001		
AT 298484	B	19720510	AT 1970-10346	19701117
AT 300790	B	19720810	AT 1971-5147	19701117
AT 300791	B	19720810	AT 1971-5148	19701117
ES 388480	A1	19740116	ES 1971-388480	19710220
ES 388481	A1	19740116	ES 1971-388481	19710220
JP 49017265	B	19740427	JP 1972-65867	19720630
SE 415758	B	19801027	SE 1973-7442	19730225

Serial No.:10/598,508

DK 132077	B	19751020	DK 1974-325	19740122
DK 7502612	A	19750915	DK 1975-2612	19750610
DK 134519	B	19761122		

PRIORITY APPLN. INFO.: DE 1969-1957722 A 19691117
DK 1970-5817 A 19701116

ED Entered STN: 12 May 1984

GI For diagram(s), see printed CA Issue.


AB The title compds. (I) were mainly prepared by alkylation of I (R = R1 = H). Only R was displaced. Thus, from I (Ar = 2,4-Cl(Me)C6H3, R = R1 = H), O(CH2CH2)2NCH2CH2Cl.HCl, and Na2CO3 in MeOCH2CH2OH there was obtained I (Ar = 2,4-Cl(Me)C6H3, R = O(CH2CH2)2NCH2CH2, R1 = H). In this manner .apprx.100 other I were prepared

IT 34397-09-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 34397-09-6 HCAPLUS

CN Benzonitrile, 4-[(4,5-dihydro-1H-imidazol-2-yl)[2-(4-morpholinyl)ethyl]amino]- (CA INDEX NAME)



L44 ANSWER 31 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1972:3754 HCAPLUS Full-text

DOCUMENT NUMBER: 76:3754

ORIGINAL REFERENCE NO.: 76:662h,663a

TITLE: Syntheses in the 2-aminoimidazoline series

AUTHOR(S): Staehle, Helmut; Pook, Karl H.

CORPORATE SOURCE: Wiss. Abt., Firma C. H. Boehringer Sohn,
Ingelheim/Rhein, Fed. Rep. Ger.

SOURCE: Justus Liebigs Annalen der Chemie (1971), 751, 159-67
CODEN: JLACBF; ISSN: 0075-4617

DOCUMENT TYPE: Journal

LANGUAGE: German

ED Entered STN: 12 May 1984

GI For diagram(s), see printed CA Issue.


AB Reaction of 2-anilino-2-imidazolines with Cl(CH2)nNR1R2 gave the corresponding 2-[N-phenyl-N-(amino-alkyl)amino]-2-imidazolines (I), which were isomers of 1-(aminoalkyl)-2-anilino-2-imidazolines. These were prepared independently from N-phenyl-S-methylisothiuronium salts and H2NCH2CH2NH(CH2)nNR1R2.

IT 34397-09-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 34397-09-6 HCAPLUS

CN Benzonitrile, 4-[(4,5-dihydro-1H-imidazol-2-yl)[2-(4-morpholinyl)ethyl]amino]- (CA INDEX NAME)



Search History

L1 STRUCTURE UPLOADED
 L2 11 SEA SSS SAM L1
 L3 774 SEA SSS FUL L1

FILE 'HCAPLUS' ENTERED AT 09:40:01 ON 26 SEP 2008

L4 37 SEA ABB=ON PLU=ON L3
 ACT ZAR508HC1A/A

L5 STR
 L6 (189)SEA SSS FUL L5
 L7 4 SEA ABB=ON PLU=ON L6

FILE 'REGISTRY' ENTERED AT 09:40:53 ON 26 SEP 2008

ACT STRCC1ZAR508/A

L8 STR
 L9 189 SEA SSS FUL L8

L10 STRUCTURE UPLOADED
 L11 18 SEA SUB=L3 SSS SAM L10
 L12 395 SEA SUB=L3 SSS FUL L10

FILE 'HCAPLUS' ENTERED AT 09:43:59 ON 26 SEP 2008

L13 16 SEA ABB=ON PLU=ON L12

FILE 'REGISTRY' ENTERED AT 09:45:52 ON 26 SEP 2008

L14 STRUCTURE UPLOADED
 L15 1 SEA SSS SAM L14
 L16 SCR 342 OR 286
 L17 2 SEA SSS SAM L16 AND L14
 L18 STRUCTURE UPLOADED
 L19 0 SEA SSS SAM L18
 L20 0 SEA SSS SAM L16 AND L18
 L21 STRUCTURE UPLOADED
 L22 0 SEA SSS SAM L21
 L23 0 SEA SSS SAM L16 AND L21
 L24 SCR 1867
 L25 0 SEA SSS SAM L24 AND L21
 L26 0 SEA SSS SAM L24 AND L16 AND L21

FILE 'HCAPLUS' ENTERED AT 10:13:42 ON 26 SEP 2008

L27 62 SEA ABB=ON PLU=ON TURNBULL P?/AU
 L28 17 SEA ABB=ON PLU=ON CADILLA R?/AU
 L29 675 SEA ABB=ON PLU=ON COWAN D?/AU
 L30 250 SEA ABB=ON PLU=ON LARKIN A?/AU
 L31 71 SEA ABB=ON PLU=ON KALDOR I?/AU
 L32 479 SEA ABB=ON PLU=ON STEWART E?/AU
 L33 1513 SEA ABB=ON PLU=ON (L27 OR L28 OR L29 OR L30 OR L31 OR L32)
 L34 6 SEA ABB=ON PLU=ON L33 AND (L4 OR L17 OR L13)

FILE 'WPIX' ENTERED AT 10:15:27 ON 26 SEP 2008

L35 10 SEA SSS SAM L8
 L36 109 SEA SSS FUL L8
 L37 2 SEA ABB=ON PLU=ON L36/DCR

Serial No.:10/598,508

L38 2 SEA ABB=ON PLU=ON L33 AND L37

FILE 'BEILSTEIN' ENTERED AT 10:16:52 ON 26 SEP 2008

L39 0 SEA ABB=ON PLU=ON L9

L40 0 SEA ABB=ON PLU=ON L9

FILE 'HCAPLUS, WPIX' ENTERED AT 10:21:37 ON 26 SEP 2008

L41 6 DUP REM L34 L38 (2 DUPLICATES REMOVED)

L42 31 SEA ABB=ON PLU=ON (L13 OR L7 OR L4) NOT L34

FILE 'WPIX' ENTERED AT 10:23:24 ON 26 SEP 2008

L43 0 SEA ABB=ON PLU=ON L37 NOT L38

FILE 'HCAPLUS' ENTERED AT 10:24:44 ON 26 SEP 2008

L44 31 DUP REM L42 L43 L40 (0 DUPLICATES REMOVED)